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Abstract 
 
Although Epstein–Barr virus (EBV) usually establishes a harmless infection in human 
memory B cells, it is implicated in the development of germinal centre (GC) B-cell-derived 
malignancies, including Hodgkin’s lymphoma (HL). I have shown using gene expression 
profiling that lymphoblastoid cell lines derived from GC B cells are a useful model for 
studying early EBV-associated changes contributing to the pathogenesis of HL. EBV 
infection of GC B cells is followed by the up-regulation of the DNA methyltransferases, 
DNMT3A, and the down-regulation of DNMT1 and DNMT3B, a pattern of expression which 
is re-capitulated in HL cell lines. I have also shown that the major EBV oncogene, LMP1, is 
responsible for the down-regulation in GC B cells of DNMT1, and that DNMT3A binds to the 
EBV promoter, Wp which is silenced by DNA methylation. Genome-wide promoter arrays 
revealed that EBV infection of GC B cells is followed by methylation changes in a substantial 
number of cellular genes. These changes were not randomly distributed across the genome but 
clustered at certain chromosomal locations and were strongly associated with the CpG content 
of gene promoters. Finally, I have shown that EBV also modulates the expression of another 
set of epigenetic regulators which control arginine methylation. 
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Introduction 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
       
1.1  Introduction 
The introduction to my thesis is in three sections. The first section provides a brief 
introduction to epigenetics before focusing on the DNA methyltransferases, and the 
relationship between DNA methylation and transcriptional changes, and how these changes 
contribute to carcinogenesis. I also introduce the protein arginine methyltransferases 
(PRMTs).  In the second section, I introduce the Epstein-Barr virus (EBV) before outlining 
how the expression of its genes varies during the viral life-cycle, and how the expression of 
these genes might be epigenetically regulated. Finally in the third section, I briefly review 
how oncogenic viruses disrupt the cellular epigenome before focusing on how EBV-induced 
methylation changes in cellular genes contribute to the pathogenesis of EBV-associated 
malignancies. 
 
1.2 Overview of Epigenetics  
Epigenetics is the study of mitotically heritable changes in gene expression not encoded by 
the DNA sequence.  Epigenetic modifications are essential for normal development and the 
maintenance of gene expression patterns in mammalian cells. A failure to maintain heritable 
epigenetic marks can result in inappropriate activation or inhibition of signalling pathways, 
leading to disease (Robertson 2005).  
Epigenetic modifications are dependent upon some change in chromatin structure which 
defines how genetic information is organised within a cell.  Chromatin is made up of 
nucleosomes which consist of ~146 base pairs of DNA wrapped around an octamer of four 
core histone proteins (H3, H4, H2A and H2B) (Luger et al.,  1997). The epigenetic processes 
which modify chromatin structure include: DNA methylation, covalent histone modifications, 
non-covalent mechanisms (nucleosome remodelling) and microRNAs.  Co-operation between 
       
these processes regulates the accessibility and compactness of chromatin, and in so doing 
modulate gene expression. 
 
1.2.1 DNA methylation 
Methylation is the only known epigenetic modification of DNA. Methylation is carried out by 
DNA methyltransferases (DNMTs) using S-adenosyl-methionine (SAM) as the methyl donor 
(Herman and Baylin 2003) (Figure 1.1).  In mammals, methylation primarily occurs at the 
carbon-5 position of cytosine residues within CpG dinucleotides. CpG dinucleotides are not 
evenly distributed across the genome but are instead found clustered in CpG rich DNA 
stretches called CpG islands and in repetitive sequences such as centromeric repeats, 
retrotransposon elements and rDNA. CpG islands are defined as regions 500 bp in length with 
a G+C content greater than 55% (Takai and Jones 2002).  There are around 30000 CpG 
islands in the human genome; these are generally associated with the 5’ end of genes and are 
found in ~60% of human gene promoters and first exons.  Whereas the majority of CpG sites 
throughout the genome are methylated, CpG islands remain unmethylated in the majority of 
promoters (Illington and Bird 2009).  
 
 
 
 
 
       
 
Figure 1.1: DNA cytosine methylation at ring carbon C5.  Methylation of cytosine within 
CpG dinucleotides is conducted by the methyltransferases that use S-adenosyl-L-methionine 
as a donor of a methyl group (Diagram adapted from Herman and Baylin 2003). 
 
 
Figure 1.2: Structure of the known DNMT proteins.  DNMT1, DNMT3A and DNMT3B 
can be divided into two domains, regulatory and catalytic. Conserved motifs (roman 
numerals) involved in catalysis are indicated with black boxes. Other structural features such 
as the replication foci targeting domain and zinc binding region are also indicated (Diagram 
from Robertson 2001). 
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1.2.2 DNA methylation in normal cells 
DNA methylation is essential for the normal function and development of mammalian cells.    
It is a stable modification that is inherited through cell divisions allowing daughter cells to 
retain the same expression patterns as the parent cell, a process that is particularly important 
for genomic imprinting and X chromosome inactivation in females (Bird 2002).  In somatic 
cells, changes in the pattern of DNA methylation first contribute to embryonic development, 
and then at a later stage to lineage specificity and terminal differentiation (Santos et al., 
2002). DNA methylation also ensures silencing of transposons and other parasitic elements 
that have been acquired by the genome over time, and which were they to be activated, would 
be detrimental to the cell (Reik 2007).  
The distribution of methylation changes in normal cell backgrounds is now being investigated 
using genome wide methylation arrays (Rauch et al., 2009; Yang et al., 2010). A global 
explanation as to why some genes are methylation targets, whereas others are not, has yet to 
be provided. This is one of the issues addressed in my thesis in the context of germinal centre 
(GC) B cells infected with EBV. 
 
 
 
 
 
 
 
 
 
       
1.3 DNA methyltransferases 
The mammalian DNA methyltransferase (DNMT) family which comprises DNMT1, 
DNMT3A and DNMT3B together with the accessory protein DNMT3L are responsible for 
the regulation of DNA methylation in all cell types (Figure 1.2).  The DNMTs can be divided 
into two groups, the maintenance methylation enzyme (DNMT1), and the de novo 
methylation enzymes (DNMT3A and DNMT3B) (Robertson 2001).   DNMT2, a protein that 
was originally identified as a DNMT has a highly similar sequence and structure to that of the 
other DNMTs and is responsible for the methylation of cytosine 38 in the anticodon loop of 
tRNAASP; however, it has little or no DNA methyltransferase activity (Schaefer et al., 2010).   
 
1.3.1 DNMT1 
DNMT1 is a 183kD protein responsible for the maintenance of methylation during replication 
and repair.  In vitro, it has been shown to have a preference for hemi-methylated DNA over 
unmethylated substrates thus allowing it to copy the methylation pattern of the parental strand 
to the newly synthesized daughter strand (Jeltsch 2006).  Even though it is referred to as the 
“maintenance” enzyme, there is increasing evidence that DNMT1 may also be involved in de 
novo methylation. For example, DNMT1 induced de novo methylation of CpG islands has 
been observed in human colon cancer cells (Jair et al., 2006).  DNMT1 is essential for 
maintaining epidermal progenitor cell function and its loss leads to premature differentiation 
(Sen et al., 2010).  Two fully functional isoforms of DNMT1 exist. The longer form is found 
in somatic and embryonic stem (ES) cells, and the shorter form in oocytes and pre-
implantation embryos (Gaudet et al., 1998).  DNMT1 has been shown to be essential for cell 
survival (Egger et al., 2006) and mutation of DNMT1 results in genome wide 
hypomethylation and embryonic lethality in mice (Li et al., 1992). DNMT1 also seems to be 
       
essential for the viability of cancer cells, for example, knockout of this enzyme results in 
HCT116 cell death (Chen et al., 2007).  In many cancers, for example, cervical cancer 
(Sawada et al., 2007), hepatocellular carcinomas (Saito et al., 2003) and stomach cancer 
(Etoh et al., 2004), DNMT1 is over-expressed. However, down-regulation of DNMT1 may 
also contribute to carcinogenesis by causing hypomethylation.  For example introduction of a 
hypomorphic allele of DNMT1 in mice has been shown to cause genomic hypomethylation 
along with the accelerated development of sarcomas (Eden et al., 2003), and the carcinogenic 
agent cadmium, causes down-regulation of DNMT1 in a mouse testicular cell line (Singh et 
al., 2009).  
 
1.3.2 DNMT3 family 
DNTM3A and DNMT3B are the active de novo methyltransferases responsible for cytosine 
methylation at previously unmethylated CpG sites.  Both enzymes have a conserved PWWP 
domain responsible for their methyltransferase activity.    
DNMT3A and DNMT3B can act independently of one another. For example, DNMT3B but 
not DNMT3A, has been shown to be responsible for the methylation of centromeric minor 
satellite repeats (Okano et al., 1999).  DNMT3A, but not DNMT3B, can restore methylation 
of the imprinted genes, XIST and H19 (Chen et al., 2003).  Although both enzymes are 
essential for male gametogenesis, they are uniquely responsible for methylation at different 
stages of this process (Turek-Plewa and Jagodzinski 2005).   
On the other hand, there are circumstances in which the methylation of cellular genes is 
dependent on the contemporaneous binding of both DNMTA and DNTM3B to the same 
sequence (Chen et al., 2003).  For example, deletion of both DNMT3A and DNMT3B 
       
catalytic domains is followed at certain loci by loss of methylation; this loss does not occur 
when the catalytic domain is deleted from only one of these enzymes (Okano et al., 1999). 
Although we know both DNMT3A and DNMT3B are localized to the nucleus, it is still 
unclear whether their activity is dependent on specific DNA target sequences (Jones and 
Liang 2009). Mechanisms that trigger de novo methylation are also unknown.  One possibility 
is that these enzymes are recruited by its PWWP domain to target genes; another, that their 
recruitment is dependent on binding to transcriptional factors such as MYC which has been 
shown to interact with DNMT3A leading to the repression of CDKN1A. It has also been 
suggested that RNAi systems may be involved in the targeting of the DNMTs but as yet this 
mechanism has not been fully defined (Klose and Bird 2006). 
 
1.3.2.1 DNMT3A 
The DNMT3A gene is located on chromosome 2p23 and the protein is found in both the 
cytoplasm and nucleus where its expression is developmentally regulated.  Alternative 
splicing of DNMT3A results in multiple transcript variants that encode four different 
isoforms. The DNA binding domain in DNMT3A is 50 residues long, the protein can 
dimerize, thus doubling the DNA binding surface and allowing it to methylate in one binding 
event, two CpGs separated by one helical turn (Klimasauskas et al., 1994).  DNMT3A is 
expressed at low levels in somatic cells, and at high levels in embryonal stem cells.  
Knockdown of DNMT3A inhibits melanoma growth and metastasis in mouse melanoma 
models suggesting that it may have an essential role in the pathogenesis of this tumour (Deng 
et al., 2009).  
1.3.2.2 DNMT3B 
       
The DNMT3B gene is located on chromosome 20q11.2. Six alternatively spliced transcript 
variants have been described although the full length sequences of variants 4 and 5 have not 
been determined.  DNMT3B over-expression has been reported in breast cancer (Butcher and 
Rodenhiser 2007) and in colorectal cancer (Kanai et al., 2001), and an increased risk of 
cancer at several sites has been associated with a polymorphism in this enzyme (Hu et al., 
2010). 
Immunodeficiency, centromere instability and facial anomalies syndrome (ICF) is 
characterised by and is associated with point mutations in DNMT3B (Hansen et al., 1999).  
DNA hypomethylation of pericentromeric heterochromatin is characteristic of the ICF 
syndrome.  Commonly demethylated regions include satellite 2 and 3 repeats, cancer testes 
antigens and the inactive X chromosome (Jin et al., 2008).  A comparison of LCLs derived 
from healthy patients and those derived from patients with ICF syndrome has led to the 
identification of 800 genes which are potential DNMT3B targets.  This study also suggested a 
possible interaction between the DNA and histone methylation systems.  In ICF LCLs, loss of 
DNMT3B expression was associated with loss of H3K27me3, and reduced binding of a 
polycomb protein, SUZ12, to de-repressed genes (Jin et al., 2008).   
 
 
 
 
 
1.3.2.3 DNMT3L 
DNMT3L lacks those residues in the C-terminal domain which are required for 
methyltransferase activity and its contribution to DNA methylation is dependent on its 
       
cooperation with the de novo DNMTs. DNMT3L has been shown to colocalize and co-
immunoprecipitate with DNTM3A and DNMT3B (Hata et al., 2002), and to enhance the 
activity of both enzymes (Kareta et al., 2006; Suetake et al., 2004).  Disruption of DNMT3L 
in mice results in the failure to establish maternal methylation imprints (Bourc’his et al., 
2001).   
 
1.4 DNA demethylation 
Although it has yet to be established as to whether demethylation of DNA regulatory 
sequences occurs in a passive or active manner, various proteins have been suggested as 
possible DNA demethylases. One early candidate, MBD2 (Zhang et al., 1999) was dismissed 
when Hendrich et al., 2001 discovered that mice lacking MBD2 had normal patterns of DNA 
methylation and a normal phenotype.  Although Barreto et al., 2007 suggested that GADD45a 
might be a DNA demethylase, Jin et al., 2008 could not confirm this.  However, there is 
evidence for DNA demethylases in plants where it has been shown that lack of ROS1, DML2 
and DML3 leads to the accumulation of methylated cytosines (Zheng et al., 2008).  More 
recently it has been suggested that DNMT3A and DNMT3B might initiate DNA 
demethylation (Metivier et al., 2008; Kangaspeska et al., 2008).  Both studies suggest that 
DNMT3A and DNMT3B are involved in a dynamic cyclical recruitment of methylation to the 
promoters of oestrogen receptor target genes.   
 
 
 
 
 
       
1.5 DNA methylation and regulation of transcription 
DNA methylation, histone modifications and chromatin remodelling all contribute to the 
regulation of gene expression. This regulation is mediated by changes in chromatin state 
which can either be “open and active” or “closed and silent” depending on the interactions 
between transcription factors, cis-acting elements, and epigenetic modifications of the DNA 
sequence. In this thesis, I will focus on how changes in virus induced DNA methylation 
modulate changes in gene expression and therefore I now discuss in some detail the 
mechanisms which potentially regulate these changes.  
 
1.5.1 Mechanisms of DNA methylation induced transcriptional change 
In general, hypermethylation has been associated with gene repression and a closed chromatin 
structure, whereas hypomethylation has been associated with an open or loose chromatin 
structure resulting in gene activation.  A number of mechanisms have been suggested to 
explain how the presence or absence of methyl groups can modulate gene expression (Bird et 
al., 2002). 
First, it has been suggested that the binding of transcription factors to gene promoters may 
prevent the addition of methyl groups, for example E2F, AP-2, c-myc, CREB/ATF and NF-
kB have all been shown to bind unmethylated promoters but not methylated sequences. 
Consistent with these observations, Gebhard et al., 2010 found that CpG islands that remain 
unmethylated in normal and in malignant cells contain specific sequence motifs that are 
identical to the consensus sequence for general TFs.  These investigators went on to show that 
when these sites were stably bound by TFs in normal cells they are highly resistant to de novo 
methylation. Genes marked by methylation of histone H3 lysine 4 (H3K4) are usually 
transcriptionally active, and it has been suggested that this histone mark can also protect gene 
       
promoters from de novo DNA methylation (Weber et al., 2007; Appanah et al., 2007).  
However, DNA methylation may not always act as a barrier, the viral transcription factor, 
BZLF1, preferentially binds methylated CpGs (Bhende et al., 2004).   
The transcriptional silencing of methylated genes has also been attributed to the activity of the 
methyl-binding proteins.  Complexes which include either the methyl-CpG-binding protein 1 
(MECP1) or MECP2 and one or more of the methyl binding domain proteins (MBD1, MBD2, 
MBD3, MBD4 and KAISO), have been shown to bind preferentially to methylated DNA and 
to inhibit transcription (Nan et al., 1993).  The binding of these complexes either limits access 
to transcription factors or results in the recruitment of transcriptional repressors or repressive 
complexes such as histone deacetylase complexes, chromatin remodelling complexes, or 
polycomb proteins (Wade 2001).    More recently, the zinc finger and BTB domain containing 
proteins, ZBTB4 and ZBTB38, have been shown to repress transcription in a methylation 
dependent manner (Sasai and defossez 2009; Filion et al., 2006).   
A third model suggests that the impact of DNA methylation on gene expression may be 
mediated by changes to the nucleosome. For example, DNA methylation may result in a 
change in nucleosome positioning which may in turn result in a change in gene expression 
(Kass et al., 1997).  Alternatively, incorporation into the nucleosome of histone variants such 
as H3.3 and H2A.Z may prevent DNA methylation (Zilberman et al., 2008). 
 
 
 
 
 
 
       
1.6 Contribution of DNA methylation changes to carcinogenesis 
Both increased DNA methylation and global reductions in DNA methylation are early 
epigenetic change contributing to carcinogenesis. I now briefly describe the evidence linking 
these changes to carcinogenesis before discussing how epigenetic therapy might be used in 
the treatment of malignancy. 
 
1.6.1 Methylation changes in cancer 
Although increased methylation at certain CpG islands has been observed in almost all 
cancers, global levels of DNA methylation have been shown to decrease with tumour 
progression (Feinberg and Vogelstein 1983; Laird 2005). Cancer cells have 20-60% less 
methylation than their normal counterparts (Esteller et al., 2005) and this loss is consistently 
found in repetitive elements and in the introns of genes. Loss of methylation may contribute 
to tumourigenesis in several ways: loss of imprinting (Sakatani et al., 2005); generation of 
chromosomal instability (Eden et al., 2003; Daskalos et al., 2009); reactivation of transposons 
(Bestor 2005); and reactivation of normally methylated oncogenes (Kim et al., 2006; Honda 
et al., 2004)  
Hypermethylation of CpG islands and the associated silencing of tumour suppressor genes 
(TSG) have been found in both the early and late stages of tumourigenesis. The list of TSGs 
known to be methylated in cancer is now substantial but no single gene has been identified 
which is always methylated in cancer (Sharma et al., 2010). Epigenetic silencing of tumour 
suppressor genes can lead to tumour initiation either by providing the second hit in the 
Knudson’s “two-hit” model (Jones and Laird 1999) or through the silencing of both alleles.  
As to why some genes are hypermethylated in cancer and others not is unclear.  However, it 
has been reported that  regions which are hypermethylated in cancer are significantly more 
       
likely to be marked by H3K27me3 in human embryonic stem cells (Ohm et al., 2007; 
Schlesinger et al., 2007; Widschwendter et al., 2007) suggesting that the permanent silencing 
of these developmental genes may be important in tumourigenesis.   
 
1.6.2 The use of epigenetic agents in the treatment of cancer 
Unlike genetic aberrations, epigenetic changes are potentially reversible following therapeutic 
intervention. To date, the most commonly studied intervention has been the use of DNMT 
inhibitors. A number of these are now being tested in cancer.  5-azacytidine (azacitidine) and 
5-aza-2’-deoxycytidine (decitabine) have been approved by the US food and Drug 
Administration (FDA) for the treatment of myelodysplastic syndrome. However, the toxicity 
associated with these drugs is not trivial. 1-(Beta-d-ribofuranosyl)-1,2-dihydropyrimidin-2-
one (zebularine) may be a more effective anticancer drug as it appears to be more selective for 
cancer cells (Kantarjian et al., 2003).  All of these drugs act as a substrate for the DNMT 
enzymes and their use is associated with a global decrease in DNA methylation as a result of 
the passive demethylation of the genome which occurs after each round of cell division (Tao 
and Robertson 2003).   However, when these different demethylating agents were used to 
“treat” an acute myeloid leukaemia cell line, they were found to have different effects on its 
transcriptional profile (Flotho et al., 2009).    
 
 
 
 
 
 
       
1.7 Arginine methylation 
Histone proteins are susceptible to methylation, acetylation, ubiquitylation, sumoylation and 
phosphorylation on residues protruding from the N-terminal tail.  The transcriptional 
consequences of these changes are dependent on the residue modified and the nature of the 
modification.  For example, trimethylation of lysine 4 on histone H3 (H3K4me3) is associated 
with the activation of gene promoters (Liang et al., 2004), whereas trimethylation of H3K9 
and H3K27 is associated with transcriptional repression (Kouzarides 2007).   
In this thesis I will focus on one particular histone modification, post-translational arginine 
methylation.  Post-translational arginine methylation is important for regulating cellular 
processes such as signalling, gene transcription, mRNA splicing and DNA repair (Bedford 
and Clarke 2009).  Nine protein arginine methyltransferases (PRMTs) have been identified in 
humans.  PRMTs methylate and regulate not only transcription factors (TF) but also co-
regulators and histones.  Examples of TF regulated directly by PRMTs include p53, NF-κB, 
and RUNX1 (Zhao et al., 2008).  Co-regulators modulated by the PRMTs include p300 and 
CBP. PRMTs can also methylate histone tails and in so doing directly regulate gene 
expression.  
Protein arginine methylation is also important in the replication of oncogenic viruses and for 
the transcriptional activation and stabilisation of viral proteins. Both PRMT1 and PRMT5 
bind to the EBV protein EBNA1 which is important for the replication and mitotic 
segregation of viral genomes, and which is re-localised following inhibition of PRMT1 (Shire 
et al., 2006).  Arginine dimethylation of another EBV oncoprotein, EBNA2, is necessary for 
its efficient association with DNA bound transcription factors and with other viral promoters 
(Gross et al., 2010). These examples illustrate how viruses can exploit the cell’s arginine 
methylation machinery.  However, with the exception of the Scophthalmus maximus 
       
rhabdovirus which has been shown to up-regulate a fish PRMT1, virus-induced de-regulation 
of the PRMT has not been reported.  I now describe in some detail three PRMTs (PRMT1, 
PRMT5 and CARM1) which are considered further in this thesis. 
 
1.7.1 PRMT1 
PRMT1, an 80 kDA protein, is the most abundant of the PRMTs and has been shown to be 
responsible for up to 85% of the total arginine methylation activity in RAT1 fibroblast cells 
and in mouse liver (Tang et al., 2000).   PRMT1 regulates gene transcription by methylating 
histone 4 and also Spt5, a transcriptional elongator which interacts with RNA polymerase II 
(Zhang and Chen 2003). The regulation of gene transcription by PRMT1 is sometimes 
dependant on its co-operation with other PRMTs (Kleinschmidt et al., 2008). For example, 
both CARM1 and PRMT1 are necessary for steroid hormone receptor-mediated reporter gene 
activation (Bedford and Richard 2005).  Whereas, knockdown of both CARM1 or PRMT1 
has been shown to result in the down-regulation of STAT5-controlled genes, knockdown of 
only one of these genes had no effect (Kleinshmidt et al., 2008).  
 
1.7.2 CARM1 
CARM1, also known as PRMT4, has restricted substrate specificity (Lee and Bedford 2002).  
CARM1 recruitment to transcriptional promoters results in elevated levels of methylation on 
the 17th and 26th arginine residues of histone 3 (H3R17 and H3R26, respectively); both of 
these methylation marks are associated with transcriptional activation.  In addition to the 
methylation of histones, CARM1 also methylates other transcriptional co-activators for 
example, SNRPB, a small nuclear protein involved in pre- mRNA splicing (Cheng et al., 
2007).   
       
 
1.7.3 PRMT5 
PRMT5 functions in several nuclear and cytoplasmic complexes.  It plays an important role in 
the control and modulation of gene transcription, regulating for example, the expression of 
IL2 and CCNE1 (Richard et al., 2005; Fabbrizio et al., 2002).  Homozygous PRMT5 
deletions in mice lead to death of zygotes (Krause et al., 2007).  PRMT5 can act as a 
transcriptional co-activator or co-repressor. For example, it acts as a transcriptional co 
repressor when bound to COPR5, a histone binding protein; this complex preferentially 
methylates specific arginine residues on histone 4 (Lacroix et al., 2008). Alternatively, 
PRMT5 can act as a co-activator when it binds to the SWI/SNF family (Pal et al., 2003, 
Dacwag et al., 2007). PRMT5 has also been shown to repress PRDM1, the master regulator of 
B cell differentiation (Ancelin et al., 2006). 
 
1.7.4 Links between PRMT and DNA methylation  
Recently a link between the PRMTs and DNA methylation has been established.  It has been 
demonstrated that the symmetric di-methylation of histone H4 arginine 3 (H4R3me2s) by 
PRMT5 is required for the subsequent DNA methylation of the human β-globulin locus (Zhao 
et al., 2009).  The investigators concluded that DNMT3A was responsible for this methylation 
event as knockdown of PRMT5 led to a reduction in DNMT3A binding, loss of DNA 
methylation and gene activation.   
 
 
 
 
       
1.8 Epstein-Barr virus  
EBV, the first DNA tumour virus to be discovered, is a member of the family Herpesviridae.  
Although more than 130 herpesviruses have been identified, only eight have been isolated 
from humans and are divided into three subfamilies, the Alphaherpesvirinae, the 
Betaherpesvirinae and the Gammaherpesvirinae (Table 1.1).   
 
 
Herpes sub-
family Type Disease 
Herpes simplex virus-1 Recurrent facial herpetic lesions 
Herpes simplex virus-2 Recurrent genital herpetic lesions 
Alpha 
Varicella-zoster virus 
Chicken pox (primary) 
Shingles (reactivation) 
Human cytomegalovirus Typically asymptomatic but can be a complication in immunosuppressed patients 
Human herpes virus-6 Mild childhood roseola 
Beta 
Human herpes virus-7 Mild childhood roseola 
 
Epstein-Barr virus 
Asymptomatic 
Infectious mononucleosis 
Associated with a subset of cancers Gamma 
Kaposi sarcoma 
associated herpesvirus Associated with a subset of cancers 
 
 
 
 
 
 
 
 
Table 1.1: The human herpesviruses 
       
 
All herpesviruses share four biological properties: 
• they use a large number of enzymes for protein processing and DNA synthesis 
• the production of progeny virus destroys the infected cell 
• synthesis of viral DNA occurs in the nucleus  
• each is able to establish a latent life-time infection in their natural host. 
 
Although they share these biological properties they differ in terms of their genomes.  In 
particular, their nucleotide composition varies considerably, for example, HHV-6 has a G+C 
content of 43%, HSV-1 of 68% and EBV of 60% (Weir 1998).   They also differ in terms of 
CpG methylation which is believed to be related to the location of virus replication (Weir 
1998). The alphaherpesviruses, which establish latency in non-dividing neuronal cells lack 
CpG methylation, they do not undergo replication and methylation as a result of cell division 
(Dressler et al., 1987).  The betaherpesviruses exhibit a local CpG methylation over the major 
immediate early region. The specific CpG suppression observed in the major immediate-early 
region of the betaherpesviruses is not yet understood, but may be the result of localized 
exposure of this region to methylases during latency (Gompels et al., 1995).  Finally, EBV 
and other gammaherpesviruses that are maintained as episomes in proliferating 
lymphoblastoid cells may be routinely methylated by host cell enzymes during multiple cell 
divisions, which may aid in allowing the virus to go undetected by the immune system (Tao 
and Robertson 2003, Gunther and Grundhoff 2010). 
 
Only two members within the gamma herpesvirus subfamily infect humans, EBV and 
Kaposi’s sarcoma-associated herpesvirus (KSHV), both have been linked to human 
       
malignancy.  Within the gamma herpesviruses, EBV belongs to the Lymphocryptovirus 
(LCV) genus, members of which display lymphoid cell tropism and are oncogenic.  An EBV-
related virus has also been isolated from the spontaneous B cell lymphomas arising in 
common marmosets.  This virus termed marmoset LCV or Callitrichine herpesvirus 3 was 
first identified in animals with spontaneous B cell lymphomas at the Wisconsin National 
Primate Research Center. Subsequent work has revealed that 40-60% of captive marmosets 
are seropositive for this virus with most animals not revealing overt signs of clinical disease. 
Definition of the viral gene repertoire revealed collinear genomic organization and 60 open 
reading frames with homology to those seen in EBV and other primate LCVs (Rivailler et al., 
2002).  However, whether this virus is subject to methylation similar to EBV is still unknown. 
 
1.8.1 Virus structure 
EBV has a toroid-shaped protein core which is wrapped in DNA and surrounded by a 
nucleocapsid consisting of 162 capsomeres.  The nucleocapsid is found inside a protein 
tegument located between an inner and an outer envelope from which project external 
glycoproteins (Kieff and Rickinson 2001). The EBV genome is composed of linear double 
stranded DNA, approximately 184 kilobase pairs (kbp) in length.  As the EBV genome was 
sequenced from a BamHI fragment library, its genes, their promoters, open reading frames, 
and polyadenylation sites are defined by their position on the BamHI restriction fragment map 
and named in a descending order of size, with A being the largest (Figure 1.3). 
 
 
 
 
       
 
 
 
 
 
 
 
 
Figure 1.3 The EBV genome. A. Diagram showing the location of open reading frames for 
the EBV latent proteins on a BamHI restriction endonuclease map of the prototype B95.8 
EBV genome. B. Diagram showing the location and transcription of the EBV latent genes on 
the double-stranded viral DNA episome. The origin of plasmid replication (oriP) and lytic 
replication (ori lyt) are shown in orange. The large solid blocks (in purple) represent coding 
exons for each of the latent proteins and the arrows indicate the direction in which they are 
transcribed (modified from Young and Murray 2003). 
A 
B 
       
 
 
 
1.8.2 Repeat regions of the EBV genome 
The EBV genome is characterised by tandem reiterated 0.5 kbp repeat sequences which are 
called terminal repeats (TRs), and which are located at both ends of a linear genome (Figure 
1.3).  Fusion of these TRs following EBV infection of B cells results in the circularisation of 
viral DNA and the formation of a closed episome (Kintner and Sugden 1979).  Quantitation of 
TRs can be used to determine the clonality of EBV infected cell populations because different 
infectious events will give rise to latent episomes with varying numbers of TRs which remain 
constant in each subsequent generation (Given et al., 1979).  Also within the EBV genome is 
a large tandem repeat region known as the major internal repeat 1, IR1; this region comprises 
numerous repeats of a 3072bp BamHI W region containing one of the EBNA promoters, Wp.  
The number of tandem repeats within IR1 varies among EBV strains and their progeny (Allan 
and Rowe 1989); for example, the prototype B95.8 EBV genome has 11 of these repeats as 
shown in the linear map in Figure 1.3a.   
 
1.8.3 EBV strains 
EBV isolates can be classified into two distinct families, types 1 and 2 (these were once 
referred to as type A (B95.8-like) and type B (AG876-like). The difference between the two 
types is based on variations in the sequence of their EBV nuclear antigens, EBNA2, EBNA3 
and EBNA-leader protein (EBNA-LP) (Sample et al., 1990).  The most common EBV strain 
is type1, with type 2 found mainly in equatorial Africa or in people infected with human 
immunodeficiency virus (HIV) (Falk et al., 1997). 
       
 
 
 
1.8.4 Virus binding, entry and circularisation 
In vitro studies have shown that early in the course of primary infection, EBV infects B cells 
by binding the CD21 receptor which is expressed almost exclusively in B lymphocytes.  Two 
interactions, one between the viral glycoprotein gp 350/220 and CD21, and another, between 
the viral envelope protein complex gp42/gH/gL and the major histocompatability complex 
(MHC) class II molecules, allow EBV to attach to and to penetrate B cells (Molesworth et al., 
2000).  Following endocytosis of the virus into the host cell, the genome circularises to 
produce the covalently closed extrachromosomal episome characteristic of latently infected 
cells (Figure 1.5B). Episomes are maintained by the host cell DNA polymerase which 
replicates EBV episomes once per cycle in early S phase (Adams 1987). Amplification of the 
viral genome occurs early after transformation and latently infected cells harbour numerous 
viral episomes in their nucleus (Kinter and Sugden 1979).  
 
 
 
 
 
 
 
 
 
       
1.9 Primary EBV infection 
EBV infects approximately 95% of the world’s adult population.  The virus has at least two 
potential target cells, B-cells and oropharyngeal epithelial cells. As EBV is transmitted orally, 
the oropharynx is normally the primary site of infection but whether the primary target is a B 
cell or an epithelial cell is unknown.  Children who become infected with EBV are generally 
asymptomatic or show vague symptoms indistinguishable from those associated with other 
childhood illnesses. If infection occurs in adolescence or adulthood it may cause infectious 
mononucleosis (IM) which is characterised by sore throat, fever and fatigue.  In IM, virus 
induced activation of B cells results in the enlargement and ulceration of the tonsils.  
Following primary infection, EBV persists in the infected host as a lifelong asymptomatic 
infection.   To achieve life-long persistence, EBV colonises the B cell pool where it 
establishes a latent infection which is characterised by the expression of a limited subset of 
virus genes known as “latent” genes (Thorley-Lawson 2001).  I next describe each of these 
viral latent genes before commenting on the latent states with which they are associated. 
 
 
 
 
 
 
 
 
1.10 Latency  
       
In its different latent states, EBV produces a limited number of “latent proteins” which 
include the EBV nuclear antigens EBNA1, 2, 3A, 3B, 3C and LP; the latent membrane 
proteins (LMP)1, 2A and 2B;  the BamHI A RNA, BARF1; the EBV-encoded RNAs, EBER 
1 and EBER 2; and BART RNA transcripts.  EBV also codes for at least 23 miRNAs that are 
expressed in latently infected cells (Yun Zhu et al., 2009).  The contribution of each of the 
latent genes to viral maintenance and transformation is shown in Table 1.1. 
 
1.10.1 Latency states during viral persistence in vivo 
EBV persists within the B cell compartment in four different latent states dependent on the 
stage of B cell development. In each of these four latency states, “Latency 0”, “Latency I”, 
“Latency II” and “Latency III” a different pattern of viral gene expression is observed.  Initial 
infection of B cells with EBV activates the Latency III transformation program during which 
all of the EBV-latent genes are expressed. This pattern of gene expression is found in most 
cases of Post Transplant Lymphoproliferative disease (PTLD). Following the activation of the 
growth transcription program, the cells migrate to the germinal centre (GC) where they 
continue to proliferate and mature but fail to expand in numbers (Roughan et al., 2010).  
Here, these cells express the Latency II genes, the EBERs, BARTs, EBNA1, LMP1 and 
LMP2; this pattern is also seen in Hodgkin’s lymphoma (HL) and in nasopharyngeal 
carcinoma (NPC) (Young et al., 1988).  In response to survival signals, these cells exit the GC 
as resting memory B cells where they do not express any EBV proteins (Latency 0). When 
resting memory cells divide the Latency I genes, the EBERs, BARTs and EBNA are 
expressed, a pattern also seen in Burkitt’s lymphoma (BL) (Rowe et al., 1987). These cells 
eventually return to the tonsil where they may undergo plasma cell differentiation which can 
       
trigger viral replication. The virus is then either shed from the host through saliva, or it can re-
infect other B cells, or both (Figure 1.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EBNA1 EBNA1 is required for the replication and maintenance of the episomal genome (Lee et al., 1999). 
EBNA2 
EBNA2 plays a key role in B-cell growth transformation by initiating and 
maintaining the proliferation of infected B-cells upon EBV infection in 
vitro. (Skare et al., 1985; Farrell et al., 2004). 
EBNA3 
family 
In vitro studies with EBV recombinants have demonstrated that EBNA3A 
and EBNA3C (Tomkinson et al., 1993) are essential for B-cell 
transformation, whereas EBNA3B is not (Tomkinson and Kieff, 1992). 
EBNA-LP This protein is not essential for B cell transformation in vitro but is required for the outgrowth of LCLs (Allan et al., 1992). 
LMP1 LMP1 behaves as a classical oncogene and is essential for B cell transformation in vitro (Kaye et al., 1993). It is also responsible for the 
       
activation of at least four signalling pathways; the nuclear factor-kappa B 
(NF-κB) pathway (Huen et al., 1995); the c-Jun N-terminal kinase 
(JNK)/activator protein (AP)-1 pathway (Kieser et al., 1997); the 
p38/mitogen-activated protein kinase (MAPK) pathway (Roberts and 
Cooper, 1998); and the JAK/STAT pathway (Gires  et al., 1999). 
LMP2 
The gene encoding LMP2 yields two distinct proteins LMP2A and LMP2B 
(Longnecker and Miller, 1996). Neither LMP2A nor LMP2B are essential 
for B-cell transformation in vitro (Longnecker, 2000).  LMP2A is capable 
of driving proliferation and survival of B cells in the absence of signalling 
through the BCR (Caldwell et al., 1998). 
BARF1 BARF1 acts as an oncogene (Hayes et al., 1999) but is dispensable for B-cell transformation (Cohen and Lekstrom 1999). 
EBERs 
The EBV-encoded RNAs, EBER 1 and 2 are expressed in all latency states. 
They are not essential for EBV-induced transformation but can enhance 
immortalisation of B lymphocytes (Yajima et al., 2005). 
BARTs The BARTs are a group of RNAs that may be involved in the maintenance of the latent state (van Beek et al., 2003). 
EBV-
encoded 
miRNAs 
EBV encodes 23 miRNAs identified to date (Grundhoff et al., 2006). These 
are arranged in two clusters in the EBV genome, one located in the introns 
of the BART gene, and the other adjacent to the BamHI fragment H 
rightward open reading frame 1 (BHRF1) gene. These miRNAs are thought 
to play a role in the regulation of gene expression (Cai et al., 2006; Pfeffer 
et al., 2004). 
 
Table 1.2: Latent genes:  The contribution of each of the latent genes to viral maintenance 
and transformation is described. 
 
       
 
Figure 1.4 The current model of viral infection and persistence: EBV enters the 
epithelium where it probably initiates a lytic infection. It may then spread to B-cells where it 
initiates a latency III transformation program. EBV-infected B-cell numbers are controlled by 
a latent-antigen-specific primary-T-cell response but a fraction of these cells down-regulate 
antigen expression to evade immune recognition. Activation of the growth transcription 
       
programme allows the cells to migrate to the GC where they activate a “default transcription 
programme” (Latency II).  Rescue or survival signals allow the cell to exit the GC as a resting 
memory cell and the “latency transcription programme” is initiated (Latency 0).  When these 
cells divide they express the Latency I programme of gene expression.  The cells eventually 
return to the tonsil where they may undergo plasma cell differentiation which can trigger viral 
replication. (Diagram from Thorley-Lawson and Allday 2008).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
1.11    Viral gene expression following primary infection in vitro 
EBV is the most effective transforming agent known for human cells in vitro, and infection of 
resting human B lymphocytes in culture consistently produces permanently proliferating 
lymphoblastoid cell lines (LCLs) (Henle et al., 1967).  These lines express the full range of 
latency III viral proteins causing B cells to enter the cell cycle and proliferate. Thereafter they 
undergo a change in their cellular phenotype and begin clumping together with the expression 
of adhesion molecules and activation markers (Alfieri et al., 1991).  In terms of their growth 
and expression of activation, adhesion and differentiation markers, these EBV transformed 
LCLs resemble uninfected B cells proliferating in response to antigen and T-cell help 
(Hollyoake et al., 1995). Although the majority of cells are in latency state III, a small 
proportion of cells enter the lytic cycle, producing virus particles (Kieff and Rickinson 2007).  
 
1.11.1     Promoter regulation of viral gene expression following primary infection in 
vitro 
The first viral promoter activated following infection of primary B cells with EBV is the 
BamHI W promoter, Wp, from which the transcripts for all six EBNAs are initiated. Although 
it is the first promoter to drive EBNA expression, this function is soon taken over by Cp, the 
dominant promoter in most LCLs (Schlager et al., 1996). Approximately 24 hours after in 
vitro infection of B-cells with EBV, the first viral genes are expressed - EBNA-LP and 
EBNA2 (Alfieri et al., 1991). Subsequently, EBNA2 transactivates LMP1, LMP2 and other 
cellular genes including CD21 and CD23, a B-lymphocyte activation antigen (Wang et al., 
1990). By 32 hours, all the EBNAs, and LMP1 are expressed and CD21 and CD23 are further 
up-regulated. The mechanism for the onset of LMP2A and LMP2B expression still remains 
unknown (Longnecker and Kieff, 1990).  In Latency I and II, EBNA1 is transcribed from the 
       
BamHI Q (Qp) promoter rather than Wp or Cp. The alternate use of promoters during 
different latency stages may provide the virus with a greater flexibility in controlling 
transcription. Understanding the virus’ strategy for persistence in vivo may help us understand 
more about EBV-associated diseases. 
 
1.11.2    DNA methylation of promoters regulating viral gene expression in vitro and in 
vivo 
Oncoviruses have developed different strategies for evading the host immune response, all of 
which are essentially aimed at camouflaging the virus in the host cell. By restricting the 
expression of certain viral genes and those associated with the immune response the virus can 
go undetected.  One mechanism by which this might be achieved is by DNA methylation. 
(Tao and Robertson 2003; Niller et al., 2008; Fernandez et al., 2009).  
DNA methylation and its involvement in the regulation of EBV latent promoters was first 
observed when latently EBV-infected human lymphoid lines were demethylated using 5-aza-
cytidine (Ben-Sasson and Klein 1981, Szyf et al., 1985).  This was followed by various 
methylation studies of EBV-positive BL cell lines (Allday et al., 1990, Ernberg et al., 1989, 
Jansson et al., 1992) and since then the methylation profile of specific viral genes has been 
extensively described (Fejer et al., 2008, Park et al., 2007; Paulson and Speck 1999; 
Ambinder et al., 1999; Takacs et al., 2010).  
Recently, a comprehensive methylation analysis of 94 transcriptional start sites of EBV was 
carried out on the EBV DNA methylomes from 22 different lymphoid samples; these included 
Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, Burkitt’s lymphoma primary tissue and cell 
lines, as well as LCLs (Fernandez et al., 2009).  This analysis revealed that only five 
promoters are consistently unmethylated in the genome; these include the Qp promoter and 
       
those regulating EBER1 and EBER2, BZLF1 and LMP2B/LMP1. This study concluded that 
the EBV genome is extensively methylated in the majority of lymphomas and primary 
tumours but not in cells from IM patients and from LCLs.  This study also revealed a 
functional association between viral methylation and transcription; the presence of 
hypermethylated EBV transcription start sites in cancer cells was associated with 
transcriptional silencing of neighbouring viral genes.   
 
1.11.2.1 Regulation of Wp 
The first evidence that DNA methylation was involved in the regulation of Wp was found 
when treatment of the BL line, Rael-BL with 5-aza-deoxycytidine resulted in the expression 
of all six EBNAs (Masucci et al., 1989).  Since then, Wp has been shown to be methylated in 
BL cell lines displaying Latency I form of infection (Tierney et al., 2000); the majority of 
EBV positive lymphomas (Fernandez et al., 2009); PTLD tumours; and in the B cells of acute 
IM patients (Tierney et al., 2000, Tao and Robertson 2003).  
Wp remains unmethylated in freshly established LCLs.  However, four weeks post infection 
Wp is methylated even though not all copies are silenced (Hutchings et al. 2006).  It is has 
been suggested that DNA methylation may interfere with Wp expression by blocking the 
binding of BSAP, a transcription factor that has been shown to contribute to Wp activity, 
(Tierney et al., 2000). 
 
 
1.11.2.2 Cp, Fp and Qp methylation  
Cp and Fp, (a promoter that mediates the expression of EBNA1) are unmethylated and active 
in LCLs, in PTLD and in B cells of acute IM patients (Tierney et al., 2000; Fernandez et al., 
       
2009), but hypermethylated and silent in NPC, HL, and BL (Fernandez et al., 2009; 
Robertson et al., 1996).  Qp has never been found to be methylated regardless of its 
transcriptional activity and is thought to be regulated by another epigenetic mechanism (Tao 
et al., 1998; Fernandez et al., 2009).  
 
1.11.2.3 LMP promoter methylation 
A number of observations suggest that LMP1 expression is regulated by methylation of its 
LRS promoter. In Latency I BLs and in NPC tumours where LMP1 is silent, the promoter is 
highly methylated. However in LMP1 expressing latency III cells and in all other lymphoma 
and primary tumours, the promoter is predominantly unmethylated (Minarovits et al., 1994, 
Falk et al., 1998, Salamon et al., 2001, Takacs et al., 2001, Fernandez et al., 2009).  The 
LMP2A promoter is methylated and inactive in the NPC cell line C-666.1 but remains 
unmethylated in LCLs and in the majority of lymphomas (Fernandez et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
       
1.12 Lytic EBV infection 
Completion of the EBV life-cycle is marked by the production of infectious virus. For this to 
happen, EBV must be reactivated from its latent state in B cells.  Lytic infection is initiated by 
the expression of BZLF1 and BRLF1, viral transactivator proteins which trigger the initiation 
of a generative replication cycle in which cellular RNA, DNA and protein synthesis are 
repressed and virus DNA synthesis takes over.  At the final stages of lytic cycle, icosahedral 
nucleocapsids are assembled, viruses are enveloped by budding out from the nuclear 
membrane, and the cell is lysed to release infectious enveloped virions containing linear 
genomes (Kieff and Rickinson 2007).  
 Lytic viral genes are expressed in three phases. The late (L) lytic genes are the last to be 
expressed 48-72 hours post-induction of the lytic cycle. EBV L lytic genes mostly code for 
structural proteins which can be grouped into glycoproteins and non-glycoproteins (Farina et 
al., 2005). The glycoprotein group includes BILF2, BDLF3, BALF4, BXLF2 and BLLF1; 
and the non-glycoprotein group includes BCLF1, BNRF1 and BXRF1.  The latter code for 
proteins of the nucleocapsid and tegument which form the major external virus component 
(Kieff and Rickinson 2007).   
The transcription of the early (E) lytic genes of which there are at least 30 mRNAs, is 
independent of cellular protein and viral DNA synthesis (Biggin et al., 1987). In early lytic 
infection, two abundant early nuclear proteins BMRF1 and BMLF1 are expressed (Wong and 
Levine, 1986), along with the BALF2 and BHRF1 early EBV proteins (Pearson et al., 1987). 
The immediate-early (IE) genes are the first lytic genes to be expressed and are now discussed 
in more detail because of their known regulation by methylation. 
 
 
       
1.12.1           IE lytic genes 
BZLF1 (Zta) and BRLF1 (Rta) are the IE lytic genes involved in initiating the switch from the 
latent state. Ectopic expression of BZLF1 alone has been shown to be sufficient to induce 
lytic cycle in vitro (Rooney et al., 1989 Kudoh et al., 2003). BZLF1 is a sequence specific 
DNA-binding protein which regulates the expression of viral and cellular genes by 
binding to Zta response elements (ZREs) found in their promoters (Heather et al., 2009; 
Flower et al., 2010). Whether BZLF1 binds to a ZRE or not depends on the methylation status 
of that ZRE; it will bind to some ZRE when they are unmethylated but only bind to others 
when they are methylated (Dickerson et al., 2009; Bhende et al., 2005; Karlsson et al., 2008). 
For example, BZLF1 binds to and activates the methylated form of the BRLF1 promoter more 
efficiently than it does the unmethylated form (Dickerson et al., 2009) 
Although BZLF1 is expressed very early following infection in the majority of primary B 
cells, it fails to induce the EBV lytic phase at this time. It now appears that for BZLF1 to 
activate the gene expression cascade leading to lytic infection, it must first bind to a number 
of viral promoters involved in that cascade. However, BZLF1 can only bind to these 
promoters which are likely to be downstream of BRLF1 after they have become methylated 
(Kalla et al., 2010) This  inevitably delays the onset of lytic infection because the viral 
genome is unmethylated when cells are first infected, and only becomes methylated over time, 
presumably following virus-induced activation of the cell’s DNA methylation machinery. To 
regulate its own life-cycle, EBV appears to have evolved a time-dependent epigenetic switch, 
one which can be tripped by host cell induced changes in the methylation status of viral 
promoters bound by BZFL1. However which of the host DNMTs binds to the BZLF1 
promoter has yet to be determined and is one of the objectives of this thesis. 
   
       
1.13 The impact of oncogenic viruses on the regulation of DNMTs 
and methylation of the cellular genome 
In this section, I first introduce those viruses which have been implicated in the aetiology and 
pathogenesis of human malignancy. I next briefly review the evidence implicating HBV, 
KSHV, HTLV-1 and HPV in the de-regulation of the DNMTs, and the impact of this de-
regulation on the viral and cellular epigenome. I then provide a brief description of the EBV 
associated malignancies and the contribution of EBV-associated methylation changes in 
cellular genes to the pathogenesis of these tumours.  Finally, I review the prospects for using 
methylation inhibitors in the management of these tumours.  
 
1.13.1 Introduction to oncogenic viruses 
In recent years an increasing number of human cancers have been shown to be virus 
associated and it has been suggested that viruses have a causal role in 15% of all cancers 
worldwide (Pisani et al., 1997).  Five virus families are associated with human cancers; 
Herpesviruses, Hepadnaviruses, Papillomaviruses, Flaviviruses and Retroviruses each of 
which is ubiquitous and capable of establishing persistent infection (Flanagan 2007). Not only 
may the establishment of persistent infections be dependent on epigenetic changes in the viral 
genome, oncogenic viruses can also cause aberrant DNA methylation and other epigenetic 
changes in cellular genes (Flanagan 2007, Ferrari et al., 2009).  
 
 
 
 
 
       
1.13.1.1 Hepatitis B virus 
HBV is a DNA virus associated with hepatocellular carcinoma. Although methylation of the 
HBV genome increases from early to late stages of carcinogenesis (Fernandez et al., 2009), 
that of the X gene, coding for the HBx protein, appears to remain unmethylated throughout 
the viral life cycle. HBX is responsible for the up-regulation of DNMT1 and DNMT3A and 
has been shown to cause the hypermethylation of the TSG, IGFBP3 (Park et al., 2007).  It has 
also been shown to interact with DNMT3A and to recruit it to the regulatory promoters of 
MT1F and IL4R which are then silenced.   
 
1.13.1.2 Kaposi’s sarcoma-associated herpesvirus 
KSHV, like EBV, is a persistent herpesvirus.  DNA methylation regulates the viral gene 
promoter ORF50, thus ensuring its repression during latency (Shamay et al., 2006).  The main 
transforming KSHV gene, latency-associated nuclear protein (LANA), is unmethylated 
throughout the viral life cycle (Chen et al., 2001) and has been shown to interact with a 
number of epigenetic regulators including the DNA methyl binding protein MeCP2, the 
mSin3 transcriptional repression complex and the histone methyltransferase SUV39H1, 
(Flanagan 2007). Like HBx, LANA can bind to and retarget DNMT3A.  It preferentially 
relocalizes DNMT3A from the nuclear matrix into the chromatin fraction (Shamay et al., 
2006) and   recruitment of de novo DNMTs by the virus has been shown to repress CDH13 
and TGF-β cellular promoters by DNA methylation (Shamay et al., 2006; Di Bartolo et al., 
2008).   
 
 
 
       
1.13.1.3 Human T-cell leukemia virus type 1 
HTLV-1 is a single stranded RNA retrovirus associated with adult T-cell leukemia (ATL).  
Tax, the main transforming protein of HTLV-1, controls viral gene expression through long 
terminal repeats (LTRs).  Several studies have found DNA hypermethylation of the 5’LTR is 
more frequent in ATL cells than in normal carriers (Taniguchi et al., 2005). However, it is 
unknown which of the DNMTs is responsible for these changes. 
 
1.13.1.4 Human papilloma virus (HPV) 
HPV is responsible for a variety of benign proliferations but infection with the high-risk 
mucosal HPV types, such as HPV16 and HPV18 cause squamous intraepithelial lesions of the 
cervix which may progress to invasive squamous cell carcinoma. Whereas both viruses are 
almost completely unmethylated in preimmortal keratinocytes, the viral genome in their 
immortal counterparts is densely methylated (Fernandez et al., 2009).  The virally encoded 
oncoprotein, E7 can associate directly in vitro and in vivo with DNMT1 through the E7 CR3 
zinc finger domain, leading to increased activity of the enzyme (Burgers et al., 2006). It has 
also been shown that HPV 16 and 18 infection up-regulates DNMT3B, and that this is 
associated with p16INK4a promoter hypermethylation. However, this association was only 
found in non-smoking lung cancer patients, and only then in females (Lin et al., 2005); the 
viral gene responsible for this remains to be elucidated. 
 
 
 
 
 
       
1.14 EBV-associated cancers 
In this section, I provide a brief summary of the EBV-associated cancers focusing in the main 
on HL. In EBV-associated malignancies, the virus is almost exclusively found in a latent 
state.  The pattern of virus latent gene expression depends upon the type of tumour and state 
of differentiation of the infected cell indicating that the contribution of EBV to carcinogenesis 
varies according to tumour type (Landais et al., 2005). Diseases such as PTLD and endemic 
BL, are nearly 100% EBV-positive, suggesting an essential role for EBV. Other neoplasms 
such as HL and gastric carcinoma are less frequently associated with EBV.  In these tumours, 
the contribution of EBV to malignant transformation may be replaced by other mutations in 
virus-negative disease.   
 
1.14.1 Nasopharyngeal carcinoma 
Nasopharyngeal carcinoma (NPC) is a tumour of the surface epithelium of the nasopharynx.  
NPC has a high incidence in China and many parts of Southeast Asia, intermediate in North 
and East Africa and a low incidence in the rest of the world (Epstein and Achong, 1979).  
There are  three forms of NPC: keratinizing squamous cell carcinoma (WHO1) and non-
keratinizing squamous cell carcinoma (WHO2/3) which is further divided into differentiated 
(WHO2) and undifferentiated (WHO3) ( Shah and Young 2009). Both WHO2 and WHO3 are 
associated with EBV; these tumours contain monoclonal viral genomes indicating that viral 
infection occurs before malignant expansion (Raab-Traub and Flynn 1986).    It has been 
suggested that genetic alterations in pre-malignant cells facilitate stable maintenance of latent 
EBV infection which when followed by other transforming events, can drive that clonal 
expansion of the cells necessary for tumour formation (Young and Rickenson 2004). Thus, in 
NPC, EBV may act as a tumour promoting agent rather than an initiating factor.  
       
EBV infection of human epithelial cells has been reported to be followed by the up-regulation 
of DNMT1, DNMT3B and DNMT3A. The EBV oncogene, LMP1, up-regulates DNMT1 in 
both un-transformed (MDCK) and transformed cells (NPC079) and has been shown to induce 
hypermethylation of the CDH1 tumour suppressor gene in both (Tsai et al., 2002).  The same 
group have also reported that the up-regulation of DNMT1 by LMP1 occurs through the c-Jun 
NH2-terminal kinase (JNK)-activator protein AP-1 signalling pathway (Tsai et al., 2006). In 
NPC cells, LMP1 induces promoter hypermethylation of RAR-beta2 via the up-regulation of 
DNMT1, DNMT3A, and DNMT3B, leading to a decrease in RAR-beta2 expression (Seo et 
al., 2008).    
 
1.14.2 Gastric carcinoma 
Approximately 10% of gastric cancers test positive for EBV. However, whereas the more 
common diffuse and intestinal types are rarely found to be EBV positive (< 10%), the less 
common lymphoepithelioma-type is found to be EBV positive in 90% of cases. EBV positive 
tumours are more common in women, in tumours of the gastric cardia, and in the stump 
remnant left after gastric surgery (Murphy 2009).  Monoclonal EBV is present in every 
malignant cell in virus positive disease implying that infection occurred prior to clonal 
expansion (Imai et al., 1994).   In gastric carcinoma cell lines, LMP2A was found to activate 
DNMT1 through the phosphorylation of STAT3, resulting in loss of PTEN expression 
following methylation of its promoter (Hino et al., 2009).  A number of studies have reported 
substantial and significant differences in the frequency in which TSG are differentially 
methylated in EBV-positive and EBV negative tumours. TSG methylation is significantly 
more common when EBV is present.  
 
       
1.14.3 Burkitt’s lymphoma  
Burkitt’s lymphoma (BL) is a lymphatic tumour that occurs in both endemic and sporadic 
forms.  The endemic form is associated with Plasmodium falciparium malaria (Morrow 1985) 
and is restricted to equatorial Africa; EBV is present in 95% of cases.  The sporadic form 
occurs 10 to 100 times less frequently and EBV is present in only 15% of cases (Magrath 
1990). BL is also common among adult HIV carriers in the developed world and often arises 
as the first AIDS-associated illness in relatively immunocompetent patients; 30-40% of these 
tumours are EBV-positive (Kieff and Rickinson, 2007). Irrespective of their EBV status, the 
phenotype of BL cells (CD10+, CD77+, BCL6+) is remarkably similar to that of GC 
centroblasts, and coupled with detection of ongoing Ig-gene mutation in tumour cells, these 
observations suggest that BL originate in GCs. A distinctive feature of BL is the presence of a 
reciprocal c-myc proto-oncogene translocation into the immunoglobulin regulatory elements 
on either chromosome 14 (the heavy chain locus), chromosome 22 or chromosome 2 (the light 
chain locus) (Manolov and Manolova 1972; Dalla-Favera et al., 1987; Klein 1983).  This 
translocation leads to over-expression of the c-myc protein contributing to the high rate of cell 
proliferation in BL tumours.   
 
 
 
1.14.4 Hodgkin’s lymphoma 
Hodgkin’s lymphoma is one of the most frequently occurring lymphomas in the Western 
world (Schmitz et al., 2009). There are two types of HL, lymphocyte predominant (LP-HL) 
and classical (c-HL). The latter is further divided into four subtypes: nodular sclerosis (NS); 
mixed cellularity (MC); and the rarer forms, lymphocyte rich (LR) and lymphocyte depleted 
       
(LD).  The presence of large malignant Hodgkin’s Reed-Sternberg (HRS) cells characterises 
classical HL.  This tumour is unusual, in that only 1-2% of the total tumour mass is made up 
of HRS cells, with the remainder comprising infiltrating non-neoplastic cells which include B 
cells, T cells, macrophages, neutrophils and eosinophils.  The malignant cells of LP-HL, 
lymphocytic and histocytic cells, differ immunophenotypically and morphologically from the 
malignant HR-S cells of c-HL; HR-S cells are generally multinucleated whereas L&H cells 
are typically mononuclear and small.  HR-S cells have an unusual immunophenotype.  They 
express markers of various haematopoietic cell lineages such as CD3, CD4 and CCL17 and 
show a global loss in their B cell phenotype characterised by the down-regulation of B-cell 
specific transcription factors such as Oct-2 and BOB1 (Kuppers 2009).   It is now believed 
that HR-S cells are derived from pre-apoptotic germinal-centre (GC) B cells. These cells have 
Ig VH and VL gene rearrangements which are restricted to B cells. In many cases, the Ig V-
region of the gene shows somatic hypermutations, an event that normally occurs in antigen 
stimulated mature B cells proliferating in GCs (Schmitz et al., 2009).   
An association between EBV and HL first emerged from serological studies that found 
elevated EBV antibody titres in HL patients (Levine Ablashi et al., 1971).  Subsequently, it 
was found that individuals who suffered from IM were at an increased risk of developing this 
disease (Gutensohn and Cole 1980).  This was followed by the discovery of monoclonal EBV 
genomes in HR-S cells (Weiss et al., 1989).  Approximately 50% of cases of HL test positive 
for EBV and it has been proposed that the virus may be responsible for the rescue of pre-
apoptotic cells since only EBV-positive cases of HL harbour crippled Ig gene rearrangements 
(Siemer et al., 2008).  In these cases BCR-deficient GC B cells may be rescued from 
apoptosis by EBV infection, possibly by LMP2A (Bechtel et al., 2005).  Further evidence 
supporting a role for EBV in the pathogenesis of HL is provided by observations from our 
       
laboratory, which showed that the major EBV oncogene LMP1 could induce in GC B cells, 
the presumptive progenitors of HL, the down-regulation of B cell genes which is 
characteristic of this condition (Vockerodt et al., 2008). 
Although no global methylation analysis has been carried out on HRS cells compared to their 
normal counterpart, many of the B cell specific genes down-regulated in HL, for example, 
CD19, MS4A1, CD79B, SPI1, SYK, POU2AF1, TNFRSF17, LCK, TCL1A and, IGH@ have 
been shown to be silenced by DNA methylation in HL cell lines and HRS cells (Ushmorov et 
al., 2005; Doerr et al., 2005; Ushmorov et al., 2004).  Treatment of B cell lines with both 5-
aza-deoxycytidine, a DNA demethylating agent in combination with trichostatin A, a histone 
acetylating agent led to the induction of a Hodgkin-like gene expression programme in the B 
cell lines (Ehlers et al., 2008).  
However, a number of important question remain unanswered. What is the impact of EBV 
infection on the transcriptional profile of GC B cells? Is EBV infection of these cells followed 
by changes in the expression of the DNMTs. What consequences, if any, does this have for 
the cellular epigenome? Is the expression of the DNMTs de-regulated in HL. I aim to address 
these questions in my thesis.  
 
 
 
 
 
 
 
 
       
1.15 DNMT inhibitors in EBV-associated malignancies 
As methylation plays a major role in the silencing of EBV promoters, a demethylating agent 
may re-activate those promoters which could in turn facilitate immune mediated destruction 
of tumour cells.  A clinical trial has been undertaken in which biopsies from 10 patients with 
EBV- associated malignancies were taken before and after treatment with 5-azacytidine (Chan 
et al, 2004). Although analyses of several EBV promoters before and after treatment in 
patients with NPC or AIDS lymphoma revealed demethylation of the latent promoters Cp, 
Wp and LMP1 and also at the lytic promoters BZLF1 and BRLF1,  the only viral gene to be 
reactivated was BZLF1. However, it has been suggested that HDAC inhibitor treatment in 
combination with the DNMT inhibitor may lead to the re-expression of other silenced genes 
(Chan et al, 2004).  A phase 2 clinical trial of azacitidine and a HDAC inhibitor is currently 
being carried out on patients with relapsed or refractory Hodgkin lymphoma. Therefore there 
are compelling reasons for attempting to understand in more detail the methylation changes in 
cellular genes induced by EBV. This is one of the objectives of my thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
Chapter 2 
 
 
 
Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
       
2.1 Cell culture 
2.1.1 Maintenance of cell lines 
Suspension cells were maintained in exponential growth at 37ºC in 75 cm3 flasks in RPMI 
1640 medium (Sigma) supplemented with 10% v/v selected foetal calf serum (FCS; PAA the 
cell culture company) and 1% v/v penicillin/streptomycin (Gibco). Adherent cell lines were 
maintained in 10 cm dishes in (N-[2-Hydroxyethyl] piperazine-N’-[2-ethanesulphonic acid]) 
(HEPES)-buffered Dulbecco’s Modified Eagle’s Medium (DME/HEPES, Sigma) with the 
same supplements as above.  Once cells were approximately 80% confluent, they were sub-
cultured to reduce cell density and prevent inhibition of growth.   
 
2.1.1.1 Culturing non-adherent cells 
For non-adherent cells, media was removed from flasks and centrifuged.  The supernatant was 
discarded and cell pellets re-suspended in fresh pre-warmed media, counted and the 
appropriate number of cells transferred into sterile tissue culture vessels.   
 
2.1.1.2 Culturing adherent cells 
Prior to splitting, adherent cells were washed twice in phosphate-buffered saline (PBS: 1 PBS 
tablet dissolved in 100 ml of water, sterilised by autoclaving at 121ºC, 15 psi for 15 minutes). 
Trypsin solution (Gibco) was then added to the cells and incubated at 37ºC for 5 minutes to 
allow detachment.  The trypsinized cells were centrifuged at 1000 rpm for 5 minutes, re-
suspended in media, counted, and the appropriate number of cells transferred into sterile 
tissue culture vessels.   
 
 
       
 
2.1.2  Cell lines used 
 
 
 
Cell line Growth Characteristic Info (origin) 
Growth 
conditions 
GC B cell derived 
LCL suspension 
GC B cells infected with wild type 2089 
EBV 
RPMI 1640, 2mM 
glutamine, 10% 
FCS, 1% 
pen/strep. 37oC in 
5% carbon dioxide 
L591 suspension 
 
EBV-positive cell line that originated 
from the pleural effusion of a female 
patient with histologically confirmed 
nodular sclerosis HL (Diehl et al., 1982). 
RPMI 1640, 2mM 
glutamine, 10% 
FCS, 1% 
pen/strep. 37oC in 
5% carbon dioxide 
L1236 suspension 
EBV-negative cell line established from 
the peripheral blood of a patient with 
advanced HL (Wolf et al., 1996). The 
HRS cell origin of L1236 cells has been 
confirmed by the finding of identical Ig 
gene rearrangement sequences in L1236 
cells and HRS cells of the same patient's 
bone marrow (Kanzler et al., 1996). 
RPMI 1640, 2mM 
glutamine, 10% 
FCS, 1% 
pen/strep. 37oC in 
5% carbon dioxide 
L540 suspension 
EBV-negative HL cell line derived from 
the pleural effusion of a HL patient, and 
genomic analysis of the cell line has 
revealed monoclonal rearrangements of 
T-cell receptor beta and gamma loci and 
germ line configuration of Ig genes, 
suggesting a T-cell origin for the cell line 
(Falk et al., 1987; Drexler et al., 1988). 
RPMI 1640, 2mM 
glutamine, 10% 
FCS, 1% 
pen/strep. 37oC in 
5% carbon dioxide 
L428 suspension 
 
EBV-negative cell line established from 
the pleural effusion of a patient with 
histologically confirmed HL (Schaadt et 
al., 1980). 
RPMI 1640, 2mM 
glutamine, 10% 
FCS, 1% 
pen/strep. 37oC in 
5% carbon dioxide 
KM-H2 suspension 
 
EBV-negative cell line originally 
established from the pleural effusion of a 
patient with mixed cellularity HL 
(Kamesaki et al., 1986). 
RPMI 1640, 2mM 
glutamine, 10% 
FCS, 1% 
pen/strep. 37oC in 
5% carbon dioxide 
B95.8 LCL suspension 
Marmoset monkey peripheral blood 
leukocytes infected with EBV (Miller 
and Lipman 1973) 
RPMI 1640, 2mM 
glutamine, 10% 
FCS, 1% 
pen/strep. 37oC in 
5% carbon dioxide 
2W LCL suspension 
LCL containing recombinant EBVs with 
2 copies of the BamHI W repeat 
generated by Dr. Rosemary Tierney 
(CRUK) 
RPMI 1640, 2mM 
glutamine, 10% 
FCS, 1% 
pen/strep. 37oC in 
5% carbon dioxide 
11W LCL suspension LCL containing recombinant EBVs with 11 copies of the BamHI W repeat 
RPMI 1640, 2mM 
glutamine, 10% 
       
generated by Dr. Rosemary Tierney 
(CRUK) 
FCS, 1% 
pen/strep. 37oC in 
5% carbon dioxide 
Rael suspension 
Latency I Burkitt’s lymphoma line 
derived from endemic EBV positive BL 
biopsies 
RPMI 1640, 2mM 
glutamine, 10% 
FCS, 1% 
pen/strep. 37oC in 
5% carbon dioxide 
X50-7 LCL suspension 
EBV positive LCL derived from cord 
blood cells. Viral genome is deleted for 
Cp thus they are Wp using (Miller et al., 
1984). 
RPMI 1640, 2mM 
glutamine, 10% 
FCS, 1% 
pen/strep. 37oC in 
5% carbon dioxide 
HeLa Adherent HPV 18 positive cell line derived from cervical cancer cells 
DMEM, 10% FCS, 
1% pen/strep. 37oC 
in 5% carbon 
dioxide 
293/2089 Adherent 293 cells stably carrying the 2089 EBV genome. (Feederle et al., 2005) 
DMEM, 10% FCS, 
1% pen/strep. 37oC 
in 5% carbon 
dioxide 
Fibroblasts Adherent Cells originating from connective tissue.  Used as a feeder layer for GC B cells. 
DMEM, 10% FCS, 
1% pen/strep. 37oC 
in 5% carbon 
dioxide 
 
 
2.1.3   Cryopreservation of cells 
1 x 107 cells were pelleted by centrifugation at 1000 rpm in a 5810R Eppendorf centrifuge for 
5 minutes and re-suspended in 1 ml freezing solution (50% v/v supplemented medium, 40% 
v/v FCS and 10% v/v dimethyl sulphoxide (DMSO; Sigma)).  Cells were transferred to 
cryopreservation tubes and cooled slowly overnight to -80ºC in a freezing box surrounded by 
sponge soaked in isopropanol.  Cells were then moved to the vapour phase of a liquid nitrogen 
freezer for long-term storage. 
 
2.1.4   Recovery of cells from nitrogen storage 
Cells were thawed quickly at 37ºC to minimize exposure to DMSO and transferred to a 15 ml 
tube.  Warmed RPMI with supplements was added gradually to the cells to dilute the DMSO 
and allow the cells to recover slowly. Cells were pelleted by centrifugation at 1000 rpm in a 
       
5810R Eppendorf centrifuge for 5 minutes, re-suspended in 10 ml medium and transferred to 
a 25 cm3 at 37ºC. 
2.1.5  Cell counting   
After harvesting cells in the same manner as for sub-culture, disposable Glasstic™ slides 
(Hycor Biomedical Ltd., Edinburgh, UK) were used to determine cell concentration in 
culture.  100 μl of cell suspension was removed from culture and mixed with 100 μl of trypan 
blue.  20 μl of this was pipetted into a well on the Glasstic™ slide.  Using an inverted light 
microscope, all live (bright spherical) cells contained within three diagonal zones of the 
Glasstic™ grid were counted.  This number was divided by three to obtain an average count of 
cell number per zone.  This average value was then multiplied by 104 to obtain the number of 
cells per ml of culture medium.  
 
 
2.1.6  Mycoplasma testing 
All cell lines were periodically tested using the MycoAlert mycoplasma detection kit and 
were found to be consistently negative for mycoplasma. 
 
 
 
 
 
 
 
       
2.2 RNA, DNA and protein isolation and quantification from cells 
 
2.2.1  RNA isolation 
Total RNA was isolated from cells using the QIAGEN RNeasy™ mini kit according to the 
manufacturer's protocol (QIAGEN):  5 x 106 cells were transferred directly from culture to a 
sterile universal tube and pelleted by centrifugation at room temperature for 5 minutes at 400 
g.  The supernatant was aspirated but the cells were not washed (to reduce the possibility of 
mRNA degradation).  Cells were lysed using 350 μl of the lysis buffer and then incubated at 
room temperature for at least 5 minutes.  Cell lysates were mixed thoroughly with 350 μl of 
70% ethanol diluted in DNase/RNase-free water and transferred to spin columns placed in 
collection tubes. Columns were then centrifuged at 8000 g for 15 seconds.  Flow-through was 
discarded and 700 μl Buffer RW was pipetted into spin columns before being centrifuged 
again at 8000 g for 15 seconds.  Flow-through was discarded and columns were transferred to 
fresh collection tubes.  500 μl of Buffer RPE was pipetted into spin columns before being 
centrifuged at 8000 g for 15 seconds.  Flow-through was discarded and another 500 μl Buffer 
RPE was added.  Columns were centrifuged at 8000 g for 2 minutes.  Flow-through and 
collection tubes were discarded and columns were transferred to microcentrifuge tubes with 
their lids removed.  They were centrifuged for 1 minute at 16000 g to completely dry the 
membrane in the columns.  Columns were transferred to centrifuge tubes provided in the 
RNeasy™ kit and 30 μl of DEPC water was pipetted directly onto membranes. Columns were 
centrifuged for 1 minute at 8000 g to elute the RNA. 
 
 
 
       
2.2.2  RNA quantification 
The RNA concentration of each sample was measured on a NanoDrop ND-1000 
Spectrophotometer (Labtech International): 2 μl of DNase/RNase-free water was applied to 
the sample well to initialize the NanoDrop.  The sample well was wiped clean with tissue; 1 
μl RNase-free water (from RNeasy™ kit) was applied and used as a blank measurement.  
Again the sample well was wiped clean and 1 μl of eluted RNA was used to obtain RNA 
concentration and quality (ratio A260/280) for each sample, the well being wiped clean 
between each measurement.  
 
2.2.3  DNA extraction from cells 
2.2.3.1 Cell lysis 
Total cellular DNA was extracted from cells by lysis using proteinase K. 1 x 107 cells were 
harvested by centrifugation, washed in PBS and re-suspended in 200 µl lysis buffer (1X PCR 
buffer (Sigma), 0.5% Tween 20 (Sigma) and 1.3 M proteinase K (Roche).  Cells were 
incubated overnight at 55ºC.   
 
2.2.3.2 Chloroform/phenol extraction 
DNA was purified by phenol/chloroform (Sigma) extractions.  An equal volume of phenol 
was added to the sample and vortexed thoroughly.  The sample was centrifuged at maximum 
speed in an Eppendorf microfuge for 5 minutes.  The upper aqueous layer was retained and 
transferred to a new tube.  An equal volume of phenol/chloroform was added to the sample, 
vortexed and centrifuged for 5 minutes. The upper aqueous layer was retained and transferred 
to a new tube.  An equal volume of chloroform was added to the sample, vortexed and 
       
centrifuged for 5 minutes.  The upper aqueous layer was removed and precipitated in cold 
ethanol. 
2.2.3.3 DNA ethanol precipitation  
The DNA was precipitated by adding 0.1X volume of 3 M sodium acetate (Sigma), 2.5X 
volume of 100% ethanol and 1 µl of glycogen (Invitrogen) to the aqueous layer and incubated 
at -20ºC overnight.  DNA was pelleted by centrifugation at maximum speed in a microfuge 
for 30 minutes.  The pellet was washed in 70% v/v cold ethanol, air dried and re-suspended in 
50 µl sterile distilled water.  
 
2.2.4  DNA quantification 
The DNA concentration of each sample was measured on a NanoDrop ND-1000 
Spectrophotometer (Labtech International): 2 μl of DNase/RNase-free water was applied to 
the sample well to initialize and blank the NanoDrop.  The sample well was wiped clean and 
1 μl DNA was used to obtain the DNA concentration and quality (ratio 260/280) for each 
sample.  The ratio of optical density (OD) at 260 nm to 280 nm should lie between 1.8 and 2.2 
for samples without contamination.   
 
2.2.5 Protein extraction 
1 x 107 cells were harvested by centrifugation at 1000 rpm for 5 minutes. The culture media 
was decanted and discarded and the cell pellet was re-suspended in 5 ml PBS. Cells were 
washed and centrifuged again in PBS to ensure complete removal of culture media.  The 
supernatant was discarded and the pellet re-suspended in 100 µl RadioImmuno Precipitation 
Assay (RIPA) buffer (50 mM Tris-HCl  pH 8, 150 mM NaCl, 1% Triton X-100, 0.5% sodium 
Deoxycholate, 0.1% SDS, 1 mM sodium vanadate and 1X protease inhibitor cocktail 
       
(Roche)).  Samples were left on ice for 30 minutes, followed by centrifugation at 4ºC for 15 
minutes.  The supernatant was transferred to a new 1.5 ml microcentrifuge tube and kept on 
ice during the determination of protein concentration. 
2.2.6 Determination of protein concentration 
Protein was quantified using the Bio-Rad Protein Assay Kit (Bio-Rad Laboratories). 10 
mg/ml stock bovine serum albumin (BSA; Sigma-Aldrich) was diluted to 1.5, 0.8, 0.4, 0.2, 
0.1 and 0 mg/ml concentrations with distilled water for protein standards.  2 μl of protein 
samples were diluted in 18 μl distilled water.  10 µl of each sample and standard was plated 
out in duplicate into each well of a 96 well plate (IWAKI).  Bio-Rad Protein Assay Reagent 
was diluted 1:5 in distilled water and 200 µl added to each standard and sample. This was 
incubated for 5 minutes at room temperature.  The absorbance of standards was read on a Bio-
Rad 680 microplate reader at 750 nm and used to plot a calibration curve from which the 
protein content of the samples was determined.  
 
 
 
 
 
 
 
 
 
 
       
2.3  Complimentary DNA synthesis and polymerase chain reaction 
 
2.3.1 Primer design 
Polymerase chain reaction (PCR) primers were designed using primer 3 software 
(www.primer3.com).  Human genomic sequences were obtained from the UCSC genome 
browser (www.ucsc.com). Viral genomic sequences were obtained from the EMBL-EBI 
website (www.ebi.ac.uk/genomes/virus).  Desirable characteristics of the primer sequences 
were a length of 18-25 bp, G+C content of 40-60% and with an annealing temperature of 58 - 
62ºC.  For the amplification of complimentary DNA (cDNA), oligonucleotide primers were 
designed to bind specifically the gene of interest.  Basic local alignment search tool (BLAST) 
searches (http://www.ncbi.nlm.nih.gov/BLAST/) were performed in all cases to ensure that 
primers were not complimentary to other regions of the genome and bound specifically to the 
target sequences.  Primers were synthesised by Alta-Biosciences (University of Birmingham) 
and supplied as lyophilized pellets.  Primers were reconstituted in DEPC treated water 
(Applied Biosystems) to a concentration of 100 µM and stocks stored at -20ºC in aliquots.   
 
2.3.2 Reverse transcription (RT) reaction 
RNA was reverse transcribed to cDNA using Superscript® III first-strand synthesis system 
(Invitrogen).  500 ng RNA from each sample was pipetted into sterile 0.2 ml PCR tubes along 
with 50 ng random primers (Promega), 1 μl of 10 mM deoxyribonucleotide triphosphates 
(Roche)  and the volume made up to 10 μl using DNase/RNase-free water (Promega).  A 
negative control with DNase/RNase-free water instead of cDNA was set up in parallel.  The 
mixture was then incubated at 65°C for 5 minutes and then cooled on ice for 1 minute to 
denature RNA and prohibit re-annealing. Meanwhile, an RT-reaction master mix consisting of 
       
the following components was made up in a sterile microcentrifuge tube for each of the RNA 
samples plus one (to allow for pipetting error):  2 μl 10 X RT buffer, 4 μl 25 mM MgCl2, 2 μl 
0.1 M DTT, 1 μl RNaseOUT™, 1 μl Superscript™ III RT (all Invitrogen).  10 μl of the 
master mix was added to each cDNA sample. Using an Eppendorf Thermal Cycler, cDNA 
was synthesized by incubating samples at 25oC for 10 minutes followed by 50oC for 1 hour.  
The reaction was terminated by heating the samples to 85oC for 5 minutes and then by 
chilling to 4oC.  The cDNA samples were stored at -20oC until required.  
 
2.3.3 DNA PCR and RT-PCR 
A PCR-reaction master mix consisting of the following components was made up in a sterile 
Eppendorf tube for each of the cDNA or DNA samples plus one (to allow for pipetting error):  
12.5 μl 2X PCR master mix (Promega), 2.5 μl 3’ primer, 2.5 μl 5’ primer (final concentration 
2 μM of each, see individual chapters for specific primer sequences).  17.5 μl of this master 
mix was pipetted into sterile 0.2 ml PCR tubes, 2 μl of synthesized cDNA or 50 ng of DNA 
was added to the master mix and the total volume made up to 25 μl with RNase/DNase free 
water.  PCR amplification in an Eppendorf Thermal Cycler involved an initial 5 minute 
denaturation at 94°C, followed by 30 cycles consisting of a denaturing step for 30 seconds at 
94°C, an annealing step for 1 minute at a temperature specific for primers (see individual 
chapters), and an extension for 1 minute at 72°C.  A final extension step of 72°C for 10 
minutes ensures all single stranded molecules have been replicated.   PCR products were 
stored at 4oC until required. 
 
 
 
       
 
 
2.3.4 Agarose gel electrophoresis of PCR products 
 
2.3.4.1 Agarose gel preparation 
Amplified samples were analysed by electrophoresis through agarose gels.  A 1.5% agarose 
gel was made by melting 1.7 g agarose (Eurogentec) in 115 ml of 1X tris-borate buffer 
solution (TBE; 45 mM tris, 45 mM boric acid, 1 mM EDTA pH 8.3 (all Fisher Scientific)) in 
a conical flask.  The mixture was boiled using a microwave set at full power until all agarose 
had dissolved.  The melted solution was cooled by running cold tap water over the base of the 
conical flask.  At this point, 3 μl of 5 mg/ml stock ethidium bromide (Fluka Biochemika) was 
added and the gel was poured into a standard gel casting tray (Fisher Scientific), sealed by 
masking tape, producing a 1 cm thick gel.  A 16-tooth comb was positioned near the top of 
the gel plate so that 16 complete wells formed once the gel had set.  The gel was allowed to 
stand at room temperature for 1 hour or at 4oC for 30 minutes to harden.  Once the gel had set, 
the comb and masking tape were removed and the gel submerged into 1X TBE in a submarine 
mini-gel electrophoresis unit (Fisher Scientific). 
 
2.3.4.2 Gel electrophoresis 
PCR products were pulse centrifuged before use. Each 25 μl of PCR sample was mixed with 
5 μl of 6X blue/orange loading dye.  5 μl of 100 bp Ready-Load™ DNA ladder (Invitrogen) 
was added to the first lane of the submerged gel in the gel electrophoresis tank.  30 μl of each 
PCR product was added to other lanes alongside a negative (water) control.  The gel was run 
for 1 hour at 120 V, 95 mA.  The negatively charged products migrate through the gel to the 
       
cathode, separating on the basis of size.  Photographs were taken under UV light and 
documented using a GeneFlash Syngene Bio Imaging analyzer. 
 
2.4 Quantitative PCR (Q-PCR) 
Q-PCR requires a combination of two oligonucleotide primers and a dual-labeled fluorogenic 
hybridization probe to detect the gene of interest (Heid et al., 1996).  One fluorescent dye 
serves as a reporter (FAM), and its emission spectra is quenched by a second fluorescent dye 
(TAMRA). During the extension phase of PCR, the 5’ to 3’ exonuclease activity of the Taq 
DNA polymerase cleaves the reporter from the probe, thus releasing it from the quencher, 
resulting in an increase in fluorescent emission at 518 nm. 
  
2.4.1 Q-PCR and Q RT-PCR reaction 
All equipment was irradiated under UV light to remove any DNA contaminations.  cDNA or 
DNA for use in the Q-PCR was prepared as described in Section 2.3.3 or 2.2.3.  PCR 
reactions were set up on ice and performed in 96-well reaction plates (Applied Biosystems).  
2 µl cDNA or 50 ng DNA was generally used per reaction; however for genes with low 
transcript levels more cDNA was required.  15 µl of a mastermix comprising 12.5 µl 2X 
Taqman universal mastermix, 1.25 µl 20X endogenous control and 1.25 µl 20X primer and 
probe mix (all Applied Biosystems) was added to each well along with the cDNA or DNA 
and the total volume made up to 25 µl with DEPC treated water (Applied Biosystems).  All 
samples were run in triplicate and wells sealed using optically clear caps (Applied 
Biosystems).  The plate was then placed in the ABI Prism 7700 Sequence Detection System 
(Applied Biosystems) and subjected to an enzyme activation step at 50ºC for  2 minutes, a 
denaturation step at 95°C for 10 minutes followed by 40 cycles of denaturation at 95°C for 15 
       
seconds and an extension step at 60°C for 1 minute.  Taqman assays used within the thesis are 
shown in Table 2.1. 
 
2.4.2 cDNA synthesis for EBV RNA 
The synthesis of viral cDNA was performed using a different method.  Briefly, 400 ng RNA 
was denatured at 90ºC for 2 minutes and cooled on ice.  Denatured RNA was reverse-
transcribed in a 20 µl reaction containing 1X avian myeloblastosis virus reverse transcriptase 
(AMV-RT) reaction buffer (50 mM Tris-HCL pH 8.5, 30 mM KCL, 8 mM MgCl2, 1 mM 
dithiothreitol (DTT) (Roche), 200 µM each of dATP, dCTP, dGTP, dTTP (Roche), 1 µM of 
the 3’ gene-specific primer (Dr. Andy Bell), 5 units of AMV-RT enzyme (Roche) and 1 unit 
of RNAse inhibitor (Roche).  This mixture was incubated at 42ºC for 90 minutes, followed by 
heat inactivation of the AMV-RT at 90ºC for 5 minutes.  cDNA was diluted to a final volume 
of 80 µl and stored at -20ºC. 
 
2.4.3 Assays to detect EBV mRNAs 
Taqman Q RT-PCR was used to detect expression of EBV mRNAs. Primer/probe 
combinations specific for detection of Wp- and Cp- initiated, EBNA2, Y3-U-K and Q-U-K 
spliced EBNA1, LMP1, LMP2A and BZLF1 transcripts were kindly provided by Dr. Andy 
Bell.  All EBV specific probes were FAM-labelled, while GAPDH mRNA was quantified 
using a pre-developed assay reagent containing primers and a VIC-labelled probe (Applied 
Biosystems).  25 ng cDNA was used in a 25 µl reaction containing 1X Taqman Universal 
PCR Mastermix, 5’ and 3’ primers and probes and 1X GAPDH mix.  All samples were 
analysed in triplicate and subjected to an initial uracil-N glycosylase incubation (50ºC for 2 
minutes) and AmpliTaq Gold activation (95ºC for 10 minutes), followed by 40 cycles of 95ºC 
       
for 15 seconds and 60ºC for 1 minute.  Fluorescent signals were detected by an ABI Prism 
7700 Sequence Detection System (Applied Biosystems).  Template-negative and RT- 
negative reactions served as controls for contamination. 
 
2.4.4 The comparative Ct method (ddCt) for relative quantitation of gene expression 
The delta-delta (dd)Ct method (Livak and Schmittgen, 2001) enables relative quantitation of 
transcripts without the need for standard curves when looking at expression levels of a target 
gene relative to an endogenous control (e.g. GAPDH).  The ddCt method was used to measure 
differences in the amount of target gene transcripts between samples.  First, the difference 
(dCt) between the Ct values of the target gene and the endogenous gene was calculated for 
each sample studied (dCt = target Ct - endogenous Ct).  The sample selected as the “baseline” 
sample for expression of the target gene is referred to as the reference sample.  The difference 
between each of the samples dCt and the reference samples dCt was calculated, generating the 
ddCt value for each sample (ddCt = reference dCt - target dCt).  The ddCt for each sample 
was then converted to an absolute value using the following equation: fold change in 
expression level = 2-ddCt.  
 
 
 
NCBI gene symbol Applied Biosystems assay number 
DNMT1 Hs00154749_m1 
DNMT3B Hs01027166_m1 
DNMT3A Hs00171876_m1 
PRMT1 Hs01587651_g1 
PRMT5 Hs01047356_m1 
CARM1 Hs00406354_m1 
PADI4 Hs00202612_m1 
 
Table 2.1: Taqman Q-RT-PCR assays 
       
2.5 Analysis of protein expression by Western blotting 
 
2.5.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gels were set up in 
two phases using the mini-Protean 3 Bio-rad apparatus.  An 8% resolving gel containing 30:1 
acylamide:bisacrylamide (Bio-rad), 390 mM Tris-HCL pH 8.8, 0.1% w/v SDS, 0.06% w/v 
N,N,N’,N’- tetramethylethylenediamine (TEMED, Sigma) and 0.1% w/v ammonium 
persulphate (APS, Sigma) was made.  300 µl isopropanol was applied on top to give a 
uniform surface.  A stacking gel containing 3% acrylamide, 125 mM Tris-HCL pH 6.8, 0.1% 
w/v SDS 0.1% w/v TEMED and 0.1% w/v APS was poured on top of the resolving gel, a 
comb was placed in the stacking gel and allowed to set for 30 minutes.  The appropriate 
protein concentrations of samples were boiled in 2X laemilli buffer (Sigma) for 10 minutes 
and protein was loaded into each well together with 10 µl of a protein marker (Bio-rad).  Gels 
were run in 1X running buffer consisting of 30 g TRIS, 144 g glycine (Fisher), 10 g SDS in 
10 L distilled water.  Solubilised proteins were separated by electrophoresis at 125 V, 400 mA 
for 2 hours. 
 
2.5.2 Protein transfer 
Six sponges, six pieces of Whatman® chromatography paper (Sigma-Aldrich) and one piece 
of BioTrace NT membrane (VWR International), all cut to gel size, were soaked in a tank of 
transfer buffer (30 g tris, 144 g glycine, 2 L methanol in 8 L distilled water). The ‘transfer 
sandwich’ was set up in a XCell II Blot Module (Invitrogen), ensuring air bubbles were 
pushed out between each layer, in the following order: 3 sponges, 3 pieces of filter paper, gel, 
BioTrace NT membrane, 3 pieces of filter paper, and 3 sponges.  The transfer module was 
       
then placed into the XCell Surelock Mini-Cell (Invitrogen) and filled with transfer buffer.  
Transfer buffer was poured into the tank around the plates to a depth of 10 cm.  Protein was 
then transferred from the gel to the BioTrace NT membrane on ice at 40 V, 400 mA for 2 
hours.  
 
2.5.3 Protein detection 
Non-specific protein binding was blocked by incubating the membrane for 1 hour at room 
temperature in 5% milk dissolved in tween-tris buffered saline (T-TBS), consisting of 1.21 g 
TRIS and 8.77 g NaCl in 1 L distilled water (pH adjusted to 7.6 using concentrated HCl) with 
0.5 ml Tween 20 (Fisher Scientific).  The membrane was incubated overnight at 4 ºC in 
diluted primary antibody (Table 2.2).  
 
Target protein Antibody Species Dilution 
DNMT1  190 kDa 
DNMT1 190 kDa 
Ab1-6632 
IMG 07703648959 
Rabbit polyclonal 
Mouse monoclonal 
1:500 
1:500 
DNMT3A  85 kDa 
DNMT3A 100-130 kDa 
DNMT3A 120 kDa 
Ab-16704 
IMG-268A 
Sc-10231 
Rabbit polyclonal 
Mouse monoclonal 
Goat polyclonal 
1:200 
1:100 
1:100 
DNMT3B 100 kDa 
DNMT3B 130 kDa 
IMG-184A 
Ab-2851 
Mouse monoclonal 
Rabbit polyclonal 
1:200 
1:500 
PRMT1  42 kDa Sc-59648 Mouse monoclonal 1:2000 
PRMT5  70 kDa Ab-12191 mouse 1:2000 
CARM1 63 kDa Ab-50278 mouse 1:1000 
HA tag 16B12 Mouse monoclonal 1:1000 
 
Table 2.2:  List of primary antibodies  
 
       
After rinsing three times for 5 minute in T-TBS the membrane was incubated for 1 hour in 
HRP-conjugated secondary IgG (DakoCytomation) and then rinsed as before. 
 
2.5.4 Visualization 
Antibody-protein complexes were detected using the enhanced chemiluminescence (ECL) kit 
(Amersham Biosciences). 1 ml of each ECL reagent was mixed in a universal tube 
immediately prior to use.  The membrane was incubated in the ECL mixture for 1 minute 
before being wrapped carefully in Saran wrap (Fisher Scientific). 
 
2.5.5 Autoradiography 
The wrapped BioTrace NT membrane was placed into a Hypercassette™ autoradiography 
cassette with a sheet of Hyperfilm™ (both Amersham Biosciences) on top, which was 
developed for between 30 seconds to 1 hour.  The Hyperfilm™ was developed in a Kodak X-
OMAT 1000 processor (Kodak Limited).   
 
 
 
 
 
 
 
 
 
       
2.6    EBV infection experiments 
 
2.6.1 Preparation of virus stocks 
293 cells carrying the EBV 2089 genome (Dr. Claire Shannon-Lowe) were plated into 6 well 
plates 24 hours prior to transfection. 0.75 µg BZLF1 expression plasmid and 0.75 µg BALF4 
(gp110) plasmid (Dr. Claire Shannon-Lowe) were co-transfected per well using 
LipofectamineTM (Invitrogen) transfection reagent.  For each well, 750 ng of plasmid was 
diluted in 100µl Optimem (Gibco) and mixed gently. 1.5 µl Plus reagent was added to DNA, 
mixed gently and incubated for 15 minutes at room temperature.  6 µl Lipofectamine LTX 
reagent was added to the DNA and incubated for 30 minutes at room temperature.  100 µl of 
DNA-Lipofectamine LTX complexes was added to each well and mixed by rocking.  
Supernatant was harvested 72 hours later, centrifuged at 2000 rpm for 5 minutes and filtered 
using a 0.2 µm filter to remove cellular contaminants.  This supernatant was used as a virus 
source; 100 µl was retained for quantification, the rest was stored in aliquots at -80ºC 
 
2.6.2   Quantification of virus titre 
An equal volume of lysis buffer (100 µg/ml proteinase K (Roche), 10 mM Tris-HCL pH 8.8, 
1.5 mM MgCl2, 50 mM KCL, 0.1% v/v Triton X-100) was added to the viral supernatant and 
incubated at 55ºC for 1 hour followed by 99ºC for 10 minutes to heat inactivate the proteinase 
K.  Q-PCR was then carried out for the EBV polymerase gene (BALF5).  5 µl of processed 
viral supernatant was added per well of a 96-well plate to determine the number of virus 
genomes per ml of supernatant. 
A multiplex PCR reaction allowed simultaneous amplification and detection of BALF5 with a 
FAM-labelled probe and the endogenous beta-2-microglobulin gene (B2M) with a VIC-
       
labelled probe.  Primers and probes were designed by Dr. Claire Shannon Lowe.  5 µl of viral 
supernatant, 1X Taqman Universal PCR Mastermix (Applied Biosystems), 200 nM of each 
EBV Pol primer, 200 nM EBV Pol probe (Eurogentec), 60 nM of each B2M primer and 100 
M B2M probe (Eurogentec) was added to a PCR tube and made up to 25 µl with DEPC 
treated water.  Template-negative controls were included in each experiment to check for 
PCR contamination.  All samples were analysed in triplicate and subjected to the same Q-
PCR conditions as described in Section 2.4.3. 
Ct values are directly related to the initial amount of DNA. To generate a standard curve to 
calculate Pol and B2M copy numbers, I used serial dilutions prepared from Namalwa BL, 
which is known to have 2 integrated EBV genome copies per cell (Henderson et al., 1983).  
Assuming one Namalwa BL cell contains 6.6pg of DNA and 2 EBV genomes, then 132 ng/µl 
DNA corresponds to 40.000 EBV genomes/µl. This value was used as the highest standard 
and serial dilutions (10,000, 2000, 200, etc) made from this.  A linear standard curve was 
generated by plotting Ct value against log10 Pol copy number, allowing the number of EBV 
genomes in the test samples to be calculated.  
 
 
 
 
 
 
 
 
       
2.7 Preparation of Germinal Centre B cells from tonsillar tissue 
 
2.7.1 GC B cell extractions 
Tonsillar tissue was obtained from the Children’s Hospital Birmingham following routine 
tonsillectomy. Tonsils were kept on ice at all times during processing.  RPMI supplemented 
with 10% FCS, 1% pen/strep and 2 mg/ml Ciproxin (Bayer) was used throughout the 
preparation for washing and re-suspending the cells.  Tonsils were processed one at a time in 
a petri dish containing 10 ml media.  The tonsil was pressed gently using a scalpel to release 
the cells, these were then aspirated to a 50 ml falcon tube avoiding clumps.  The tonsil was 
continuously tapped and pressed until all cells were released and aspirated to falcon tubes on 
ice.  15 ml lymphoprep (Axis-shield) was pippeted into 50 ml falcon tubes and 35 ml of cell 
mixture was carefully layered on top of the lymphoprep.  This was then centrifuged at 2200 
rpm in an Eppendorf centrifuge at room temperature for 30 minutes without a brake.  A 
Pasteur pipette was used to remove the live white mononuclear cells to a clean falcon tube 
and topped up to 50 ml with RPMI.  This was then centrifuged at 1000 rpm for 10 minutes at 
4ºC.  The supernatant was removed and the cell pellet washed with RPMI once again.  The 
pellet was re-suspended in 20 ml autoMACs rinsing solution (MACS®) supplemented with 
BSA, Pen/strep and ciproxin.  200 µl of cells was used for counting with trypan blue. 100 µl 
of cell suspension was diluted 1:10 with autoMACs solution and mixed with trypan blue in a 
1:1 ratio.  The total number of tonsillar mononuclear cells (TMCs) was calculated to be used 
for CD10 enrichment. 
 
 
 
       
 
2.7.2 CD10 selection 
CD10 expressing cells are a population of cells made up of centroblasts and centrocytes.  
Both subsets of cells are CD10 positive, thus can be selected for using α-CD10-phycoerythrin 
(PE) and α -PE microbeads. 
TMCs were centrifuged at 1000 rpm for 10 minutes at 4ºC and re-suspended in 100 µl 
AutoMACs/107cells.  The PE conjugated anti-human CD10 antibody (EBioscience) was 
added to the cells at a 1:50 dilution and incubated for 15 minutes at 4ºC.  Cells and antibody 
were then washed with AutoMACs solution. This was centrifuged at 1000 rpm for 10 minutes 
at 4ºC. Cells were re-suspended in AutoMACs at a concentration of 80 µl/107 cells.  Anti-PE 
microbeads diluted 1:5 (20 µl beads/107 cells) were added and incubated for 15 minutes at 
4ºC.  10X volume of autoMACs buffer was added and centrifuged at 1000 rpm for 10 minutes 
at 4ºC.  LS columns and magnet (both MACS®) were assembled and cells re-suspended so 
that 500 µl are used in each column.  The column was rinsed once with 3 ml autoMACs 
buffer.  500 µl of cells and beads were added directly to each filter and allowed to flow 
through. The column was then washed three times with 3 ml autoMACs buffer. The columns 
were removed from the magnet and put into fresh 15 ml falcon tubes. 5 ml autoMACs was 
added to each column and a plunger used to elute the cells on ice.  Cells were combined in 
one tube and counted using trypan blue. The yield was usually about 10% of original cells. 
 
2.7.3  Setting up a fibroblast feeder layer. 
Fibroblasts were harvested (Section 2.1.1), 24 hours before isolating GC B cells. Cells were 
irradiated and seeded at 2 x104 cells per well in a 24 well plate containing 0.5ml DMEM with 
added supplements.  Cells were incubated overnight at 37ºC. 
       
 
 
2.7.4 GC B cell infection with EBV 
CD10+ cells were centrifuged at 1000 rpm for 5 minutes and re-suspended in the appropriate 
volume of RPMI supplemented with 10% v/v FCS.  Media was removed from the fibroblast 
feeder layer and 5 x106 CD10+ cells in 1 ml media were added.  Virus supernatant was thawed 
at 37ºC, and was added to the cells at a multiplicity of infection (MOI) of 50 and incubated 
overnight.  A negative control of 5x106 CD10+ cells without virus was included.  The 
following day, 1 ml media was removed from each well and replaced with fresh RPMI/10% 
v/v FCS.  Each well was checked microscopically to check the efficiency of infection using 
the gfp tag.   At each time point, three wells were harvested for RNA, DNA and protein 
isolation.  Once cells were confluent they were transferred to 25cm3 flasks and continued in 
culture, splitting every 3-4 days. 
 
 
 
 
 
 
 
 
 
 
 
       
 
2.8 Microarray expression analysis 
2.8.1 Introduction to microarray expression analysis   
The GeneChip® Human Genome U133 Plus 2.0 microarray (HG-U133 Plus 2.0; Affymetrix) 
allows the simultaneous analysis of expression levels of more than 47,000 transcripts and 
variants.  The sequences from >54’000 probe set on the HG-U133 Plus 2.0 array were 
selected from Genbank®, dbEST, and RefSeq.  The sequence clusters were created from the 
UniGene database (Build 133) and then refined by analysis and comparison with a number of 
other publicly available databases giving the most comprehensive coverage.  Each probe is 
comprised of eleven pairs of 25-mer oligonucleotides that can hybridise to a probe set target 
sequence.  The hybridisation of target sequences to oligonucleotide probes is detected by 
staining with a streptavidin-phycoerythrin conjugate and measuring the light emitted at 570 
nm.  The signal produced is proportional to the amount of bound target at each location on the 
array and reflects the transcript levels present in the original target population.  A series of 
control genes are used to allow normalization and scaling between each array so that 
differences in signal intensities can be compared.   
 
2.8.2  Sample preparation 
The HG-U133 Plus 2.0 arrays were used to globally report the gene expression changes that 
followed infection of GC B cells with EBV.  Total RNA was extracted from the cells (Section 
2.2.1) and prepared for hybridization to the arrays using GeneChip® one-cycle target labelling 
and control reagents (Affymetrix).   
 
 
       
 
 
2.8.2.1 First-strand cDNA synthesis 
10 µg RNA was reverse transcribed to first-strand cDNA by adding 100 pmol T7(dT)24 
primer, 2 µl poly-A controls and made up to 11 µl with DEPC-treated water.  This reaction 
was incubated at 70ºC for 10 minutes before adding a master mix consisting of; 4 µl 5X First 
Strand buffer, 2 µl 0.1M DTT,  and 1 µl 10 mM dNTPs.  The samples were incubated at 42ºC 
for 2 minutes before adding 2 µl Superscript II Reverse Transcriptase and incubating them at 
42ºC for 1 hour followed by at least 2 minutes on ice.   
 
2.8.2.2 Second-strand cDNA synthesis 
An RNase H-mediated second-strand cDNA synthesis reaction was performed using 130 µl of 
a master mix containing; 30 µl 5 X Second strand buffer, 3 µl 10 mM dNTPs, 1 µl 10U/µl E. 
Coli DNA ligase, 4 µl 10U/µl E. Coli DNA Polymerase I, 1 µl 2U/µl E. Coli RNAse H and 
91 µl DEPC treated water was made up and added to each of the first strand reaction tubes 
and incubated at 16ºC for 2 hours.  2 µl T4 DNA Polymerase was added to each tube, 
incubated at 16ºC for a further 2 minutes, followed by the addition of 10 µl 0.5M EDTA.  
 
2.8.2.3 Clean-up of double stranded cDNA 
600 µl cDNA binding buffer was combined with the cDNA reaction mix in a 1.5 ml 
Eppendorf tube.  The sample was applied to the cDNA cleanup spin column placed in a 
collection tube and centrifuged for 1 minute at full speed.  The flow-through was discarded 
and 750 µl wash buffer was applied to the column, the sample was centrifuged again for 1 
minute at full speed.  The spin column was transferred to a new collection tube and 
       
centrifuged for 5 minutes at maximum speed with the lid open.  The spin column was then 
transferred to a new 1.5 ml Eppendorf tube and 14 µl cDNA elution buffer applied directly to 
the membrane.  This was incubated at room temperature for 1 minute and centrifuged at full 
speed for 1 minute. 
 
2.8.2.4 In vitro transcription reaction 
In vitro transcription (IVT) was then performed in the presence of T7 RNA polymerase, a 
biotinylated nucleotide analog/ribonucleotide mix for complementary RNA (cRNA) 
amplification and biotin labelling.  34 µl of a master mix comprising of; 4 µl 10 X IVT 
labelling buffer¸ 12 µl IVT labelling NTP mix, 4 µl IVT labelling enzyme mix and 14 µl 
DEPC treated water was added to 6 µl of each cDNA sample previously prepared.  This was 
incubated over night at 37ºC. 
 
2.8.2.5 Clean-up of cRNA 
The cRNA was purified to remove unincorporated NTPs, salts and enzymes.  60 µl RNAse 
free water was added to the IVT reaction and vortexed. 350 µl cRNA binding buffer was 
added and vortexed.  250 µl of 100% ethanol was then added and mixed well by pipetting.  
The sample was applied to the cRNA cleanup column in a 2 ml collection tube and 
centrifuged at full speed for 15 seconds.  The flow-through was discarded and 500 µl wash 
buffer added to the column.  This was again centrifuged, flow through discarded and 500 µl 
80% ethanol added to the spin column.  The sample was centrifuged for 15 seconds at full 
speed and transferred to a new collection tube and centrifuged for a further 5 minutes at 
maximum speed.  The spin column was transferred to a 1.5 ml Eppendorf tube, 11 µl RNase 
free water was applied directly to the spin column and incubated for 1 minute at room 
       
temperature.  The sample was centrifuged at full speed for 1 minute.  10 µl RNase-free water 
was added to the membrane and centrifuged for 1 minute at full speed.  At this point the RNA 
concentration and A260/A280 ratio was noted using the NanoDrop spectrophotometer. 
 
2.8.2.6 cRNA fragmentation 
25 µg cRNA was fragmented in 10 µl 10X fragmentation buffer made up to 50 µl with DEPC 
treated water.  The reaction was left at 94ºC for 35 minutes and placed on ice.  An aliquot of 
the cRNA and fragmented cRNA was run on a 1.5% agarose gel to check the RNA quality.  
The rest of the fragmented cRNA was stored at -80ºC until required. 
 
2.8.3 Hybridization, washing, staining and scanning 
Hybridization, washing and staining was performed as an in house service provided by Dr. 
John Arrand according to the manufacturer’s instructions.  Briefly, a hybridization cocktail 
was prepared including the fragmented target and probe array controls.  The sample was then 
hybridized to the array for 16 hours.  Immediately following hybridization the probe array 
was subjected to an automated washing and staining protocol on the fluidics station.  The 
arrays were scanned using a GeneChip Scanner 3000 using software that defines the probe 
cells and computes an intensity for each cell.  Each complete probe array image was stored in 
a separate data file identified by the experiment name and was saved with a data image file 
(.dat) extension. 
 
2.8.4  data analysed using R and Microsoft Excel software packages. 
The analysis of these arrays was performed with the help of Dr. Wenbin Wei.  Images of the 
microarrays were analysed using Affymetrix microarray Suite 5.0.  Probe level quantile 
       
normalization and robust multiarray analysis on the raw .CEL files were performed using the 
Affymetrix package of the Bioconductor (http://www.bioconductor.org) project.  
Differentially expressed genes were identified using Significance Analysis of Microarrays 
(SAM).    
 
2.9 Methylation Arrays 
2.9.1 Introduction to GeneChip® Human Promoter 1.0R Array 
The Affymetrix human promoter array 1.0R is designed for genome-wide studies of 
transcription factor binding sites, DNA methylation, histone protein modifications or other 
chromatin-protein interactions.  It is a single array comprised of over 4.6 million probes tiled 
through over 25,500 human promoter regions.  Probes are tiled at an average resolution of 35 
bp, as measured from the central position of adjacent 25-mer oligos, leaving a gap of 
approximately 7.5 kb upstream through 2.45 kb downstream of the 5’ transcription start sites.  
Sequences used in the design of the human promoter array were selected from NCBI  human 
genome assembly (Build 34) and the promoter regions were selected using sequence 
information from; Refseq, ENSMBL and GenBank.   
 
2.9.2 Preparation and sonication of genomic DNA 
DNA was isolated from LCL and GC B cell samples (section 2.2.3).  10 µg of DNA diluted in 
400 µl TE buffer was sheared to 300 - 1000 bp by sonicating the DNA for 15 minutes with 30 
second pulses followed by 30 second incubations on ice using a Diagenode® sonicator.  20 µl 
was removed and added to 4 µl 6 X orange/blue loading dye and run on a 2% agarose gel to 
ensure the fragments were the correct size.  The sheared DNA was then ethanol precipitated 
(Section 2.2.3.3).  The DNA was resuspended in 30 µl water and measured on the NanoDrop.  
       
 
2.9.3 Methylated DNA immunoprecipitation 
6 µg sheared DNA was made up to 450 µl TE buffer, denatured at 95ºC for 10 minutes and 
then cooled on ice for 10 minutes.  51 µl 10 X IP buffer (100 mM Na-Phosphate pH 7.0, 1.4 
M NaCl and 0.5 % Triton X-100) and 10 µg 5-methylcytosine antibody (Eurogentec) was 
added and incubated overnight at 4ºC on a rotating wheel.  40 µl sheep anti-mouse IgG 
Dynabeads (Dynal Biotech) were washed twice in 1 ml PBS and collected each time using a 
magnetic rack (Dynal Biotech).  The beads were resuspended in 40 µl 1 x IP buffer and added 
to the antibody/DNA sample which was left for 6 hours at 4ºC on a rotating wheel. Beads 
were collected using the magnetic rack, supernatant was removed and the unbound fraction 
stored before being purified with the elution fraction. The beads were washed three times for 
5 minutes in 1 x IP buffer.  The beads were collected for the final time and resuspended in 
250 µl proteinase K digestion buffer (50 mM Tris pH 8.0, 10 mM EDTA, 0.5 % SDS).  4 µl 
20 mg/ml proteinase K (Roche) was added to the beads and incubated over night at 50ºC at 
1000 rpm.  The beads were captured and a phenol/chloroform extraction and ethanol 
precipitation was carried out on the supernatant (Section 2.2.3.2).   The DNA was re-
suspended in 30 µl TE buffer. 
 
2.9.4 Checking for enrichment of methylated DNA by Q-PCR 
Enrichment was measured in triplicate by Q-PCR using primers specific for the methylated 
XIST sequence, and the unmethylated GAPDH sequence. Q-PCR was performed using 2.5 µl 
of isolated DNA, 12.5 µl  2X SYBR green mastermix (Applied Biosystems), 10 pmol forward 
and reverse primer in a total volume of 25 µl made up with DEPC treated water.  
Amplification involved an enzyme activation step at 50ºC for  2 minutes, a denaturation step 
       
at 95°C for 15 minutes followed by 40 cycles of denaturation at 95°C for 15 seconds and an 
extension step at 60°C for 1 minute.  Q-PCR reactions were also performed on input DNA at 
10 ng/µl, 1 ng/µl, 0.1 ng/µl, 0.01 ng/µl concentrations to generate a standard curve.  The Ct 
versus log DNA concentration was plotted.   The Ct value of the samples was used to 
extrapolate the DNA concentrations from the standard curve.  The percent enrichment was 
calculated using the following equation. 
 
% enrichment   =        Total amount of enriched DNA     x 100 
                     Amount of DNA in IP 
 
 
2.9.5 Amplification of immunoprecipitated DNA 
Amplification was carried out using round A/B/C random amplification.  10 µl 
immunoprecipitated DNA or input DNA was added to 4 µl 5 X Sequenase reaction buffer 
(USB, Affmetrix) and 4 µl 200 µM primer A. DNA was heated to 95ºC for 4 minutes and 
cooled on ice.  0.1 µl 20 mg/ml bovine serum albumin (BSA), 1 µl 0.1 M DTT, 0.5 µl 25 mM 
dNTPs and 1 µl 1.3 U/µl sequenase (USB, Affymetrix) was added to the primed DNA.  This 
mixture was ramped from 10ºC to 37ºC over 9 minutes, held at 37ºC for 8 minutes, incubated 
at 95ºC for 4 minutes and snap cooled on ice.  1 µl 1.3 U/µl sequenase was added to the 
sample, held at 10ºC for 5 minutes, ramped to 37ºC over 9 minutes, held at 37ºC for 8 minutes 
, incubated at 95ºC for 4 minutes and snap cooled on ice. 1 µl 1.3 U/µl sequenase was again 
added to the sample, held at 10ºC for 5 minutes, ramped to 37ºC over 9 minutes, held at 37ºC 
for 8 minutes , incubated at 95ºC for 4 minutes and snap cooled on ice . 1 µl 1.3 U/µl 
sequenase was added to the sample once again and the ramping and cooling process carried 
out once more in the same way.  The sample was held at 4ºC.  The samples were then purified 
       
using a reaction cleanup kit (Qiagen) as follows; 300 µl buffer ERC was added to each 
reaction, pipetted into a column and centrifuged at 13’000 rpm for 1 minute. 750 µl buffer PE 
was added to the column and centrifuged at 13’000 rpm for 1 minute.  The empty column was 
centrifuged at 13,000 rpm for 1 minute.  10 µl of sterile water was added to the membrane and 
incubated at room temperature for 5 minutes.  The DNA was eluted by centrifuging the tube 
for 1 minute at 13’000 rpm.  20 µl of sterile water was again added to the membrane, 
incubated and centrifuged at 13’000 rpm for 1 minute.  30 µl eluted DNA in a 0.2 ml PCR 
tube, was added to 10 µl 10 X PCR buffer (Promega), 3.75 µl dNTP and dUTP mix (10 mM 
dCTP, dATP, dGTP, 8 mM dTTP, 2 mM dUTP), 100 µM primer B. 1 µl MgCl2, 5 U/µl Taq 
polymerase (Promega) and 48.75 µl DEPC treated water.  The mixture was subjected to PCR; 
95ºC for 30 seconds, 45ºC for 30 seconds, 55ºC for 30 seconds, 72ºC for 1 minute, 15 times.  
The samples were then set for 25 cycles of 95ºC for 30 seconds, 45ºC for 30 seconds, 55ºC 
for 30 seconds, 72ºC for 1 minute plus 5 seconds for each cycle thereafter.   The sample was 
then checked again for enrichment of methylated sequences as described in the previous 
section.  The samples were purified using cDNA cleanup columns (Affymetrix). The cDNA 
was eluted in a final volume of 20 µl and measured using a NanoDrop spectrophotometer and 
stored at -20ºC.   
 
2.9.6 Fragmentation of the samples 
7.5 µg DNA was fragmented by adding 4.8 µl 10 X fragmentation buffer, 1.5 µl 10 U/µl 
UDG, 2.25 µl APE and made up to 48 µl with nuclease free water.  This was then incubated 
at 37ºC for 1 hour, 93ºC for 2 minutes and held at 4ºC for at least 4 minutes.  45 µl was 
transferred to a new tube and 3 µl run on a 1.5% agarose gel as described in Section 2.3.4 to 
ensure complete fragmentation.  1 µl of DNA was also used for analysis on the bioanalyzer. 
       
 
2.9.7 Labelling fragmented DNA 
A double-stranded DNA labelling mix was prepared as follows; 12 µl 5 X TdT buffer, 2 µl 
TdT and 1 µl 5 mM DNA labelling reagent were added together and mixed thoroughly.  15 µl 
of this mix was added to the DNA sample and incubated at 37ºC for 1 hour, 70ºC for 10 
minutes and held at 4ºC for at least 2 minutes.   
 
2.9.8 Hybridization, washing, staining and scanning 
Hybridization, washing and staining was performed as an in house service provided by Dr. 
John Arrand according to the manufacturer’s instructions.  A GeneChip Scanner 3000 was 
used to scan the promoter methylation arrays.   
 
2.9.9 Analysis of methylation arrays 
Raw array data from each of the biological replicates were quantile-normalized. TileMap 
software was used to identify regions of hypermethylation and hypomethylation.  The output 
from TileMap included final summaries for each probe and a *.bed file containing selected 
genomic regions that could be visualized using the Affymetrix Integrated Human Genome 
browser (IGB). 
 
 
 
 
 
 
       
2.10 Methylation Analysis 
 
2.10.1 Sodium bisulphite treatment of DNA 
Following sodium bisulphite treatment all unmethylated cytosines are deaminated and 
sulfonated, converting them to uracils, while 5-methylcytosines are protected and unchanged.  
Bisulphite conversion of DNA results in uncomplimentary single-stranded DNA molecules 
and subsequent PCR analysis results in the incorporation of thymines in place of the 
converted uracils.  The EZ DNA Methylation-Gold Kit (Zymo research) was used to modify 
DNA samples according to manufacturer’s instructions.  Briefly, 500 ng of DNA isolated 
from cells as described in Section 2.2.3 was re-suspended in 20 µl DEPC treated water and 
added to 130 µl CT conversion reagent in a 0.2 ml PCR tube.  The sample was subject to 
PCR; denatured at 98ºC for 10 minutes followed by an incubation at 64ºC for 2.5 hours and 
finally cooled to 4ºC.  DNA was then applied to a Zymo-Spin™ IC Column placed in a 
collection tube and 600 µl binding buffer added.  Sample was centrifuged at full speed for 30 
seconds and flow-through discarded.  The column was washed with 100 µl wash buffer and 
centrifuged at full speed for 30 seconds.  200 μl of desulphonation buffer was added to the 
column and left to stand at room temperature 20 minutes.  The sample was centrifuged at full 
speed for 30 seconds and flow-through discarded.  Column was washed twice with 100 µl 
wash buffer and centrifuged at full speed for 30 seconds.  Finally, 10 µl elution buffer was 
added directly to the column and centrifuged at full speed for 30 seconds.  Bisulphite 
modified DNA was made up to 50 µl with DEPC-treated water and stored at -20ºC for up to 6 
months. 
 
 
       
 
2.10.2 Pyrosequencing 
Pyrosequencing is a method of DNA sequencing which allows quantitative analysis of CpG 
methylation. The method allows sequencing of a single strand of DNA by synthesizing the 
complementary strand along it, one base pair at a time, and detecting which base was actually 
added at each step. The template DNA is immobile, and solutions of A, C, G, and T 
nucleotides are added and removed after the reaction, sequentially. Light is produced only 
when the nucleotide solution complements the first unpaired base of the template. The 
sequence of solutions which produce chemiluminescent signals allows the determination of 
the sequence of the template. 
 
2.10.2.1 Pyrosequencing primer design 
All primers were designed using Biotage PSQ primer design software.  The genomic 
sequences were obtained from the UCSC genome browser (http://genome.ucsc.edu) and the 
sequences were then in silico bisulphite converted. The bisulphite converted sequence was 
used to generate a biotinylated and non- biotinylated primer as well as a sequencing primer 
under the allele quantification assay type settings.  Primers were designed 
(www.Biomers.net.) to be no more than, between 18-24 bp in size and have an annealing 
temperature of ~60ºC. Products were all 100 - 200 bp in length. 
 
2.10.2.2 PCR of bisulphite modified DNA for pyrosequencing 
PCR was performed in a total volume of 50 µl including 25 µl hotstart taq master mix 
(Thermo Scientific), 5 pmol biotinylated primer, 10 pmol non-biotinylated primer and 10 µl 
bisulphite modified DNA.  No DNA controls were also amplified.   Cycling conditions were 
       
as follows: denaturation at 95ºC for 15 minutes, followed by 50 cycles at 95ºC for 15 seconds, 
54-60 ºC for 30 seconds, 72 ºC for 30 seconds and a final extension at 72ºC for 10 minutes.  
Primer details and annealing temperatures are listed in Table 2.3.  10 µl from each PCR was 
mixed with 2 µl of 6X orange/blue loading dye (Promega) and run on a 2% agarose gel 
(Section 2.3.4).   A strong single band was required for pyrosequencing. 
 
2.10.2.3 Pyrosequencing reaction 
The pyrosequencing reactions were performed using a Pyromark ID system (Biotage) 
according to the manufacturer’s instructions.  Briefly, 40µl of the biotinylated PCR product 
was bound to 3 µl streptavidin beads (GE healthcare) in 37 µl binding buffer (Biotage) on a 
96 well plate (Applied Biosystems) and left to shake for 5 minutes at 1300 rpm.  Meanwhile, 
15 pmol sequencing primer and 38.5 µl annealing buffer (Biotage) was added to each well of 
a sequencing plate (Biotage). Biotinylated and sequencing primer controls were also included 
on the sequencing plate when running a set of primers for the first time.  The vacuum 
preparation tool was used to capture the beads from the 96 well plate. The beads were lowered 
into each of the following solutions for 5 seconds: 70% ethanol, denaturation buffer (Biotage) 
and wash buffer (Biotage).  Beads were released onto the sequencing plate, heated to 80ºC for 
2 minutes and left to cool.  The appropriate volume of Pyrogold SQA reagents (enzyme, 
substrate and dNTPs; Biotage) were loaded into the reagent cartridge (Biotage) and the plate 
set to run.  Data were analysed using the pyromark ID software. 
 
 
 
 
 
       
 
 
Primer Sequence Product (bp) 
Wp region 1 fwd GAGGGGAAAAGAGGAATAAGTT 177 
Wp region 1 rev CCCTAAAACTAACAATTAACTACT  
Wp region 1 seq AGTGGGTTTGTTTGTGATT  
Wp region 2 fwd TTGATATTTTAGAGTTTTGGAGGAT 193 
Wp region 2 rev TCCTCTTTTCCCCTCTAAAAATA  
Wp region 2 seq CATAAACCCCCTCCTTCCTA  
RBM5 fwd GAGTTTTAAGTGATAGGATGGTTT 141 
RBM5 rev ATCTCCTACCCACAATACCTCA  
RBM5 seq AGTTTTAAGTGATAGGATGG  
ELL3 fwd GGATTTTGAGATAGATTATGTTGA 248 
ELL3 rev TTTTCCCTTCAAACAAATTTCC  
ELL3 seq GGATTTTGAGATAGATTATG  
MAGEA3 fwd TTGAGAGAGGGGGAAGAGTGAGTT 187 
MAGEA3 rev TCCAACAAAACAAAAACCCACTACTAAA  
MAGEA3 seq TGAGAGAGGGGGAAGA  
ICMT fwd TTGAGGATTGTGAATGATTGAGT 196 
ICMT rev CCCTACAAACCCTCTAATCTATCC  
ICMT seq TTTTTGGGGTTTGTGT  
GRB10 fwd TGGGATGTTTTTTGTGAATTTAT 158 
GRB10 rev TTTTACTCATTCCTTACCCTAATA  
GRB10 seq ATGTTTTTTGTGAATTTAT  
SMAD4 fwd TTTTTTTATTTTGAGTAAAGATTAGGTTTTGT 155 
SMAD4 rev AAATATTAACATACTTAATTATAACCAAACA  
SMAD4 seq TTTTTTTATTTTGAGTAAAGATTAG  
SPRY2 fwd GAGAGATTTTAAGGTTTGTTTGAGTA 218 
SPRY2 rev ACCCCAATTATACCATCAACAAC  
SPRY2 seq AACTACTACTAATACTTATCCTC  
ID2 fwd ATGGGAGAAGGTATTGTTTTAA 229 
ID2 rev AACCAATATAAACAAACATCTTTAA  
ID2 seq TGTAAAGTGTAAAGTGAAAT  
PRDM1 fwd TAGGTTTGGTTTTTTATTTAGTGA 233 
PRDM1 rev CACTTTTATCAATTACCTTTTCCA  
PRDM1  seq TTTTATCAATTACCTTTTCC  
TCL6 fwd AGGTTAGGGTTGTTTTGTGTATAT 259 
TCL6 rev CAAACATTTCTAAAACCTCTTTAA  
TCL6 seq TGTGAAGAAGATATAGTAAG  
CSMD1 fwd GGGGTTGGTTTTTAAATATTGATG 146 
CSMD1 rev TTATCTTTATCAATCCTCCTTCCA  
CSMD1 seq TTAAATATTGATGTGGTTAA  
FGFR2 fwd GATTTGGTATTGGGGAAGATTTTT 150 
FGFR2 rev AATCCCATCTACACACTTCCTCTA  
FGFR2 seq TTGGTATTGGGGAAGA  
 
Table 2.3 List of primers used for pyrosequencing 
 
       
2.11 Bacteriology 
 
2.11.1 Preparation of L-agar/ampicillin plates 
L-broth agar (LBA; 10 g L-broth powder and 7.5 g nutrient agar (both Invitrogen ) in 500 ml 
distilled water) and L-broth solution (10 g L-Broth powder in 500 ml distilled water) were 
made up in advance, sterilised by autoclaving at 121ºC, 15 psi for 15 minutes and allowed to 
cool for one hour.  Ampicillin (Sigma-Aldrich) was added to the LBA to a final concentration 
of 100 µg/ml.  Agar was poured into Petri dishes (Bibby Sterilin) and cooled to room 
temperature. 
 
2.11.2 Bacterial transformation 
“Top 10” chemically competent E. coli bacterial cells were thawed on ice. Approximately 500 
ng of plasmid was added to 50 µl of the bacteria and incubated on ice for 30 minutes.  Cells 
were heat-shocked at 40ºC for 1 minute.  200 µl of L-broth was added which were left to 
recover for an hour at 37ºC.  100 µl of cell suspension was spread onto L-agar/ampicillin 
plates and incubated inverted overnight at 37ºC.  
 
2.11.3 Purification of plasmid DNA 
Colonies grown on L-agar/ampicillin plates were used to inoculate 2 ml L-broth 
supplemented with 100 µg/ml ampicillin.  Cultures grown for approximately 6 hours at 37ºC 
with shaking were used to inoculate 100 ml of L-broth supplemented with 100 µg/ml 
ampicillin and grown overnight at 37ºC with shaking.  Bacterial cultures were centrifuged at 
6000 g for 15 minutes at 4 ºC.  Plasmid DNA was purified using a plasmid maxi prep kit 
(Qiagen).  Briefly, bacteria was resuspended in 10 ml buffer P1 followed by vigorous mixing 
       
and a 5 minute incubation with 10 ml buffer P2. 10 ml buffer P3 was added to the mixture and 
incubated on ice for 20 minutes.  The suspension was centrifuged at 20,000 g for 30 minutes 
at 4ºC and the supernatant containing the plasmid DNA removed.  The supernatant was 
applied to a pre-equilibrated Qiagen column and allowed to pass through.  Columns were 
washed twice with buffer QC and DNA eluted in 15 ml buffer QF.  DNA was then 
precipitated by adding 10.5 ml isopropanol and centrifuged at 15,000 g for 30 minutes at 4ºC.  
Supernatant was decanted,  the pellet washed in 5 ml 70% ethanol, centrifuged at 15,000 g for 
10 minutes, supernatant decanted again and the pellet allowed to air dry.   DNA was 
resuspended in 200 µl TE buffer and the concentration determined using the NanoDrop.  
 
2.11.4 Restriction 
A reaction master mix was prepared using; 2 μl reaction buffer, 0.5 μl of appropriate 
restriction enzymes (Roche) and 15 μl DNase/RNase-free water. 18 μl of this master mix was 
then pipetted into 0.2 ml PCR tubes and 2 μl DNA was added to each, and left for 2 hours at 
37o C or at room temperature overnight.  The sample was run on a 1.2% agarose gel (Section 
2.3.4).  The gel was viewed under UV light and photographed using a GeneFlash Syngene 
Bio Imaging analyzer.  DNA samples should have 3 bands – top is uncut DNA with vector, 
middle is cut vector and bottom is cut DNA insert.  Vector samples should have 2 bands – top 
is uncut empty vector, bottom is cut vector. 
 
 
 
 
 
       
2.12 Transfection of plasmid DNA into mammalian cells 
2.12.1 Lipofectamine mediated transfection of HeLa cells 
Plasmid DNA was transiently transfected into cells using Lipofectamine™ LTX and PLUS 
reagent (Invitrogen).  Prior to the day of transfection, HeLa cells were plated in 500 µl of 
media at 6 x 104 cells per well of a 24 well plate.  For each well, 250 ng of plasmid was 
diluted in 100 µl Optimem (Gibco) and mixed gently. 0.5 µl Plus reagent was added to DNA, 
mixed gently and incubated for 15 minutes at room temperature. 1.25 µl Lipofectamine LTX 
reagent was added to the DNA and incubated for 30 minutes at room temperature.  100 µl of 
the DNA-Lipofectamine LTX complexes were added to each well and mixed by rocking.  
Media was changed the following day. Cells were harvested 48 hours following transfection. 
 
2.12.2 Electroporation of suspension cells 
Cells were split 24 hours before transfection to ensure they were in the log phase of growth.  
Cells were centrifuged at 1000 rpm for 10 minutes at 4ºC and re-suspended in 10 ml PBS. 1 x 
107 cells were required per reaction and each reaction was carried out in duplicate for the 
plasmid containing the gene of interest and for the vector control.  Cells were counted and the 
appropriate volume of cells removed. Cells were centrifuged at 1000 rpm for 10 minutes at 
4ºC and re-suspended in 10 ml Optimem (Gibco).  Cells were centrifuged again and re-
suspended in 300 µl Optimem per reaction.  The optimised amount of DNA plasmid (10 – 30 
µg) was pipetted into a 1.5 ml Eppendorf and 300 µl of cells in Optimem were added and 
mixed gently.  The cells plus DNA were transferred to sterile electroporation cuvettes 
(Geneflow) and placed inside the Bio-Rad Gene Pulser.  Cells were electroporated at 230 V, 
975 µF and quickly transferred using a Pasteur pipette to 10 ml warm media in a 25 cm3 tissue 
       
culture flask. Cells were grown at 37ºC and the media was changed the following day.  Cells 
were harvested 48 hours post transfection. 
 
2.13 Cross-linked chromatin immunoprecipitation (X-ChIP) 
Cross-linked chromatin immunoprecipitation (X-ChIP) was used to study DNMT binding in 
vivo, a method previously optimised by Dr. Laura O Neill (Institute of Infection and 
Immunity).  Briefly, formaldehyde was used to cross-link protein-DNA interactions in the 
cell. Chromatin was then prepared from these cells and an immunoprecipitation (IP) 
performed using a specific antibody.  Immune complexes were collected with protein G 
magnetic beads, the protein was removed and the DNA eluted and purified.  DNA in the 
precipitates was then analysed by Q-PCR for cellular and EBV DNA. 
 
2.13.1 Cross-linking and chromatin shearing 
IP reactions were performed on cells split 24 hours prior to harvesting to ensure they were in 
log phase of growth.  Cells were harvested in three times the volume of ice cold PBS 
containing 5 mM sodium butyrate (Millipore) and counted.  Chromatin was isolated from 4 x 
106 cells, the appropriate volume of cells was removed and pelleted by centrifugation at 400 g 
at 4ºC for 5 minutes in an Eppendorf centrifuge.  Cells were resuspended in 2 ml PBS/sodium 
butyrate. 37% formaldehyde solution (Fisher) was added to the cells to a final concentration 
of 1% and incubated at room temperature for 8 minutes on a roller.  To stop the cross-linking 
reaction, glycine was added to a final concentration of 0.15 M and samples incubated at room 
temperature for 5 minutes.  Cells were pelleted by centrifugation at 470 g at 4ºC for 10 
minutes and the supernatant removed.  Cells were washed twice in 2 ml ice cold PBS/sodium 
butyrate, centrifuged and the pellet re-suspended in 520 µl lysis buffer (10 mM EDTA, 50 
       
mM Tris-HCL pH 8, 1% w/v SDS, 5 mM Na butyrate, 0.01 mM PMSF (Sigma), 1X protease 
inhibitor cocktail (Roche)).  Lysate was then split into four 0.5 ml Eppendorf tubes and 
sonicated on ice using a Bioruptor (Diagenode) for 30 minutes at the highest power with 0.5 
minute breaks in between each pulse.  Samples were centrifuged at 10,000 g in a table top 
centrifuge at 4ºC for 10 minutes.  The supernatant was removed and the DNA measured on 
the NanoDrop at A260/280.  2 µg of chromatin was de-crosslinked in 500 µl lysis buffer in 
containing 50 mM proteinase K at 68ºC for 2 hours, to check DNA size.  DNA was extracted 
using the ChIP DNA clean and concentrator™ kit (Zymo Research).  The eluted DNA in a 
total volume of 30 µl was run on a 1.5% agarose gel (Section 2.3.4).  DNA fragments were 
required to be 200 – 1000 bp in size. Chromatin was then either used immediately for IP or 
frozen at -80ºC. 
 
2.13.2 Preparation of Protein G Dynabeads 
For each IP reaction, 100 µl Protein G Dynabeads (Invitrogen) were transferred to 1.5 ml 
Eppendorf tubes and the washing procedure carried out facilitated by the use of a magnet 
(Dynal MPC).  The beads were placed on the magnet for 1 minute and the supernatant 
removed.  Beads were washed three times in 0.5 ml cold RIPA buffer (10 mM TRIS-HCL 
pH7.5, 1 mM EDTA, 0.5 mM EGTA (Sigma), 1% Triton X-100, 0.1% SDS, 150 mM NaCl, 
0.1% sodium doeoxycholate).  Finally the beads were re-suspended in 90 µl RIPA buffer. 
 
2.13.3 Immunoprecipitation 
100 µl of beads in RIPA buffer were incubated with 2.4 µg of a polyclonal antibody over 
night at 4ºC with rotation.  A non-specific IgG antibody and an IP with no antibody were used 
as controls and run with every IP.  Antibodies used are shown below.  After incubation, the 
       
antibody bound beads were isolated using the magnet and the supernatant removed.  10 µg 
sonicated chromatin diluted in 100 µl RIPA buffer was added to the beads and incubated for 8 
hours at 4ºC on a rotating wheel.  The immune complexes were isolated using the magnet and 
washed three times with 100 µl RIPA buffer end over end for 4 minutes.  The beads were re-
suspended in 100 µl TE buffer pH8. 
Target protein Antibody Species 
DNMT1 
DNMT1 
Ab1-6632 
IMG 07703648959 
Rabbit polyclonal 
Mouse monoclonal 
DNMT3A Sc-10231 Goat polyclonal 
DNMT3B Ab-2851 Rabbit polyclonal 
 
Table 2.4 Antibodies used in X-ChIP 
 
2.13.4 DNA elution and reversal of cross-links 
The DNA-bead complexes were captured, TE removed and the beads re-suspended in 150 µl 
elution buffer (20 mM TRIS-HCL pH7.5, 5 mM EDTA, 5 mM sodium butyrate, 50 mM 
NaCl, 1% SDS), 50 mM proteinase K and incubated over night at 68ºC on an Eppendorf 
thermomixer.  Beads were again captured using the magnet and the supernatant transferred to 
a new Eppendorf.  Beads were washed in 150 µl elution buffer, supernatant removed and 
added to the previously collected supernatant.  A further 200 µl elution buffer without SDS 
was added to the eluent.  
 
2.13.5 DNA isolation and purification  
Input and IP DNA was purified using the ChIP DNA clean and concentrator™ kit. Briefly, 5 
volumes of ChIP DNA binding buffer was added to each sample, mixed and transferred to a 
spin column.  The sample was centrifuged at 13’000 RPM for 30 seconds and the flow-
       
through discarded.  200 μl wash buffer to the column. The sample was centrifuged at 13’000 
RPM for 30 seconds and the flow-through discarded.  The wash step was repeated. The 
column was transferred to a new 1.5 ml microcentrifuge tube and 30 μl elution buffer  added 
to the column and centrifuged at 13’000 RPM for 30 seconds. 
 
 
2.13.6 Q-PCR to amplify DNA in the X-ChIP immunoprecipitates 
Q-PCR was performed using SYBR green to detect DNA in chromatin IPs and input samples.  
Overlapping primers were designed in the Wp and Cp promoter to detect where the DNMTs 
were binding.  GAPDH primers were designed as a negative control.  The primers used are 
listed below.  Q-PCR reactions were run in triplicate with 1 µl DNA, 12.5 µl SYBR green 
master mix, 15 mM forward and reverse primers in a total reaction volume of 25 µl.  Cycling 
conditions were as follows: denaturation at 95ºC for 15 minutes, followed by 40 cycles at 
95ºC for 15 seconds, 58ºC for 30 seconds, 72ºC for 1 minute.  The amount of DNA present in 
the IP fractions was determined as a % of input and compared to the negative controls. 
 
 
 
 
 
 
 
 
 
       
 
Primer Sequence Product size Temperature 
GAPDH fwd TCGGTGCGTGCCCAGTTGAAC 
GAPDH rev ATGCGGCTGACTGTCGAACAGGAG 64°C 246 bp 
Sat 2 fwd ATTCGAGTCCATTCGATGATTCCAT 
Sat 2 rev ATGGAAATGAAAGGGGTCATCATCT 57°C 398 bp 
HoxA7 reg E fwd CCCTCTATTCTCCATCGGAGAC 
HoxA7 reg E rev CTGCACCATGTTGCACCAG 60°C 522 bp 
HoxA7 reg F fwd CTGGTGCAACATGGTGCAG 
HoxA7 reg F rev CCTCCTCCCGGACGCTG 60°C 497 bp 
Wp region 1 fwd TTCATCATGTAACCCACAAATCA 
Wp region 1 rev CGGAAGTGACACCAAATATCTCT 58°C 405 bp 
Wp region 2 fwd CACTTCCGCATTTTAAGTTTCAG 
Wp region 2 rev TCTGCTCGTTACCAGAGAGAATG 58°C 431 bp 
Wp reg 3 fwd TCTGGTAACGAGCAGAGAAGAAG 
Wp reg 3 rev ACAGAGAGAGGGGCAGAACC 58°C 572 bp 
Wp reg 4 fwd TCTCTCTGTCCTTCAGAGGAACC 
Wp reg 4 rev GTCTAGGGTGGAGCGAAGGT 58°C 461 bp 
Wp reg 5 fwd GCTTCAGAGCCCAGGATGTC 
Wp reg 5 rev GAGGCTGGACTTTACAGACAGTG 58°C 473 bp 
Wp reg 6 fwd GTCTCCTGTGCACTGTCTGTAAA 
Wp reg 6 rev AGATTTCGGGTCCAAATCACTAC 58°C 484 bp 
Wp reg 7 fwd GACCCGAAATCTGACACTTTAGA 
Wp reg 7 rev GAGGTAGAAGACCCCCTCTTACA 58°C 423 bp 
Wp reg 8 fwd TGTAAGAGGGGGTCTTCTACCTC 
Wp reg 8 rev ACTAAGCCTCCCTTTATGTGAGC 58°C 469 bp 
Wp reg 9 fwd GCTCACATAAAGGGAGGCTTAGT 
Wp reg 9 rev TCTGCTCGTTACCAGAGAGAATG 58°C 493 bp 
Cp fwd AAATGTTGAGGGACCTAAGAGATG 
Cp rev TGGCTTTAATTGTCATGTATGCTT 58°C 414 bp 
 
Table 2.5:  List of primers used for X-ChIP    
 
 
2.13.7 Normalizing ChIP Q-PCR data 
Two methods are commonly used to normalize ChIP Q-PCR data – the percent input method 
and the fold enrichment method.  Analyzing the data relative to input is a better method as it 
included normalization for both background levels and input chromatin going into ChIP.  An 
example of how each method is used to calculate the ChIP results is shown below. 
 
 
 
       
2.13.7.1 Percent Input Method 
In this method signals obtained from the ChIP are divided by those signals obtained from an 
input sample. The input sample represents the amount of chromatin used in the ChIP.  
Typically 1-10% of starting chromatin is used as input.  An example of how this is calculated 
is shown below. Step1: As the starting input fraction is 10%, then a dilution factor of 10 0r 
3.32 cycles (i.e., log2 of 10) is subtracted from the Ct value of the diluted input. Step 2; The 
percent input is calculated using the formula 100*2^(Adjusted input – Ct (IP).  The % input is 
then plotted on the x axis against each antibody on the y axis. 
 
 
 
 
 Raw Ct 
Ct adjusted to 100% 
(Ct Input-3.32) 
Input 10% 25.917 22.59 
 
 
 Average Ct 100*2^(Adjusted input – Ct (IP) 
Adjusted Input 22.59  
No Antibody 28.864 1.3 
IgG 28.625 1.53 
DNMT3A 27.413 3.53 
 
 
 
 
Step 1 
Step 2 
       
2.13.7.2 Fold Enrichment Method 
This normalization method is also called ‘signal over background’ or ‘relative to the no 
antibody’.  With this method the ChIP signals are divided by IgG antibody signals, 
representing the ChIP signal as the fold increase in signal relative to the background signal (as 
shown below).  The assumption of this method is that the level of background signal is 
reproducible between different primer sets, samples and replicate experiments.  
 
 
Average 
Ct 
Ct (IP) – Ct IgG Ct (IP) – Ct IgG 
IgG 28.625 0 0 
No Antibody 28.864 0.239 .85 
DNMT3A 27.413 -1.451 2.73 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
2.14 Immunohistochemistry 
2.14.1 Preparation of cultured cells for immunohistochemistry 
Adhesive-coated slides were assembled with Cytofunnel® disposable sample chambers, filter 
cards and Cytoclips™ (Thermo Electron) according to the manufacturer’s instructions and 
inserted into the Shandon Cytospin centrifuge (Thermo Electron).  2 x 106 cells were 
harvested and re-suspended in 1 ml PBS and fixed in 100 μl formalin.  100 μl of fixed cells 
were transferred into the Cytofunnels®. Cells were adhered to slides by centrifugation in the 
Cytospin at 1000 g for 5 minutes. Cells were air dried, fixed for 10 minutes in 10% formal-
saline solution (Genta Medical), and air dried.  Cytospin preparations were stored in foil at -
20o C. When required, slides were thawed and washed in running tap water for 5 minutes 
before continuing with standard immunohistochemistry technique. 
 
2.14.2 Preparation of tissue biopsy sections for immunohistochemistry 
Sections of paraffin-embedded tissue biopsies were dewaxed and rehydrated using xylene and 
ethanol, 2 x 5 minutes each.  
 
2.14.3 Blocking of endogenous peroxidase activity and antigen retrieval 
Endogenous peroxidase activity was blocked for 10 minutes in 3% hydrogen peroxide in 
methanol (both Sigma-Aldrich).  Slides were rinsed thoroughly in running tap water. Antigen 
retrieval was performed using the agitated low temperature epitope retrieval (ALTER) method 
by incubation of slides in EDTA buffer pH8 for 16 hours, and then cooled in running cold 
water for 5 minutes. 
 
 
       
 
2.14.4 Detection of antigen 
Slides were incubated in 1X PBS for 5 minutes, then blocked using 2X casein blocking 
solution (Vector laboratories),  washed for 5 minutes in 1X PBS and incubated with diluted 
primary antibody for 1 hour.  Samples were washed in PBS for 5 minutes.  Secondary 
detection was with DakoChemate envision secondary antibody (Dako) using 2 drops of 
biotinylated universal secondary antibody was added to each tissue section for 30 minutes.  
Sections were washed again in PBS for 5 minutes.  
 
2.14.5 Visualization and counterstaining 
Visualization was carried out using diaminobenzidine (DAB) (Vector laboratories).  A 
minimum of 100 μl of substrate solution was applied to each tissue section for between 30 
seconds to 1 minute, during which time the substrate was converted to an insoluble brown 
product by the antigen-bound peroxidases.  Slides were rinsed with PBS, counterstained with 
Mayer’s haematoxylin (Sigma) for 10 seconds, washed under running tap water for 5 minutes, 
and dehydrated through two lots of ethanol and xylene for 5 minutes each, before being 
mounted with coverslips and one drop of DPX mounting (Invitrogen).  
 
 
 
 
 
 
 
 
 
 
 
 
       
 
Chapter 3 
 
A genome wide analysis of 
transcriptional and methylation changes 
which follow Epstein Barr Virus 
infection of Germinal Centre B cells 
 
 
 
 
 
 
 
 
 
       
Aims of Chapter 3: 
To describe the transcriptional and DNA methylation changes associated with EBV infection. 
 
Objectives: 
1) To profile virus gene expression in lymphoblastoid cell lines (LCLs) established from GC 
B cells isolated from tonsillar tissue. 
2) To describe the genome wide transcriptional changes which follow the infection of GC B 
cells with EBV and the extent to which these changes overlap with; 
i) those observed following the transfection of GC B cells with LMP1 and LMP2A 
ii) the transcriptional programme of transformed HL cell lines and of  micro-dissected 
HR-S cells. 
3) To describe the genome wide changes in DNA promoter methylation which follow 
infection of GC B cells with EBV.  
4) To determine;  
i) if the distribution of methylation changes are related to chromosomal location, 
CpG content and baseline gene intensity scores. 
ii) the association between methylation and transcriptional changes. 
5) The ontological associations of those genes found to be more or less methylated following 
EBV infection and their relevance to the pathogenesis of HL. 
 
 
 
 
 
       
 
In this section, I first describe the establishment of lymphoblastoid cell lines from 
germinal centre B cells before profiling the expression of viral genes in these cells. 
I next describe the preparation of RNA, the assessment of its integrity and its 
subsequent hybridization to the transcriptional array platforms.  After summarising 
the transcriptional changes observed in this array, I measure the extent to which the 
transcriptional profile of EBV infected GC B cells overlaps that of GC B cells 
transfected with LMP1 or LMP2A; that of HL cell lines when compared with GC B 
cells; and that of micro-dissected HRS cells compared with centrocytes and 
centroblasts. 
 
 
 
3.1  Establishment of lymphoblastoid cell lines from germinal centre B 
cells and genome wide profiling of EBV associated transcriptional changes 
in these cells 
One of the difficulties faced when studying the contribution of EBV to the early stages of its 
associated malignancies, is that the cell lines used to model disease are already fully 
transformed and rarely resemble their progenitor cell.  Therefore, a cell line model which 
allows us to study the early consequences of EBV infection and their possible contribution to 
the pathogenesis of disease is needed.  My disease focus is on HL, and therefore I chose to 
infect germinal centre B cells, the presumed progenitor cells of HL with EBV. This model 
was used to identify the global transcriptional and methylation changes that occur following 
infection and transformation.   
       
 
3.1.1  Infection of freshly isolated GC B cells with 2089 virus particles 
Isolation of CD10+ cells from tonsillar tissue:  GC B cells were isolated from tonsillar tissue 
using CD10+ selection and magnetic separation as described in Section 2.7.  Following 
magnetic separation, more than 90% of the GC B cells were found to be CD10+, comprising 
centroblasts (CD77+) and centrocytes (CD77-).  Figure 3.1 shows the flow cytometric analysis 
of tonsillar mononuclear cells from one patient before and after enrichment. 
 
Infection of GC B cells:  GC B cells isolated from three different tonsils were infected with 
EBV at a multiplicity of infection (MOI) of 50.  A green fluorescent protein (GFP) tag on the 
virus was used to indicate the efficiency of viral infection which was found to be >80%, 48 
hours post infection (Figure 3.2).  Cells were harvested daily for the first four days following 
infection and then at weekly intervals up to 3 weeks with the last sample collected 6 weeks 
post infection.  DNA, RNA and protein were prepared at each time point for subsequent 
analyses.    
 
 
 
 
 
 
       
 
Figure 3.1:  Enrichment of CD10+ GC B cells.  Flow cytometric analysis of tonsillar 
mononuclear cells before enrichment (left panel) and after (right panel), stained for CD10 and 
CD77. 
 
 
 
 
 
Figure 3.2:  Infection of GC B cells with EBV.  Infection efficiency was determined using 
UV microscopy.  Infected cells express GFP that can be detected upon exposure to UV light 
(right).  Phase contrast (left) reveals the number of cells within the same area. 
 
 
Phase contrast 2089 expressing cells 
Before enrichment After enrichment 
       
3.1.2  Gene expression profiling revealed a typical latency III pattern in infected GC B 
cells  
Total RNA was isolated and reverse-transcribed into cDNA as described in Sections 2.2.1 and 
2.4.2.   Q RT-PCR was carried out using primers and probes specific for latent gene 
transcripts.  The EBV transcript was normalised to the endogenous control, GAPDH, and 
results plotted relative to GC B cells.  Although Figure 3.3 illustrates using data from three 
independent experiments, variation between LCLs established from different donors, the 
trends in viral gene expression are similar and can be summarised as follows. 
• Wp is activated within 24 hours of infection, peaking between 48-72 hours, 
declining thereafter but remaining detectable at six weeks. 
•  Cp activation was first detected in one tonsil within 24 hours of infection and 
in the remaining two tonsils after 48 hours, increasing thereafter over the 
following six weeks.  
• EBNA1 (Y3-U-K) and EBNA2 transcripts, both indicators of Wp or Cp 
activity, were detectable 24 hours after infection, increasing in expression 
thereafter. 
• There was no evidence of Q-U-K spliced EBNA1 mRNA indicative of Qp 
usage.   
• LMP1 expression was detectable in all three tonsils within 24 hours of 
infection, increasing gradually thereafter.  
•  LMP2A, the last viral gene to be expressed in all three LCLs, was detected 72 
hours post-infection.   
• BZLF1 expression was low and variable across the three tonsils, suggesting 
that different numbers of cells were entering the lytic cycle.  
Days post infection
Figure 3.3: Analysis of EBV gene expression following infection of GC B cells with EBV.  Q‐RT PCR showing Wp, Cp, Y3‐U‐K‐
 
spliced 
 
EBNA1, 
 
EBNA2, 
 
LMP1, 
 
LMP2A 
 
and 
 
BZLF1 
 
expression 
 
in 
 
three 
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at 
 
different 
 
time‐points 
 
post 
 
infection. Assays were performed in triplicate and results are presented as raw Ct values.
       
3.1.3 Preparation of RNA for Transcriptional arrays 
Total RNA from GC B cells (10 µg) and from LCLs (10 µg) six weeks post-infection with 
EBV was prepared for hybridization to Affymetrix GeneChip®Human Genome U133 Plus 
2.0 arrays as described in Section 2.8. The RNA was used to synthesize double stranded 
cDNA which was then transcribed to cRNA.   This cRNA was then fragmented, labelled and 
hybridized to the arrays.  The efficiency of fragmentation was checked by running the product 
on a 1.5% agarose gel (Figure 3.4). 
 
3.1.4 Assessment of RNA quality  
Although the pre-processing RNA quality checks had been entirely satisfactory for both the 
uninfected GC B cells and their EBV infected counterparts,  the number of genes recorded as 
present on these uninfected GC B cell arrays was substantially less than that found to be 
present on other GC B arrays performed within this Institute (Table 3.1). This was possibly 
due to an insufficient amount of good quality RNA prior to amplification of the GC B cell 
sample. Therefore I decided to discard this data set, and instead compared the transcriptional 
profile of EBV infected GC B cells with another set of unamplified GC B cells which had 
been used in an earlier array experiment performed in this institute (Vockerodt et al., 2008). 
 
 
 
 
 
 
 
       
 
       GC B cell RNA              LCL RNA 
            
 
Figure 3.4:  Validation of RNA samples on an agarose gel.  An aliquot of fragmented and 
unfragmented RNA was run on an agarose gel to ensure the fragmentation step has worked 
successfully.  
 
 
 
 
Present on all 
6 arrays 
Absent on all 
6 arrays 
Absent on all   
3 GC B cell 
arrays but  
present on all 
3 LCL arrays 
Absent on all 
3 LCL 
arrays but 
present on 
all 3 GC B 
cell arrays 
Matching GC B 
cell arrays 5562 29206 60 73 
Alternative GC B 
cell arrays 15222 24184 1452 715 
 
Table 3.1:  Summary of present or absent call on each array.  Probes that bind target 
transcripts above background noise are called present. Probes that do not bind target 
transcripts are called absent.   
 
Fragmented RNA Fragmented RNA Unfragmented RNA Unfragmented RNA 
  1      2      3                   1      2       3         1        2         3         1        2        3 
       
 
3.1.5 Measurement of gene expression changes in GC B cells following infection with 
EBV 
Affymetrix GeneChip®Human Genome U133 Plus 2.0 arrays were used to analyze the gene 
expression changes following infection of GC B cells with EBV.  These arrays allow for the 
analysis of 20765 genes with recognised gene symbols.  The analysis of these arrays was 
performed with the help of Dr. Wenbin Wei, Head of the Bioinformatics department in the 
School of Cancer Sciences. The microarrays were scanned and the images analysed using 
Affymetrix microarray Suite 5.0.  Probe level quantile normalization and robust multiarray 
analysis on the raw .CEL files were performed using the Affymetrix package of the 
Bioconductor (http://www.bioconductor.org) project.   
 
3.1.6  Overall summary of transcriptional changes 
Differentially expressed genes were identified using Significance Analysis of Microarrays 
(SAM).  Using a false discovery rate (FDR) threshold of 5% with no fold - change cut off, a 
change in transcript binding was detected in 25474 probe sets; in 13548, there was an increase 
in binding and in 11926 a decrease. These probe sets mapped onto 13962 named genes; 6766 
were up-regulated and 7196 were down-regulated (Table 3.2).   
 
 
 
 
 
 
       
 
 
Probe sets 
 
N = 25474 
Named genes 
 
N = 13962 
increased decreased increased decreased 
11926 13548 6766 7196 
 
 
Table 3.2: Results of the SAM analysis performed using an FDR threshold of 5% on 
EBV infected GC B cells.   
 
 
3.1.7 Comparison of in-house and published arrays with EBV infected GC B cell 
arrays 
The results of the EBV infected GC B cell arrays were compared with a number of in house 
and published arrays.  In two of these arrays, GC B cells had been transfected with EBV latent 
genes, LMP1 or LMP2A (Vockerodt et al., 2008, Vockerodt et al., unpublished data).  In the 
third, the transcriptional profile of four HL cell lines (L428, L591, KMH2 and L1236) had 
been compared with that of the GC B cells.  I also compared the results of my array with a 
published dataset which compared the transcriptional profile of micro-dissected HRS cells 
with that of centrocytes and centroblasts (Brune et al., 2008).  All datasets contributing to 
these comparisons were re-analysed using SAM (5% FDR with no fold change cut-off), with 
the exception of the LMP2A array which was analysed using the Limma programme (5% 
FDR and 1.3 fold change cut off). 
 
 
       
 
 
3.1.8 Assessment of significance of over-laps between transcriptional arrays 
When comparing each of these data sets with my EBV infected GC B cell array, I first 
identified for each set of arrays, those genes that were concordantly up-regulated and those 
which were concordantly down-regulated.  In order to exclude the possibility that the 
observed over-laps could have arisen by chance, I estimated the number of genes which I 
would have expected to be differentially expressed in both arrays given the frequency with 
which they were found to be differentially expressed in EBV infected GC B cells (Table 3.3).  
For example, of the 20765 genes on the U133 array, 6766 were up-regulated by EBV in GC B 
cells and 849 were up-regulated by LMP1 in GC B cells. By chance alone we would expect 
that some of the genes up-regulated by EBV in GC B cells would also be up-regulated by 
LMP1 in GC B cells.  It might be expected that of the 849 genes up-regulated on the LMP1 
GC B cell array, a proportion, 0.325 (6766/20765) would be up-regulated by EBV in GC B 
cells.  However, rather than the 276 genes (0.325*849) that I would have expected to be up-
regulated by both LMP1 and EBV in GC B cells, I found that in fact, 556 genes were up-
regulated on both arrays.  The difference between the observed and expected number of over-
lapping genes provides the basis for significance testing using a simple chi-square test.   
As well as measuring the significance of the association, we can also measure the magnitude 
of the association. A common statistic used to describe the magnitude of the association is the 
odds ratio. A worked example shown below compares the relative odds of being up-regulated 
by LMP1 in two groups of genes, one of which comprises genes up-regulated by EBV in GC 
B cells, the other genes which were transcriptionally unchanged following EBV infection.  
For those genes up-regulated by EBV, the odds of also being up-regulated by LMP1 
       
were 0.091 or approximately 1 in 10 (556/6210). For those genes not up-regulated by EBV, 
the odds of being up-regulated by LMP1, the odds were 0.021 or approximately 1 in 50 
(293/13706). The odds ratio is 4.3 (~0.091/0.021). Thus, there is greater than fourfold odds of 
a gene being up-regulated by LMP1 if it is also up-regulated by EBV than if it is not.  
worked example  
  
 
 
Up-regulated by 
LMP1 in GC B 
cells  
 Yes No  
Yes 556 (a) 
  6210 
    (b)  Up-regulated by 
EBV in GC B cells 
No    293         (c) 
 13706   
    (d)  
 
The formula for the odds ratio can be written as:       OR = a/b 
                                  c/d 
  
 
Chi-square tests were performed and odds ratios estimated for each of the array comparisons 
and the results are summarised in Table 3.3.  As a control of convenience, an array performed 
on GC B cells transfected with BMI1, a component of the Polycomb group (PcG) 
multiprotein PRC1 complex, was included in Table 3.3.  As might have been expected, we do 
not see a significant over-lap between genes differentially regulated by BMI1 and EBV in GC 
B cells.  The most compelling result from Table 3.3 is the finding that genes which were 
differentially expressed in HL cell lines compared with GC B cells were substantially and 
significantly enriched for those that were differentially regulated in GC B cells infected with 
EBV.  A 60% over-lap in concordantly regulated genes was observed between the micro-
dissected HRS cells and the EBV infected GC B cells. These results indicate that EBV 
infected GC B cells may be a good model for recapitulating those early changes associated 
       
with HL.  Not surprisingly the over-lap between the EBV infected GC B cells and the LMP1 
transfected GC B cells was substantial and significant given that LMP1 is the major 
transforming oncogene of EBV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Frequency with which genes found to be differentially expressed in GC B cells following infection with EBV were also found to be 
differentially expressed in HL cell lines, HRS cells and GC B cells transfected with LMP1 or LMP2A 
 Array comparison 
Increased 
on array 
Increased on 
array and in 
EBV infected 
GC B cells 
% concordantly 
increased 
Odds 
Ratio 95% CI p  value 
HL cell lines vs. GC B cells 1724 1313 76% 8 7.1 to 9 p = 0.0000 
HRS cells vs. centrocytes 6569 2558 39% 1.5 1.4 to 1.6 p = 0.0000 
HRS cells vs. centroblasts 4304 1856 43% 1.8 1.7 to 1.9 p = 0.0000 
LMP1-GC B vs. GC B cells 849 556 65% 4.2 3.6 to 4.8 p = 0.0000 
LMP2A-GC B vs. GC B cells 310 156 50% 2.1 1.7 to 2.6 p = 0.0000 
Increased  
in LCL     
n = 6766 
 
BMI1-GC B vs. GC B cells 139 17 12% 0.28 0.17 to 0.47  p =  0.0000 
 Array comparison 
Decreased 
on array 
Decreased on 
array and in 
EBV infected 
GC B cells 
% concordantly 
decreased 
Odds 
Ratio 95% CI p  value 
HL cell lines vs. GC B cells 2207 1764 80% 9.6 8.6 to 10.7 p = 0.0000 
HRS cells vs. centrocytes 2292 1375 60% 3.3 3 to 3.6 p = 0.0000 
HRS cells vs. centroblasts 3607 2017 56% 2.9 2.7 to 3.2 p = 0.0000 
LMP1-GC B vs. GC B cells 1347 860 64% 3.6 3.2 to 4.1 p = 0.0000 
LMP2A-GC B vs. GC B cells 440 204 46% 1.7 1.5 to 2.1 p = 0.0000 
Decreased 
in LCL     
n = 7196 
BMI1-GC B vs. GC B cells 229 73 31% 0.88 0.66 to 1.1 p = 0.3714 
        
Table 3.3: Frequency with which genes found to be differentially expressed in GC B cells following infection with EBV were also found 
to be differentially expressed in HL cell lines, HRS cells and GC B cells transfected with LMP1 or LMP2A:  Significance testing was  
carried out using a chi-square test (www.quantitativeskills.com/sisa/statistics/twoby2.htm).  The BMI1-GC B vs. GC B cells analysis serves as a 
control, as we would not expect to see a significant number of genes concordantly regulated between GC B cells transfected with BMI1 and GC 
B cells infected with EBV.  
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Summary 
In this section, I have described how I established three LCLs from different patient 
GC B cells.  I have confirmed that these LCLs express the typical Latency III pattern 
of viral gene expression. I have also shown that the transcriptional profile of EBV 
infected GC B cells overlaps that of HL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
3.2 Methylation arrays 
 
In this section, I describe how I first isolated and then hybridized to a promoter 
array, methylated DNA from EBV infected GC B cells.  Having provided a 
summary of the genome wide changes in the methylation status of cellular 
genes, I next confirmed some of these changes using pyrosequencing and a 
candidate gene approach.  Finally, I determine for selected genes, whether the 
methylation changes observed at six weeks are progressive on further cultivation 
of EBV infected GC B cells.  
 
3.2.1 Optimization of the immunoprecipitation assay 
Whole genomic DNA was isolated from both the LCLs and GC B cells as described in 
Section 2.2.3.  Methylated DNA was isolated using an immunoprecipitation method (MeDIP) 
originally described by Weber et al,. 2005.  For this MeDIP assay, a monoclonal 5-methyl-
cytosine antibody was used to immunocapture methylated genomic fragments. 
Sonication: DNA was sonicated and conditions optimised so as to yield fragments between 
200 - 1500 bp in length.  The optimum conditions were provided by 20 minutes of 30 second 
pulses at the highest setting, with 30 seconds on ice in between each pulse (Figure 3.5). 
Determining the DNA-to-antibody ratio: Varying amounts of antibody (1 µg to 15 µg) were 
added to 5 µg of LCL DNA and the methylated DNA recovered from the elution fraction as 
described in Section 2.9. The relative enrichment in the eluant was compared to input 
fractions was calculated using SYBR green Q PCR as described in Section 2.9.4.  Enrichment 
in each MeDIP assay was determined using primers specific for the methylated Xist sequence, 
(Figure 3.6).  I concluded that 5 µg of input genomic DNA incubated with 7.5 µg of 5-
       
methyl-cytosine antibody achieved optimal recovery of methylated DNA in the LCLs.  All 
subsequent MeDIP experiments were performed with this DNA-to-antibody ratio.   
 
3.2.2 Immunoprecipitation of LCL and GC B cell DNA 
To allow for the variation that may occur in a single immunoprecipitation, MeDIPs were 
carried out in triplicate for each of the three GC B cell and LCL samples.  Methylated DNA 
was assayed in triplicate using SYBR green Q-PCR as previously described in section 2.9.4.  
Enrichment in each elution fraction was determined using primers specific for the methylated 
Xist sequence, (this enrichment varied from approximately 50 – 75 % across the six samples). 
In contrast, the unmethylated GAPDH sequence formed less than 5% of the elution fraction in 
all six samples (Figure 3.7).  Following confirmation of enrichment for each MeDIP 
performed, the three elution fractions for each individual sample were pooled.    
 
3.2.3 Amplification of immunoprecipitated DNA 
Inevitably methylated DNA comprises only a fraction of the DNA in the starting sample.  
However, 7.5 µg of DNA is needed for hybridization to the promoter methylation arrays. 
Therefore, it was necessary to amplify the methylated DNA. Methylated DNA isolated from 
each of the three patient GC B cells and LCLs along with input DNA that did not undergo 
MeDIP was amplified in triplicate using round A/B/C random amplification.  (Although, 
alternative whole genome amplification methods were considered and tried at this point, the 
A/B/C random amplification method was found to be the most successful and is described in 
full in Section 2.9.5). To ensure that enriched methylated DNA had not been lost during 
amplification; amplified products were again checked for enrichment of methylated DNA. 
       
Amplified products from each sample were then pooled, and further processed in preparation 
for hybridisation to the arrays as described in Section 2.9.6.  
 
 
 
Figure 3.5:  Sonication of LCL DNA:  Sonication conditions were optimised to obtain DNA 
fragments of 700 bp in average length. 
 
 
 
 
Figure 3.6:  Optimal DNA to antibody ratio:  The optimal amount of antibody required to 
pull out methylated sequences from 5 µg DNA was calculated by varying the amount of 
antibody and performing MeDIP on each sample.  The eluted fractions were assayed using 
SYBR green Q PCR with the methylated XIST sequence.  Each reaction was performed in 
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triplicate and the percentage MeDIP/Input was calculated as described in Section 2.9.4 of 
Materials and methods. 
 
 
 
 
 
 
 
Figure 3.7: Enrichment of methylated and unmethylated sequences following MeDIP of 
LCL and GC B cell samples.  Enrichment of methylated DNA was assayed using SYBR 
green Q PCR.  GAPDH served as an unmethylated control and Xist served as a methylated 
control.  Each Q PCR reaction was carried out in triplicate.  % MeDIP / Input was calculated 
as described in Section 2.9.4 of Materials and Methods. 
 
 
XIST GAPDH 
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3.2.4 Methylation array analysis 
Following hybridization and scanning of the enriched GC B cell, LCL samples and input 
DNA, the raw array data from each of the biological replicates were quantile-normalized. 
Following normalization, a software programme, TileMap, was used to identify regions of 
hypermethylation and hypomethylation.  
 
3.2.4.1 Setting parameters for analysis using TileMap software 
The normalised data were analysed using TileMap, a software package designed for the 
analysis of tiling arrays. This package offers statistical models and algorithms for the 
detection of genomic loci showing hybridization patterns of interest.  It uses a test-statistic 
that is computed for each probe based on a hierarchical empirical Bayes model. Combination 
of test-statistic information from neighbouring probes within a genomic region can be used to 
show whether the region has a hybridization pattern of interest (Ji and Wong, 2005).   Two 
different methods, the moving average (MA) method and the hidden Markov model (HMM) 
method, were used to analyze normalized data from the methylation arrays. For the MA 
method, window size was set to 11 probes and maximum gap allowed between each set of 11 
probes, set to 300bp.  For the HMM method, expected hybridization length was set to 11 
probes, and the maximal gap allowed set to 200bp.  For both methods, peaks were merged if 
the gap between two peaks were less than the maximal gap allowed and the number of probes 
that failed to pass cut off between the two peaks less than 6.   Peaks were discarded if peak 
length was less than 100bp or did not contain at least 5 continuous probes passing the cut off.  
When calculating the false discovery rate (FDR) for the HMM method the unbalanced 
mixture subtraction (UMS) was used; “left tail” was used for the MA method.  All probe 
sequences were mapped to the genome assembly (Hg18). The output from TileMap included 
       
final summaries for each probe and a *.bed file containing selected genomic regions that 
could be visualized using the Affymetrix Integrated Human Genome browser (IGB). 
 
3.2.4.2 Analysis of methylation changes in EBV infected GC B cells 
These biological samples allowed for a number of different comparisons. For example, a 
comparison of the GC B cell arrays with the input DNA arrays allowed the identification of 
genes that are hypermethylated or hypomethylated in GC B cells.  However, because I wanted 
to identify genes that had a change in methylation status following infection of GC B cells 
with EBV, my primary interest was in the direct comparison of the GC B cell arrays with 
LCL arrays. Therefore, this is the only analysis presented in the main body of my thesis. 
 
3.2.5 Promoter methylation arrays predict widespread changes following EBV 
infection of GC B cells 
The number of genes with a change in methylation status varied according to the analytical 
method used. Methylation changes were detected in 1783 genes using the MA method of 
analysis, and 506 genes were identified using HMM (Figure 3.8).  Of the 506 genes with 
methylation changes identified using HMM, 83% were found to be concordantly methylated 
using the MA method (Table 3.4).  I decided that my preferred method of analysis would be 
predicated on the results of the validation experiments described below. 
 
 
 
 
 
       
 
 
 
 
 
 
Figure 3.8: Number of genes with a change in methylation status upon EBV infection of 
GC B cells.  Identified hypermethylated genes from each analysis are shown in red and 
hypomethylated genes reported in blue. Genes reported as containing sites of both 
hypermethylation and hypomethylation are reported in green. 
 
Table 3.4: Correspondence between HMM and MA methods of analysis. The number of 
genes reported as hypermethylated or hypomethylated, or both using MA and HMM methods 
of analysis.  The total number of genes on the promoter methylation array is 19950. 
 Hidden Markov model 
 Change in methylation status 
LCL > 
GCB 
LCL < 
GCB 
LCL > 
and < 
GCB 
LCL = 
GCB Total 
LCL > GCB 106 0 0 725 831 
LCL < GCB 1 307 0 606 914 
LCL > and < GCB 2 3 3 11 19 
LCL = GCB 61 20 0 18105 18186 
Moving 
average 
Total 170 330 3 19447 19950 
       
 
3.2.6 Validation of methylation changes predicted on the array 
Pyrosequencing, a quantitative method for analysing methylation at individual CpGs, was 
used to validate the results of the methylation array. 12 genes were chosen for validation; in 8 
of these, methylation change was predicted by both the HMM and MA method, in 2 by the 
MA alone and in 2 by the HMM alone.  
 
3.2.6.1 Criteria for selecting candidate genes for validation 
In order to meet some of the other objectives of this thesis one or more of the following 
criteria were used to select candidate genes for further validation: 
1. transcriptional change on the expression array 
2. differentially expressed in HL compared with GC B cells 
3. differentially expressed in GC B cells following transfection with LMP1 or 
LMP2A. 
4. methylation known to be increased or decreased in malignancy 
These criteria are set out in detail for each of the candidate genes in Table 3.5 
 
3.2.6.2 Pyrosequencing confirms array predictions 
Before designing primers for pyrosequencing, the integrated genome browser (IGB) was used 
to visualize regions predicted as hypermethylated or hypomethylated on the array.  The UCSC 
genome browser was then used to obtain the DNA sequences for the genes of interest.  
Pyrosequencing primers and assays were designed as described in Section 2.10.2.  To confirm 
EBV-associated changes in methylation status, pyrosequencing was performed on each of the 
       
three GC B cell and LCL samples. Illustrative examples of pyrosequencing results for 
selected candidate genes are now provided. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Predicted 
methylation 
change on 
promoter array 
Gene 
symbol 
EBV infected 
GC B cell 
transcription
al array 
Expression in HL cell 
lines or HRS cells 
 
Regulated by 
LMP2A or LMP1 
Regulated by 
methylation 
 
 
Associated to pathogenesis 
CSMD1 No change Increased in HRS cells (Brune et al 2008) 
Neither Inactivated by methylation 
(Richter et al 2005) 
TSG (Ma et al 2009) 
SPRY2 Not present 
Increased in some HL 
cell lines 
(Vockerodt et al 2008) 
 
Neither 
Decreased upon 
demethylation of L428 and 
KMH2 ( in house arrays). 
Methylated in B cells 
(Frank et al 2009) 
Its expression inhibits tumour 
growth in diffuse large B-cell 
lymphoma (DLBCL) (Sanchez 
et al 2008) 
MAGEA3 Not present 
Increased in HL cell 
lines (Vockerodt et al 
2008) 
 
 
 
Neither 
Increased following 
demethylation of L428 and 
KMH2 (in house arrays). 
Promoter hypomethylation 
in colorectal carcinomas 
and gastric cancers (Kim et 
al 2006) 
 
Expressed in malignant 
tumours and precancerous 
lesions but not in benign 
tumours (Kim et al 2006) 
PRDM1 Decreased 
Decreased in HL cell 
lines 
Down-regulated in 
HRS cells (Nie et al 
2008) 
Decreased by 
LMP2A 
Decreased by 
LMP1 
 
No 
 
May contribute to the 
phenotype maintenance and 
pathogenesis of HRS cells  
ICMT Increased 
  Increased in HRS cells 
      Increased in all HL 
cell lines 
 
Neither No 
Inactivation of Icmt 
ameliorates phenotypes of K-
RAS–induced malignancies in 
vivo  (Wahlstrom et al 2008) 
FGFR2 
 
Increased  and 
decreased 
Increased in HRS cells 
Increased in 3 HL cell 
lines, decreased in 2 
HL cell lines 
 
Neither Hypomethylated in gastric cancer (Nishigaki et al 
2005) 
Deregulation of the FGFR2 
gene has been identified in a 
number of cancers (Nan et al 
2009) 
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GRB10 Increased 
Increased in HRS cells 
Increased in all HL cell 
lines 
 
 
 
Neither 
Methylation important for 
imprinting (Sanz et al 
2008) 
 
GRB10 is a protooncogene 
up-regulated in AML (Casas 
et al 2003) 
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ELL3 Decreased Decreased HRS cells (Brune et al 2008) 
Decreased by LMP1 
 
 
 
No 
 ELL3 can regulate cell 
growth and survival and ELL 
translocations result in the 
development of human 
malignancies. (Johnstone et al 
2001) 
TCL6 Decreased 
Decreased in HRS 
cells 
Decreased in all HL 
cell lines 
Decreased by LMP1 
 
 
 
 
No 
The association of this gene 
with T-cell leukemia 
chromosome translocations 
implicates this gene as a 
candidate for leukemogenesis 
(Saitou et al 2000). 
 
RBM5 Decreased 
Decreased in HRS 
cells 
Decreased in all HL 
cell lines 
Decreased by LMP1 
 
 
 
No 
RBM5 is a  TSG  and loss of 
expression may increase the 
metastatic potential of 
tumours (Oh et al 2010 
SMAD4 Decreased 
Decreased in HRS 
cells 
Decreased in some HL 
cell lines 
Neither 
Promoter methylation 
correlates with reduced 
SMAD4 expression in 
advanced prostate cancer 
(Aitchison et al 2008) 
 
 
TSG (Liu et al 2001) 
H
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ID2 Increased Increased in all HL cell lines 
Increased by LMP1 
 
 
 
No 
ID2 is a suppressor of B-Cell-
Specific Gene Expression, in 
Hodgkin's Lymphoma (Renne 
et al 2006) 
 
 
Table 3.5:  Candidate genes for validation by pyrosequencing 
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1) The array predicted hypomethylation of the cancer testis antigen, MAGEA3 following 
infection of GC B cells with EBV (Figure 3.9 panel A). In the same figure (panel B), a 
pyrogram shows for each of the CpGs examined that the % methylation was less in the 
LCL than that observed in GC B cells; the average fall in methylation across these 4 
CpG sites was 9.75%.  
 
2) The array predicted hypermethylation of the elongation factor RNA polymerase II-like 
3 gene, ELL3, following infection of GC B cells with EBV (Figure 3.10 panel A).  In 
the same figure (panel B), a pyrogram shows that for three of the four CpGs 
examined; the % methylation was more in the LCL than in GC B cells; the % increase 
was substantial in one CpG (highlighted)  but only modest in the other two. 
 
When summarising the pyrosequencing results for the candidate genes, I report both the 
average methylation status across all CpG sites and the maximum change observed at 
individual sites.  Table 3.6 reports the pyrosequencing results for all the genes chosen as 
validation targets.  The IGB ideograms and pyrograms for each gene are shown in Appendix 
1.  All seven genes predicted as hypomethylated on the array had their hypomethylation status 
confirmed by pyrosequencing.  Four out of the five genes predicted as hypermethylated on the 
array were also found to be unambiguously hypermethylated using pyrosequencing analysis.  
All genes predicted to be hypermethylated or hypomethylated on the array using either 
analysis were confirmed using pyrosequencing.  I chose to use the MA dataset for all further 
analyses because this method identified more genes with a change in methylation status 
compared to the HMM method. 
 
Hypomethylated 
genes  
CpG 
1 
CpG 
2 
CpG 
3 
CpG 
4 
CpG 
5 
CpG 
6 
CpG 
7 
Average 
methylation  
GC B cell 98 89 87 83    89 CSMD1 
LCL 94 80 70 63    77 
GC B cell 14 12 12 16 13 16  13.8 SPRY2 
LCL 2 0 2 7 0 6  2.8 
GC B cell 18 24 37 39    29.5 MAGEA3 
LCL 10 18 29 22    19.75 
GC B cell 31 29 30 24 26   28 PRDM1 
LCL 8 7 14 12 9   10 
GC B cell 44 49 48 88 54   56.6 ICMT 
LCL 11 13 6 26 7   12.6 
GC B cell 74 65 72 76 100 86 51 74.8 FGFR2 
LCL 23 62 64 56 94 78 50 61 
GC B cell 48 91 100 100 80 74  82.2 GRB10 
LCL 20 73 99 100 85 65  73.6 
 
Hypermethylated 
genes  
CpG 
1 
CpG 
2 
CpG 
3 
CpG 
4 
CpG 
5 
CpG
6 
CpG 
7 
Average 
methylation 
GC B cell 97 62 100 73    83 ELL3 LCL 97 94 100 75    91.5 
GC B cell 31 68 56 100 21   55.2 TCL6 LCL 57 95 88 100 52   78.4 
GC B cell 4 0 4 6 4   3.6 RBM5 LCL 11 6 4 6 4   6.2 
GC B cell 62 63 50 89 100   72.8 SMAD4 LCL 75 70 57 92 100   78.8 
GC B cell 69 69 64 69 61 31  60.5 ID2 
LCL 56 90 87 56 52 26  61.2 
 
 
Table 3.6: Summary of pyrosequencing results:  The percentage methylation at each CpG 
is recorded along with the average methylation across each region for both the GC B cells 
and the LCLs. The maximum difference highlighted in yellow. In each case, pyrosequencing 
was performed on three independently derived LCLs and their counterpart GC B cells. 
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   Array prediction for MAGEA3 A. 
 
 
 
Region of hypomethylation 
GC gt LCL 
Negative 
strand 
MAGEA3
Transcriptional start site  
   Pyrosequencing results B. 
 
Average GC B 
cell methylation 
= 29.5 % 
Average LCL 
methylation     
= 19.75 % 
Figure 3.9: IGB and pyrosequencing results for MAGEA3.  A. IGB results for the hypomethylated 
gene MAGEA3.  The transcriptional start site is indicated by a red arrow and the region 
hypomethylated is indicated with a green arrow. B. Pyrosequencing results for the hypomethylated 
region indicated with the green arrow in IGB. GC B cells (top panel) and LCL (lower panel). The 
average methylation for the region analysed is shown on the right and the % methylation for each 
CpG is shown in the blue box above the CpG. Pyrosequencing was performed on three independently 
derived LCLs and their corresponding GC B cells. 
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   Array prediction for ELL3 
 
     
    
   Pyrosequencing results 
 
  
Figure 3.10: IGB and pyrosequencing results for ELL3.  A. IGB results for the hypermethylated 
gene ELL3.  The transcriptional start site is indicated by a red arrow and the region hypermethylated 
is indicated with a green arrow. B. Pyrosequencing results for the hypermethylated region indicated 
with the green arrow in IGB. GC B cells (top panel) and LCL (lower panel). The average methylation 
for the region analysed is shown on the right and the % methylation for each CpG is shown in the blue 
box above the CpG.  Highlighted with the red box is the second CpG within the sequence being 
analysed. Pyrosequencing was performed on three independently derived LCLs and their 
corresponding GC B cells. 
B. 
Negative 
strand 
LCL gt GC 
A. 
Region of hypermethylation 
ELL3
Transcriptional start site 
GC B cell 
average 
methylation   
= 81% 
LCL      
average 
methylation   
= 92% 
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3.2.6.3 EBV induced methylation changes are progressive  
Although the methylation arrays were carried out on LCLs six weeks post infection I was able 
to analyse methylation in the same LCLs kept in culture for a further six weeks.  This 
provided the opportunity to explore whether methylation changes were progressive on further 
culturing.  For example, serial pyrosequencing shows that the methylation of one of the CpGs 
in RBM5 increased from 4% at baseline to 11% at six weeks and to 20% at three months post 
infection (Figure 3.11). Similar changes in methylation were found in the other two genes 
included in this anlaysis, the results are reported in Annex 2. 
 
RBM5 
 
 
 
 
Figure 3.11: Increased methylation over time. Pyrosequencing of GC B cells (top panel), 
six week LCLs (middle panel) and three month LCLs (bottom panel).  The first CpG analysed 
is highlighted with the red box and is highlighted because it has the greatest change.  
GC B cells 
LCL six 
weeks 
LCL three 
months 
       
 
Summary 
In this section, I have described how I first isolated and then hybridized to a 
promoter array, methylated DNA from EBV infected GC B cells.  I have 
confirmed using pyrosequencing, methylation changes predicted on the array, and 
shown that methylation changes are progressive on further long-term cultivation 
of EBV infected GC B cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
3.3 Analysis of the distribution and determinants of EBV associated 
methylation events and their relationship to transcriptional change  
 
In this section, I first examine whether the methylation changes following EBV 
infection of GC B cells are randomly distributed throughout the genome.  I then 
investigate the determinants of these methylation changes. Specifically, I consider 
whether methylation changes can be related to CpG content or baseline gene 
expression.  Finally, using the methylation and transcriptional arrays, I determine 
how often changes in methylation status predict changes in expression. 
 
 
3.3.1 Methylation changes are commonly concordant in adjacent genes  
I first investigated whether those genes with increased methylation following EBV infection 
were significantly more likely to be found immediately adjacent to at least one other 
hypermethylated gene.  In order to do this, I first had to identify which genes listed on the 
Affymetrix promoter array were immediately adjacent to each other.  I excluded 1596 genes 
listed on the array because their transcriptional start site fell between the transcription start 
and end site of the immediately preceding gene. All of the remaining genes (n = 18354) on the 
Affymetrix promoter array were then ordered according to their transcriptional start site and 
numbered one to 18354. These genes included 751 genes hypermethylated and 834 
hypomethylated following infection with EBV. Of the 751 genes hypermethylated by EBV, 
177 were found to be immediately adjacent to another hypermethylated gene (Table 3.7).  In 
order to determine if this number of pairs was greater than what would have occurred by 
chance, I next measured how many concordantly methylated pairs would have been found 
       
were I to select random samples of size equal to the number of hypermethylated (751) genes 
predicted on the array. Dr. Wenbin Wei provided me with statistical support for this aspect of 
the analysis. The methods employed are now outlined in brief using hypermethylated genes as 
an illustrative example.  The computer programme R was used to generate 100000 random 
samples of size (n = 751) from the total population of 18354 genes listed on the array, and for 
each pair within each random sample, it was then determined whether the pair was 
consecutive.  The distribution of the number of adjacent pairs in 100000 samples each 
containing 751 genes randomly selected from the total of 18354 genes is shown in Figure 
3.12.  I next calculated the probability of observing within a sample of 751 randomly selected 
genes, a number of consecutively numbered genes greater than 177 (the number of 
hypermethylated genes found to be adjacent to each other). Given that my simulation exercise 
suggested that the maximum number of consecutively numbered genes in a 100000 trials was 
only 58, I conclude that the probability of observing a 177 adjacent genes which were also 
hypermethylated is less than 1 in 100000 (Table.3.8)  
 
 
Change in 
methylation status 
Number of 
concordantly 
regulated pairs 
Hypermethylated     
n = 751 177 
Hypomethylated      
n = 834 162 
Unchanged          
n = 16751 17996 
 
Table 3.7:  Frequency with which the methylation status of immediately adjacent genes 
are concordantly changed. Excluded from this analysis were 18 genes that were both 
hypermethylated and hypomethylated. 
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Figure 3.12: Histogram shows the distribution of the number of adjacent pairs in 100000 
simulated gene sets each containing 751 genes randomly selected from the total of 18354 
genes 
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Figure 3.13: Histogram shows the distribution of the number of adjacent pairs in 100000 
simulated gene sets each containing 834 genes randomly selected from the total of 18354 
genes. 
       
Hypermethylated   Hypomethylated 
Number of pairs Frequency   Number of pairs Frequency 
11 3   16 4 
12 11   17 4 
13 7   18 7 
14 28   19 16 
15 53   20 33 
16 111   21 56 
17 159   22 139 
18 343   23 216 
19 602   24 348 
20 918   25 562 
21 1385   26 810 
22 1995   27 1202 
23 2737   28 1639 
24 3528   29 2274 
25 4531   30 2989 
26 5475   31 3570 
27 6083   32 4317 
28 6843   33 5005 
29 7339   34 5825 
30 7531   35 6327 
31 7283   36 6551 
32 7181   37 6678 
33 6575   38 6671 
34 5835   39 6620 
35 5179   40 6187 
36 4445   41 5692 
37 3514   42 5101 
38 2804   43 4504 
39 2170   44 3747 
40 1579   45 3120 
41 1135   46 2483 
42 903   47 1905 
43 597   48 1539 
44 433   49 1143 
45 262   50 829 
46 150   51 600 
47 113   52 427 
48 64   53 284 
49 44   54 189 
50 19   55 145 
51 17   56 85 
52 5   57 64 
53 6   58 42 
54 4   59 17 
55 1   60 15 
      61 8 
      62 3 
      63 1 
      64 3 
      65 2 
      66 2 
       
Table 3.8 Results of simulation analysis performed on 100000 occasions generated using 
the computer programme R. 
 
This exercise was repeated for hypomethylated genes.  Of the 834 non overlapping genes 
hypomethylated following EBV infection, 162 were found to be immediately adjacent to 
another hypomethylated gene (Table 3.7). The distribution of the number of adjacent pairs in 
100000 samples each containing 834 genes randomly selected from the total of 18354 genes 
is shown in Figure 3.13.  Given that my simulation exercise suggested that the maximum 
number of consecutively numbered genes in a 100000 trials was only 66, I conclude that the 
probability of observing 162 adjacent hypomethylated genes is less than 1 in 100000 
(Table.3.8).  
 
Therefore, following infection of GC B cells with EBV, hypermethylated genes are 
substantially and significantly more likely to be found adjacent to another hypermethylated 
gene. Likewise, hypomethylated genes were found to be substantially and significantly more 
likely to be found adjacent to another hypomethylated gene. 
 
 
 
 
 
 
 
 
       
3.3.2  Methylation changes are enriched at certain chromosomal locations 
Having established that hypermethylated and hypomethylated genes are more likely to be 
found adjacent to each other, I next investigated whether clustering of genes occurred at 
certain chromosomal locations. To do this, I first counted the number of methylation events 
which occurred in each cytoband and then calculated the number of methylation events which 
would have been expected at that cytoband given the overall frequency of methylation events 
observed on the array.  A cytoband was considered to represent a hypermethylation or 
hypomethylation “hotspot” if there were significantly more methylation events occurring at 
that location than would have been expected by chance alone; the significance level was set at 
1%. 
For example, 52 genes on the promoter array map to Chr3q29.  10 genes were observed to be 
hypermethylated at this chromosomal location. Given that the overall rate of 
hypermethylation events in this experiment was 0.042 (831/19950), we would have expected 
2.2 genes (0.042*52)  to be methylated at this location by chance alone.  The difference 
between the observed and expected number provides the basis for significance testing using a 
chi-square test; in this example, hypermethylation of a gene was 27.33 times more likely to 
occur at this chromosome location (p = 0.001). The hypermethylation hotspots are shown in 
Table 3.9 and the hypomethylation hotspots are shown in Table 3.10. 
 
 
 
 
 
 
 
       
 
 
chromosome 
location 
No of 
genes in 
cytoband 
No of 
hypermethylated 
genes in 
cytoband Expected Actual Actual:Expected 
Chi-square 
(1df) p value 
chr9q34.13 23 7 0.98 6.019 >  36.95 p<0.001 
chr2p23.3 66 13 2.81 10.19 >  36.88 p<0.001 
chr6q25.3 33 8 1.41 6.593 >  30.9 p<0.001 
chr3q29 52 10 2.22 7.783 >  27.33 p<0.001 
chr3q21.1 20 5 0.85 4.147 >  20.17 p<0.001 
chr11q24.2 44 8 1.88 6.124 >  19.99 p<0.001 
chr17p13.3 70 10 2.98 7.016 >  16.49 p<0.001 
chr14q24.3 71 10 3.03 6.973 >  16.06 p<0.001 
chr1p32.3 51 8 2.17 5.826 >  15.61 p<0.001 
chr12p11.23 10 3 0.43 2.574 >  15.54 p<0.001 
chr17p13.2 64 9 2.73 6.272 >  14.42 p<0.001 
chr7q11.23 77 10 3.28 6.717 >  13.75 p<0.001 
chr11p15.3 11 3 0.47 2.531 >  13.66 p<0.001 
chr17q11.2 90 11 3.84 7.163 >  13.37 p<0.001 
chr9q34.2 27 5 1.15 3.849 >  12.87 p<0.001 
chr12q13.2 61 8 2.6 5.399 >  11.21 p<0.001 
chr22q11.21 73 9 3.11 5.888 >  11.14 p<0.001 
 
Table 3.9 Clustering of hypermethylated genes by chromosomal location 
 
 
 
 
 
 
 
 
 
 
       
 
chromosome 
location 
No of 
genes in 
cytoband 
No of 
hypomethylated 
genes in 
cytoband Expected Actual Actual:Expected 
Chi-square 
(1df) p value 
chrXq27.2 8 5 0.37 4.626 >  57.17 p<0.001 
chr1q44 64 16 2.99 13.01 >  56.49 p<0.001 
chrXp11.23 72 17 3.37 13.63 >  55.16 p<0.001 
chr15q11.2 40 10 1.87 8.129 >  35.31 p<0.001 
chr11q11 48 11 2.25 8.754 >  34.13 p<0.001 
chr19q13.42 91 16 4.26 11.74 >  32.39 p<0.001 
chrXp11.22 43 10 2.01 7.988 >  31.72 p<0.001 
chr11q25 13 5 0.61 4.392 >  31.71 p<0.001 
chr21q22.2 14 5 0.65 4.345 >  28.82 p<0.001 
chr2q21.2 6 3 0.28 2.719 >  26.34 p<0.001 
chr19q13.31 51 10 2.39 7.614 >  24.3 p<0.001 
chr20p12.1 16 5 0.75 4.251 >  24.15 p<0.001 
chr10q11.22 23 6 1.08 4.924 >  22.53 p<0.001 
chr15q13.1 7 3 0.33 2.673 >  21.81 p<0.001 
chr17q21.2 86 13 4.02 8.976 >  20.03 p<0.001 
chr1q42.2 25 6 1.17 4.83 >  19.95 p<0.001 
chr13q21.32 1 1 0.05 0.953 >  19.42 p<0.001 
chr8p23.2 1 1 0.05 0.953 >  19.42 p<0.001 
chr18q22.3 13 4 0.61 3.392 >  18.92 p<0.001 
chr4q35.2 13 4 0.61 3.392 >  18.92 p<0.001 
chr1p36.21 42 8 1.96 6.035 >  18.54 p<0.001 
chr2q37.1 60 10 2.81 7.193 >  18.43 p<0.001 
chr6p25.3 8 3 0.37 2.626 >  18.42 p<0.001 
chr8p23.1 59 9 2.76 6.24 >  14.1 p<0.001 
chr12q24.22 10 3 0.47 2.532 >  13.7 p<0.001 
chr13q21.1 5 2 0.23 1.766 >  13.33 p<0.001 
chr4p15.31 5 2 0.23 1.766 >  13.33 p<0.001 
chrXq24 42 7 1.96 5.035 >  12.9 p<0.001 
chr7q35 25 5 1.17 3.83 >  12.54 p<0.001 
chr10q26.13 34 6 1.59 4.409 >  12.22 p<0.001 
chr8p23.3 11 3 0.51 2.485 >  12 p<0.001 
 
Table 3.10 Clustering of hypomethylated genes by chromosomal location. 
 
 
 
       
3.3.3 CpG content of cellular genes predict frequency and direction of methylation 
change 
Next, I investigated how the incidence of methylation events varied with the CpG content of 
the promoter region of a gene.  Towards this end I used a classification first described by 
Weber et al., 2007. In this study, genes were categorized according to low CpG (LCP), high 
CpG (HCP) or intermediate CpG (ICP) content, dependant on their CpG ratio, GC content 
and length of the CpG-rich region; this classification has since been used by a number of 
other investigators (Rauch et al., 2009; Ruike et al., 2010).  
The analysis was restricted to 14899 genes which were:  
• listed on the Affymetrix promoter array (n =19950) and 
• listed on the Weber database (n = 15360) and exclusively assigned to either the low, 
intermediate or high CpG content category on the Weber array (444 genes assigned 
to two or more categories were excluded for this reason).  
Table 3.11 describes the number of genes in each of the CpG content categories, and the 
frequency with which methylation changes following EBV infection occurred in each 
category.   
 
  LCL = GC B LCL > GC B LCL < GC B 
LCL > and < 
GC B Total 
LCP 3737 102 294 0 4133 
ICP 1824 58 118 2 2002 
HCP 8058 465 230 11 8764 
Total 13619 625 642 13 14899 
 
Table 3.11: Number of genes with increased or decreased methylation that have high, 
low or intermediate CpG content.  LCL > and < GC B refers to genes that had both 
hypermethylated and hypomethylated regions. 
 
       
Table 3.12 describes how the frequency of hypermethylation and hypomethylation events 
varied according to CpG content using statistical methods described in Section 3.1.8. 
 
Methylation 
status changed in 
EBV infected GC 
B cells 
Odds 
ratio 95% CI p value 
  
CpG 
content Yes No       
LCP 102 3737 1 (referent) 
ICP 58 1824 1.17 0.8 to 1.6 p = 0.3597 
Increased 
methylation 
in EBV 
infected GC 
B cells HCP 465 8058 2.11 1.7 to 2.6 p = 0.0000 
              
LCP 294 3737 1 (referent) 
ICP 118 1824 0.82 0.66 to 1 p = 0.082 
Decreased 
methylation 
in EBV 
infected GC 
B cells HCP 230 8058 0.36 0.3 to 0.4 p = 0.0000 
 
Table 3.12:  Risk of decreased or increased methylation in EBV infected GC B cells in 
relation to CpG content.  Excluded from this analysis were 13 genes that were both 
hypermethylated and hypomethylated in different regions. 
 
Compared with those genes with a low CpG content, the risk of methylation following EBV 
infection was greater for those with an intermediate and high CpG content; the highest risk of 
EBV associated methylation was seen in those genes with a high CpG content (OR = 2.11, 
95% CI 1.7-2.6, p = 0.0000).  Compared with those genes with a low CpG content, the risk of 
a decrease in methylation following EBV infection was significantly less for those genes with 
an intermediate and high CpG content (OR = 0.36, 95% CI 0.3-0.4, p=0.0000). 
 
 
       
3.3.4 Baseline gene expression levels predict the frequency and direction of methylation 
change 
I next investigated whether changes in methylation status could be related to the baseline 
expression of genes in GC B cells.   
The analysis was restricted to 17667 genes which were:  
• listed on the Affymetrix promoter array (n =19950) and 
• listed on the Affymetrix transcriptional array (n = 20765) 
Baseline gene expression values were obtained from the intensity scores on the transcriptional arrays 
 
Table 3.13 describes the number of genes in each of the baseline expression categories, and 
the frequency with which methylation changes occurred in each category.  
 
Baseline 
expression 
GC B cells 
Number 
of genes 
present 
on both 
arrays 
Decreased 
methylation
Increased 
methylation
No change 
in 
methylation 
0-24 4712 346 75 4291 
25-49 2762 154 67 2541 
50-99 2433 89 112 2232 
100-199 2198 23 137 2038 
200-299 1239 18 85 1136 
300-399 844 13 67 764 
400-499 587 8 33 546 
500-999 1453 20 108 1325 
> 1000 1439 12 99 1328 
Total 17667 683 783 16201 
 
Table 3.13:  Baseline expression of genes with a change in methylation status 
 
 
       
Table 3.14 estimates the risk of hypermethylation and hypomethylation events associated with 
levels of baseline expression using statistical methods described in Section 3.1.8.  Compared 
with genes with a low baseline expression, (0-24), the risk of increased methylation following 
EBV infection increased with increasing values of baseline expression. This risk reached a 
plateau when expression values were greater than 200 when the risk was increased 
approximately 4 fold. Compared with those genes with a low baseline expression, (0-24), the 
risk of decreased methylation following EBV infection decreased with increasing values of 
baseline expression.  A sustained fall was observed in each level of expression with the 
greatest decrease found in genes with a baseline expression value greater than 1000 (OR 0.11 
95% CI, 0.1-0.2, p = 0.0000).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
  
Baseline 
gene 
intensity 
scores in GC 
B  cells  
Methylation 
status changed 
in EBV infected 
GC B cells 
Odds 
ratio 95% CI p value 
  Yes No   
0-24 75 4291 1 (referent) 
25-49 67 2541 1.51 1.1 to 2.1 p = 0.0148 
50-99 112 2232 2.87 2.1 to 3.9 p = 0.0000 
100-199 137 2038 3.84 2.9 to 5.1 p = 0.0000 
200-299 85 1136 4.28 3.1 to 5.9 p = 0.0000 
300-399 67 764 5.01 3.6 to 7.0 p = 0.0000 
400-499 33 546 3.46 2.3 to 5.3 p = 0.0000 
500-999 108 1325 4.67 3.5 to 6.3 p = 0.0000 
Risk of 
increased 
methylation 
in EBV 
infected 
GC B cells 
> 1000 99 1328 4.27 3.1 to 5.8 p = 0.0000 
  
0-24 346 4291 1 (referent) 
25-49 154 2541 0.75 0.6 to 0.9 p = 0.0042 
50-99 89 2232 0.49 0.4 to 0.6 p = 0.0000 
100-199 23 2038 0.14 0.1 to 0.2 p = 0.0000 
200-299 18 1136 0.20 0.1 to 0.3 p = 0.0000 
300-399 13 764 0.21 0.1 to 0.4 p = 0.0000 
400-499 8 546 0.18 0.1 to 0.4 p = 0.0000 
500-999 20 1325 0.19 0.1 to 0.3 p = 0.0000 
Risk of 
decreased 
methylation 
in EBV 
infected 
GC B cells 
> 1000 12 1328 0.11 0.1 to 0.2 p = 0.0000 
 
Table 3.14:  Baseline gene intensity scores in uninfected GC B cells predict methylation 
changes in GC B cells.  
 
 
 
 
 
 
       
3.3.5 CpG content and baseline expression scores are independent predictors of 
methylation change 
Given that both CpG content and baseline expression appear to predict changes in methylation 
status, I next investigated, whether these were independent effects.  
The analysis was restricted to 13997 genes which were:  
• listed on the Affymetrix promoter array (n =19950) 
• listed on the Affymetrix transcriptional array (n = 20765) 
• listed on the Weber database (n = 15360) and exclusively assigned to either the 
low, intermediate or high CpG content category on the Weber array (444 genes 
assigned to two or more categories were excluded for this reason).   
 
I first stratified the dataset by CpG content and then by baseline gene expression. Table 3.15 
shows that within each CpG content category, the risk of increased methylation following 
EBV infection increased with increasing baseline expression.  Table 3.16 shows that within 
each CpG content category the risk of decreased methylation following EBV infection is 
decreased with increasing baseline expression.  Therefore, this stratified analysis suggests that 
both CpG content and baseline expression independently predict changes in methylation 
status following EBV infection.  
 
 
 
 
 
 
       
 
CpG 
island 
content 
Baseline 
gene 
intensity 
scores in 
GC B  
cells  
Methylation status 
changed in EBV 
infected GC B cells 
Odds ratio 95% CI p value 
  Increased 
No 
change   
0-24 23 1459 1 (referent) 
25-49 10 690 0.91 0.4 to 1.9 p = 0.8255 
50-99 20 405 3.13 1.7 to 5.7 p = 0.0001 
100-199 10 239 2.65 1.2 to 5.6 p = 0.0182 
200-499 17 210 5.14 2.7 to 9.8 p = 0.0000 
LCP 
> 500 19 232 5.2 2.8 to 9.7 p = 0.0000 
              
0-24 6 592 0.64 0.3 to 1.6 p = 0.3341 
25-49 6 313 1.21 0.5 to 3.0 p = 0.6720 
50-99 12 261 2.92 1.4 to 5.9 p = 0.0020 
100-199 10 191 3.32 1.6 to 7.1 p = 0.0010 
200-499 10 179 3.54 1.7 to 7.6 p = 0.0005 
ICP 
> 500 11 181 3.86 1.8 to 8.0 p = 0.0001 
              
0-24 29 1303 1.41 0.8 to 2.5 p = 0.2188 
25-49 33 961 2.18 1.3 to 3.7 p = 0.0037 
50-99 60 1075 3.54 2.2 to 5.8 p = 0.0000 
100-199 76 1160 4.16 2.6 to 6.7 p = 0.0000 
200-499 116 1574 4.68 3.0 to 7.4 p = 0.0000 
HCP 
> 500 146 1812 5.11 3.3 to 8.0 p = 0.0000 
 
Table 3.15 Baseline gene intensity scores in uninfected GC B cells independently predict 
hypermethylation events in EBV infected GC B cells.   
 
 
 
 
 
 
 
       
CpG 
island 
content 
Baseline 
gene 
intensity 
scores in 
GC B cells  
Methylation status 
change in EBV infected 
GC B cells 
Odds ratio 95% CI p value 
  Decreased No change   
0-24 143 1459 1 (referent) 
25-49 57 690 0.84 0.6 to 1.2 p = 0.2946 
50-99 22 405 0.55 0.3 to 0.9 p = 0.0112 
100-199 5 239 0.21 0.1 to 0.5 p = 0.0002 
200-499 3 210 0.15 0.05 to 0.5 p = 0.0001 
LCP 
> 500 3 232 0.13 0.04 to 0.4 p = 0.0000 
  
0-24 48 592 0.83 0.6 to 1.2 p = 0.2745 
25-49 24 313 0.78 0.5 to 1.2 p = 0.2831 
50-99 12 261 0.47 0.3 to 0.9 p = 0.0119 
100-199 3 191 0.16 0.05 to 0.5 p = 0.0003 
200-499 2 179 0.11 0.03 to 0.5 p = 0.0002 
ICP 
> 500 4 181 0.23 0.1 to 0.6 p = 0.0015 
  
0-24 83 1303 0.65 0.5 to 0.9 p = 0.0024 
25-49 36 961 0.38 0.3 to 0.6 p = 0.0000 
50-99 43 1075 0.41 0.3 to 0.6 p = 0.0000 
100-199 15 1160 0.13 0.1 to 0.2 p = 0.0000 
200-499 23 1574 0.15 0.1 to 0.2 p = 0.0000 
HCP 
> 500 20 1812 0.11 0.1 to 0.2 p = 0.0000 
 
Table 3.16: Baseline gene intensity scores in uninfected GC B cells independently predict 
demethylation events in EBV infected GC B cells.   
 
 
 
 
 
 
 
 
 
 
       
3.3.6 EBV induced methylation changes are unreliable predictors of EBV associated 
transcriptional change 
I next investigated how often methylation changes observed in my EBV-GC B cell arrays 
were followed by transcriptional changes.  Towards this end, I used the EBV-GC B cell 
methylation array and the transcriptional array (re-analysed on this occasion using a 1% FDR 
cut-off and 1.5 fold change cut off were used).  
The analysis was restricted to 17667 genes which were:  
• listed on the Affymetrix promoter array (n =19950)  
• listed on the Affymetrix transcriptional array (n = 20765) 
 
I examined the relationship between the direction of the methylation change and the direction 
of the transcriptional change.  Table 3.17 suggests that, compared with those genes in which 
there was no change in methylation status following EBV infection, transcriptional up-
regulation was significantly more likely to occur in those genes with increased methylation 
(OR 1.54, 95% CI 1.3 to 1.8, p=1.0E-6). However, transcriptional down-regulation was not 
significantly associated with an increase in methylation (OR 1.3, 95% CI 0.96 to 1.4, 
p=0.135) (Table 3.18).  
 
  Number of genes 
Number of genes 
with increased 
expression   
following EBV 
infection of GC B 
cells 
Odds 
ratio 95% CI p value 
No change 16184 2542 1 (referent) Change in 
methylation 
status Increased 783 175 1.54 1.3   to 1.8 p=1.0E-6 
Table 3.17: An increase in methylation is significantly associated with an increase in 
expression.  
       
  Number of genes 
Number of genes 
with decreased 
expression   
following EBV 
infection of GC B 
cells 
Odds 
ratio 95% CI p value 
No change 16184 2393 1 (referent) Change in 
methylation 
status increased 783 131 1.3 0.96  to 1.4 p=0.135 
Table 3.18: An increase in methylation is not significantly associated with a decrease in 
expression.  
 
Tables 3.19 shows that, compared with those genes in which there was no change in 
methylation status following EBV infection, transcriptional up-regulation and was less likely 
to occur in those genes that were hypomethylated following infection (OR 0.3, 95% CI 0.22   
to 0.43, P =0.001). This was also the case for those transcriptionally down-regulated genes 
(OR 0.57, 95% CI 0.44   to 0.74, p=1.9E-5). 
 
  Number of genes 
Number of genes 
with increased 
expression   
following EBV 
infection of GC B 
cells 
Odds 
ratio 95% CI p value 
No change 16184 2542 1 (referent) Change in 
methylation 
status Decreased 683 37 0.3 0.22   to 0.43 P =0.001 
Table 3.19: A decrease in methylation is not associated with an increase in expression.  
 
 
  Number of genes 
Number of genes 
with decreased 
expression   
following EBV 
infection of GC B 
cells 
Odds 
ratio 95% CI p value 
No change 16184 2393 1 (referent) Change in 
methylation 
status Decreased 683 66 0.57 0.44   to 0.74 p=1.9E-5 
Table 3.20: A decrease in methylation status is not associated with a decrease in expression. 
 
       
 
Summary 
In this section, I have shown that following EBV infection, hypermethylated and 
hypomethylated genes are frequently found immediately adjacent to concordantly 
methylated genes.  I have also shown that methylation hotspots can be found at 
certain chromosomal locations.  Baseline gene expression and cellular gene CpG 
content were found to be independent predictors of the frequency and direction of 
methylation changes.  These global analyses also suggested that methylation 
changes are likely to be followed by an increased incidence of transcriptional 
changes.  However, there was no clear correspondence between the direction of 
the methylation change and the direction of the transcriptional change.  Increased 
methylation was significantly associated with  transcriptional up-regulation but 
not down-regulation, However, EBV associated hypomethylation was 
significantly less likely to be associated with transcriptional change.  
 
 
 
 
 
 
 
 
 
 
       
3.4 Ontological characterisation of EBV associated methylation changes 
 
In this section, I first report the ontological association of those genes found to 
be either hypermethylated or hypomethylated in EBV infected GC B cells. I 
next present the results of a literature search designed to identify those genes 
reported to be regulated by methylation in HL, and report how often these were 
also found to be methylated in EBV infected GC B cells. 
 
3.4.1 Genes hypomethylated by EBV in GC B cells are enriched for those involved in 
G-protein coupled signalling and for cancer testis antigens 
The ontology of those genes found to have had a change in methylation status following EBV 
infection was characterised using the PANTHER classification system.  This system uses the 
gene ontology TM for classifications by molecular function, biological process and cellular 
component.  The referent gene list used in these analyses comprised all genes listed on the 
promoter array.  Ontological profiling of genes which were hypermethylated following EBV 
infection revealed no significant associations. However, genes with reduced methylation 
following EBV infection of GC B cells were significantly enriched for a number of biological 
processes listed in Table 3.21.   
 
 
 
 
 
       
Biological Process 
Number of 
genes with 
no change 
in 
methylation 
status 
Number of 
genes with 
decreased 
methylation 
expected 
p value 
(Bonferroni 
correction 
applied) 
Chemosensory perception 149 38 7.19 4.76E-14 
Olfaction 142 37 6.85 8.31E-14 
Signal transduction 2739 204 132.15 1.34E-09 
G-protein mediated signalling 653 73 31.51 1.09E-08 
Sensory perception 389 49 18.77 7.49E-08 
Cell surface receptor mediated 
signal transduction 1312 113 63.3 2.47E-07 
Cell adhesion-mediated 
signalling 310 39 14.96 2.16E-05 
Cell communication 988 79 47.67 0.00141 
Oncogenesis 330 33 15.92 0.00302 
Ectoderm development 545 48 26.3 0.00949 
Receptor protein 
serine/threonine kinase 
signalling pathway 
26 8 1.25 0.00969  
 
Table 3.21:  Biological processes significantly enriched among genes with reduced 
methylation following EBV infection of GC B cells.   
 
Of course, as with all ontological classifications, one gene can be assigned to more than one 
biological process. For example, consider three of the biological processes listed in Table 
3.21; sensory perception, chemosensory perception and olfaction.  These three processes 
contributed to the ontological profiling of hypomethylation, 49, 38 and 37 EBV demethylated 
genes, respectively (highlighted in blue in Table 3.19). Figure 3.14 reveals that most of these 
hypomethylated genes are common to all three processes. 
 
 
       
 
Figure 3.14: Overlap of hypomethylated genes involved in sensory perception, 
chemosensory perception and olfaction. 
 
Of the 49 unique genes contributing to these analyses of perception, 39 were also found to be 
involved in G-protein mediated signalling, another biological process significantly over-
represented in EBV demethylated genes (Figure 3.15). 
 
 
 
Figure 3.15: Overlap of genes involved in perception and G protein mediated signalling. 
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If we now focus on genes involved in G-protein mediated signalling, we see that all of these 
genes (n = 73) were also involved in cell surface receptor mediated signal transduction, 
another biological process significantly over-represented in EBV demethylated genes (Figure 
3.16) 
 
Figure 3.16: Genes common to cell surface receptor mediated signalling and G protein 
mediated signalling. 
 
All of the 73 genes involved in G-protein mediated signalling are also included in the 204 
signal transduction genes referred to in Table 3.21. 
 
Therefore, it would seem that EBV-associated demethylation of G-protein mediated signalling 
genes alone can explain many of the ontological associations observed in this dataset.  Given 
that we have already shown that genes with a low CpG content are significantly more likely to 
be hypomethylated following EBV infection, it is noteworthy  that genes involved in G 
protein mediated signalling are significantly enriched for those with a low CpG content (p = 
3.98E-132). 
 
 
G‐proteinCell surface
       
PANTHER gene database does not of course identify all gene subsets of potential interest.  
For example it does not include a listing of cancer testis antigens (CTA), which are often 
hypomethylated in cancer: However, I was able to identify using the CTDatabase compiled by 
the Ludwig Institute and supplemented by a search of the NCBI database, 232 CTA. Of these, 
30 CTA were found to be hypomethylated following EBV infection of GC B cells (OR = 5.5, 
95% CI; 3.7 to 8.1; p = 0.0000).    Some of the CTA, for example, the SSX genes and others 
from the same genomic location (CT45A1) have been shown to be over-expressed in HL 
(Chen et al., 2010).   
 
 
 
 
 
 
 
 
 
Table 3.22: Cancer testis-antigens hypomethylated following EBV infection of GC B 
cells.  
 
 
 
 
 
 
 
 
Changes in the methylation status  of Cancer-Testis Antigens (CTA) 
following infection of GC B cells with EBV 
  Number of CTA 
Hypomethylated  30 
Unchanged 180 
Hypermethylated 0 
Not on promoter array 22 
       
3.4.2 Tumour suppressor genes known to be silenced by methylation in HL are not 
hypermethylated by EBV in GC B cells 
The germinal centre B cell is considered the progenitor cell for HL.  Ideally I would compare 
the results of my methylation array on EBV infected GC B cells with a comparable genome 
wide analysis of the methylation changes in HL.  However no such analysis has been 
undertaken. In order to generate a comprehensive list of those genes known to be methylated 
in HL, I performed a literature search using the terms “Hodgkin’s lymphoma” and “DNA 
methylation”.  This search identified only 21 genes which were known to be hypermethylated 
in HL (Table 3.23); one of these TP73 was also found to be methylated by EBV on my array.  
To date, no genes have been reported to be hypomethylated in HL.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene 
symbol 
Pubmed 
identifier   
DAPK2 19609235   
POU2AF1 18256685 16304050  
NFATC1 18156209   
TNFRSF8 17965727   
DLC1 17965626   
PCDH10 17341268   
SYK 16304050   
CD79B 16304050   
IGH@ 15284123   
CHEK2 15153943   
RASSF1 14961078   
CDKN2C 14645011   
DAPK1 14595709 10361133  
CDKN2A 12213729 10616196 9473234 
CDKN2B 12213729 9473234  
BCL2L11 19557159   
MSC 18368067   
BMP6 17575215   
CDH1 17214905   
FHIT 15384174   
TP73 10416592   
OPCML 18714356   
       
Table 3.23: Genes hypermethylated in HL from the literature. Pubmed identifiers are also 
recorded 
 
Summary  
In this section, I have shown that genes hypomethylated following infection 
of GC B cells with EBV are enriched for those involved in G protein 
mediated signalling. These genes are also enriched for those with a low CpG 
content, and therefore as I have shown in the previous section, are more 
susceptible to hypomethylation. Finally, I could find no compelling evidence 
to suggest that EBV-associated methylation changes in GC B cells are 
recapitulated in HL. However, this might be better interpreted as the absence 
of evidence rather than evidence of absence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
Chapter 4 
 
 
The impact of EBV and its latent genes on 
the expression of proteins regulating DNA 
and arginine methylation 
 
 
 
 
 
 
 
 
 
       
 
Aims of Chapter 4. 
 
1. To profile the expression of the DNA methyltransferases, DNMT1, DNMT3A and 
DNMT3B 
a) following  the infection of GC B  cells with EBV 
b) in different B  cell subsets 
c) in a panel of HL  cell lines 
2. To determine if expression of one or more of the DNA methyltransferases is regulated 
by the EBV  latent genes, LMP1, LMP2A and EBNA1 
3. To profile the expression of the protein arginine methyltransferases, CARM1, 
PRMT1, PRMT5,  and  the  peptidylarginine deiminase, PADI4, 
a) following  the infection of GC B  cells with EBV 
b) in a panel of HL  cell lines 
4.  To determine if the expression of those enzymes modulating arginine methylation  is 
regulated by the EBV  latent gene LMP1. 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
In the first section of this chapter, I show how the expression of DNA 
methyltransferases, DNMT1, DNMT3A and DNMT3B changes at different time-
points following EBV infection of GC B cells. I next profile the expression of 
these proteins across different B cell subsets and in a panel of HL cell lines. 
Finally, I investigate whether the expression of one or more of the DNMTs is 
modulated by the EBV latent genes, LMP1, LMP2A, or EBNA1. 
 
4.1 EBV infection of GC B cells modulates the expression of DNMTs   
The microarray performed on GC B cells and LCLs six week post infection revealed that the 
expression of DNMT3A was up-regulated more than 8 fold in the LCLs compared to GC B 
cells and that of DNMT1 and DNMT3B reduced (Table 4.1). 
 
 NCBI gene symbol Probe set ID Fold change 
DNMT1 201697_s_at -1.8 
DNMT3B 220668_s_at -2.9 
DNMT3A 222640_at 8.7 
 
Table 4.1:  Microarray analysis results for the DNMTs.  SAM was performed with an 
FDR of 5%.  
 
 
 
 
 
 
       
I next validated these changes at the RNA level using Q RT-PCR, and at the protein level 
using western blotting.  Q RT-PCR analysis of DNMT1, DNMT3A and DNMT3B was 
carried out on RNA harvested six weeks post infection on three newly established LCLs 
derived from the GC B cells of three different donors.  RNA extraction, cDNA synthesis and 
Q RT-PCR analysis was carried out using the method described in Section 2.2.1, 2.3 and 2.4. 
Taqman assays which cover the known isoforms of the DNMTs are listed in Section 2.4.4 
(page 57).  
 
Compared with uninfected GC B cells, the expression of DNMT1 and DNMT3B was 
significantly down-regulated in all three LCLs (Figure 4.1A and B).  On the other hand, there 
was a substantial increase (9-15 fold) in DNMT3A expression (Figure 4.1C).  Western 
blotting confirmed that both isoforms 1 and 2 of DNMT1 were down-regulated in LCLs 
compared to GC B cells.   DNMT3B was down-regulated in all LCLs while DNMT3A was 
up-regulated at the protein level. 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
Figure 4.1 A-C:  DNMT1, DNMT3A and DNMT3B mRNA expression in LCLs.  Blue 
bars represent three different patient GC B cell samples and red bars represent each of the 
LCLs.  The GC B cells with the highest expression of the gene in question served as the 
reference with which other GC B cell samples and LCLs were compared.  Assays were 
carried out in triplicate and results are presented as 2−∆∆CT values.  Standard error bars show 
the variation in relative DNMT expression across three independent experiments. 
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Figure 4.2 A-C: Protein expression of DNMTs in LCLs compared to GC B cells:   A. DNMT1 
expression detected using 15 µg of protein.   B.  DNMT3B expression detected using 30 µg of protein.  
C.  DNMT3A expression detected using 45µg of protein.  MCM7 was used as a loading control for 
each western blot.  The molecular weight for each protein is shown on the right. 
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4.2 Changes in the expression of the DNMTs occur soon after onset of 
EBV infection 
RNA and DNA was also taken from the freshly infected GC B cells 24 hrs, 48 hrs, 72 hrs, 96 
hrs, 1 wk, 2 wks and 3 wks post infection. These samples were used to assay the kinetics of 
EBV-induced de-regulation of the DNMTs.  Figure 4.3A shows that DNMT1 was down-
regulated within 48 hours of infection, and continued to remain low throughout the time 
course. DNMT3B was down-regulated within 24 hours (Figure 4.3B).  DNMT3A expression 
was first raised 72 hours post infection, and increased gradually thereafter (Figure 4.3C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
Figure 4.3 A-C: Kinetics of DNMT1, DNMT3A and DNMT3B expression in LCLs by    
Q-RT PCR.  The expression at each time point was compared to that of the GC B cells.   
Assays were carried out in triplicate and results are presented as 2−∆∆CT values.   Results are 
representative of an experiment performed on three different LCLs.  Standard error bars show 
the variation of DNMT expression across the three assays. 
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4.3 DNMT expression varies across B cell subsets 
 
For these experiments, I used naive B cell, centroblast, centrocyte and memory B cell subsets 
which had been isolated from tonsillar tissue by members of our laboratory. The isolation 
procedure is now described in brief. CD77+ centroblasts were enriched by magnetic 
separation with α-CD77 antibody and α-IgM microbeads using LS columns. The flow-
through of the magnetic separation containing CD77 depleted mononuclear cells was 
incubated with α-CD10-Phycoerythrin (PE) and α-PE microbeads followed by magnetic 
enrichment on LS columns. The eluate contained CD10+/CD77- centrocytes. Naïve B cells 
were isolated indirectly by depletion of all non-naïve cells using a cocktail of antibodies to 
CD10, CD2, CD16, CD27, CD36, CD43 and CD235a.  Memory B cells were first purified by 
negative depletion using antibodies against CD2, CD14, CD16, CD36, CD43 and CD235a, 
and then by positive selection with CD27 microbeads. The relative expression of the DNMTs 
in each B cell subset was analysed.   
 
Q RT-PCR showed that DNMT1 expression was highest in centroblasts and lowest in naive B 
cells, with centrocytes and memory cells having similar levels of expression (Figure 4.4A).   
DNMT3A expression was highest in the naive cells and lowest in the centroblasts, with 
centrocytes and memory cells again having similar levels of expression (Figure 4.4B).  
DNMT3B expression was highest in centroblasts and lowest in memory B cells (Figure 4.4C). 
 
       
 
 
 
 
 
 
 
Figure 4.4 A-C:  DNMT expression across B cell subsets.  DNMT1, DNMT3A and 
DNMT3B expression was assayed across different B cell subsets using Taqman Q RT-PCR.   
Assays were carried out in triplicate and results are presented as 2−∆∆CT values using naive B 
cells as the reference sample. Standard error bars show the variation of DNMT expression 
across the three assays. 
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4.4 DNMTs are differentially expressed in HL cell lines 
 
I next explored how the expression of the DNMTs at the transcriptional and protein level in a 
panel of five HL cell lines differed from that of GC B cells isolated from different donors  
The origin and culturing of these cell lines is described in section 2.1.  
 
Compared with GC B cells, Q RT-PCR revealed the down-regulation of DNMT1in all HL 
cell lines; the down-regulation of DNMT3B in all cell lines with the exception of L1236; and 
the up-regulation of DNMT3A in all cell lines with the exception of L428. However, western 
blotting confirmed the down-regulation of DNMT1 and DNTM3B and the up-regulation of 
DNMT3A in all HL cell lines at the protein level (figure 4.5A-C).    
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Figure 4.5 A-C:  Q RT-PCR and western blotting analysis of DNMT expression in a 
panel of five HL cell lines.  For Q RT -PCR data, the blue bar represents GC B cells and each 
of the red bars represents a different HL cell line.  For each DNMT, the expression in HL cell 
lines was compared to that of GC B cells.  All Q RT-PCR samples were analysed in triplicate 
and are presented as 2−∆∆CT values compared with GC B cells.   Protein levels were measured 
using western blotting with MCM7 used as a loading control.  A. DNMT1 expression in a 
panel of cell lines analysed by Q RT -PCR and WB (15 µg protein). B. DNMT3B expression 
in a panel of cell lines analysed by Q RT-PCR and WB (30 µg protein).  C. DNMT3A 
expression in a panel of cell lines analysed by Q RT-PCR and WB (45 µg protein).  The 
molecular weight of each of the proteins is shown. 
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4.5 DNMT1 is down-regulated by LMP1 but not by EBNA1 or LMP2A 
in GC B cells 
Having shown that EBV can de-regulate the DNMTs, I next investigated whether their 
expression was regulated by one or more of the EBV latent genes, LMP1, LMP2A or 
EBNA1. 
 
I first investigated whether LMP1 down-regulated DNMT1 in GC B cells using RNA from an 
experiment in which GC B cells obtained from different patients had been transfected either 
with a pSG5-LMP1expression vector or with a pSG5 vector control (Vockerodt et al., 2008).  
I was able to confirm using Q-RT PCR and RNA isolated 24 hours post transfection that 
LMP1 down-regulated DNMT1 in these GC B cells (Figure 4.6).  I next investigated whether 
DNMT1 was regulated by either LMP2A or EBNA1.  For these experiments I used RNA 
which had been obtained from GC B cells transfected with LMP2A and EBNA1.  These 
transfections had been performed by Dr. Vockerodt and Dr. Kapatai, respectively, according 
to methods previously described (Vockerodt et al., 2008).  Neither LMP2A nor EBNA1 
modulated the expression of DNMT1 in GC B cells (Figure 4.7). 
 
 
 
       
 
 
 
Figure 4.6:  Q RT-PCR of the relative quantity of DNMT1 in LMP1-expressing and 
non-expressing GC B cells.  Two different transfected tonsils were analysed in triplicate and 
the results presented as 2−∆∆CT values compared with vector control (pSG5). 
 
 
    
 
 
Figure 4.7 Q RT-PCR of the relative quantity of DNMT1 in LMP2A or EBNA1-expressing and 
non-expressing GC B cells.  Different tonsils transfected with either LMP2A or EBNA1were 
analysed in triplicate and the results presented as 2−∆∆CT values compared with vector controls.  A. GC 
B cells transfected with EBNA1 B. GC B cells transfected with LMP2A. 
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4.6 DNMT1 is down-regulated in an LMP1-inducible system 
As LMP1 was the only viral protein found to regulate DNMT1 in GC B cells, I next 
investigated if LMP1 could also down-regulate this enzyme in another B cell system. 
Towards this end I used a tetracycline-inducible expression system which is now described in 
brief.  In this model, the EBV negative BL cell line DG75 was used to generate stable clones 
carrying a tetracycline-inducible LMP1 expression plasmid.  These clones do not express 
LMP1 in the presence of tetracycline. However, once tetracycline is removed the LMP1 
promoter is activated and its transcription is initiated (Floettmann et al,. 1996).  When LMP1 
is induced in this cell line it reaches levels similar to that observed in some LCLs.    In Figure 
4.8 A, I show DNMT1 expression in both LMP1 negative and positive clones, before and 
after the removal of tetracycline. In the LMP1 negative clones, the removal of tetracycline has 
little impact on the expression of DNMT1. In contrast, in the LMP1 positive clones, 
withdrawal of tetracycline is followed by a substantial decrease in DNMT1 expression.  These 
results confirm in another system that LMP1 can down-regulate DNMT1.  However western 
blotting performed on these samples revealed no change in the expression of DNMT1at the 
protein level (Figure 4.8 B). 
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Figure 4.8 A: Q RT-PCR analysis of DNMT1 expression in DG75 with tetracycline-
inducible expression of LMP1.  Blue bars represent clones containing no LMP1 construct 
and red bars represent LMP1 containing clones. Tet + indicates cells grown in the presence of 
tetracycline and Tet- indicates cells with tetracycline removed.  Assays were carried out in 
triplicate and results are presented as 2−∆∆CT values compared with vector controls.   
 
 
 
 
 
 
Figure 4.8 B: Western blotting analysis of DNMT1 expression in DG75 with 
tetracycline-inducible expression of LMP1.  DNMT1 and LMP1 expression was detected 
using 30 µg protein.  MCM7 served as a loading control. 
 
 Tet +        Tet -        Tet +       Tet- 
 LMP1 
negative 
LMP1 
positive 
190 kDa 
60 kDa 
80 kDa 
       
4.7  Neither DNMT3A nor DNMT3B are regulated by EBV latent genes 
in GC B cells 
 
I next investigated whether the expression of DNMT3A and DNMT3B in GC B cells was 
regulated by LMP1, LMP2A or EBNA1.  For these experiments, I used RNA which had been 
obtained following transfection of GC B cells with these latent genes as described in section 
4.6. Figure 4.9A shows that DNMT3A expression was decreased in one of the samples 
transfected with LMP2A but increased in the other. Transfection of GC B cells with LMP1 or 
EBNA1 did not cause any significant change in DNMT3A expression.  (Figure 4.9 B and C).   
DNMT3B expression remained unchanged following transfection of GC B cells with LMP1, 
EBNA1 or LMP2A (Figure 4.10 A-C).  The viral gene that regulates DNMT3A and 
DNMT3B remain to be identified. 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
Figure 4.9:  DNMT3A expression in GC B cells transfected with LMP1, LMP2A or 
EBNA1 expression vectors.   Each assay was carried out in triplicate and the results shown 
are presented as 2−∆∆CT values compared with suitable vector control.  Standard error bars 
show the variation of DNMT3A expression across the three assays.  A. Expression of 
DNMT3A in LMP2A transfected GC B cells.  B. Expression of DNMT3A in LMP1 
transfected GC B cells. C.  Expression of DNMT3A in EBNA1 transfected GC B cells.   
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Figure 4.10: DNMT3B expression in GC B cells transfected with LMP1, LMP2A or 
EBNA1 expression vectors.   Each assay was carried out in triplicate and the results shown 
are presented as 2−∆∆CT values compared with suitable vector control.  Standard error bars 
show the variation of DNMT3B expression across the three assays.  A. Expression of 
DNMT3B in LMP2A transfected GC B cells.  B. Expression of DNMT3B in LMP1 
transfected GC B cells.  C. Expression of DNMT3B in EBNA1 transfected GC B cells.   
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     Summary  
In this section, I have shown that the expression of DNMT3A was increased, and 
that of DNMT1 and DNMT3B decreased soon after EBV infection. The expression 
of DNMT3A was increased, that of DNMT1 and DNMT3B was decreased in a panel 
of HL cell lines when compared with GC B cells. Finally, I have shown that 
DNMT1 is down-regulated in B cells by the EBV oncogene LMP1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
In the last section of this chapter, I show how the expression of the protein 
arginine methyltransferases, CARM1, PRMT1 and PRMT5, and the 
peptidylarginine deiminase, PADI4 changes following EBV infection of GC 
B cells. I profile the expression of these proteins across a panel of HL cell lines 
before investigating whether the expression of one or more of them is modulated 
by the EBV latent gene LMP1. 
 
 
4.8 EBV infection of GC B cells modulates the expression of enzymes 
regulating arginine methylation  
The microarray performed on GC B cells and LCLs six week post infection revealed up-
regulation of the arginine methyltransferases, PRMT1, PRMT5 and CARM1 in LCLs 
compared to GC B cells, and down-regulation of the peptidyl-arginine deiminase, PADI4 
(Table 4.2). 
 
 
NCBI gene symbol Probe set ID Fold change 
CARM1 212512_s_at 1.8 
PRMT1 206445_s_at 1.76 
PRMT5 217786_at 1.5 
PADI4 220001_at -1.84 
 
Table 4.2:  Microarray analysis results for the PRMTs. SAM analysis was performed with 
a FDR of 5%.  
 
       
I next validated changes in the expression of these enzymes using RNA harvested six weeks 
post infection from the three newly established GC B cell derived LCLs. Taqman assays used 
are listed in Section 2.4.4 (page 57).   
 
Compared with uninfected GC B cells, Q-RT-PCR showed that the expression of PRMT1, 
PRMT5 and CARM1 was significantly up-regulated in all three LCLs (Figure 4.11 A, B and 
C).  While, there was a decrease in PADI4 expression, the overall level of this transcript was 
very low in both the GC B cells and LCLs (Figure 4.11 D). 
 
Western blotting confirmed that PRMT1, PRMT5 and CARM1 were up-regulated in LCLs as 
compared to GC B cells (Figure 4.12).  The list of antibodies used is presented in section 2.5.3 
(page 59).  I did not perform a western blot for the PADI4 protein as there was no 
commercially available antibody at the time. 
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 Figure 4.11: PRMT and PADI4 mRNA expression in LCLs.  Blue bars represent three 
different patient GC B cell samples and red bars represent each of the LCLs.  The GC B cells 
with the highest expression of the gene in question served as the reference with which other 
GC B cell samples and LCLs were compared.  Each assay was carried out in triplicate and the 
results shown are presented as 2−∆∆CT values.  Standard error bars show the variation in 
relative PRMT expression across three independent experiments. A. PRMT1 expression        
B. PRMT5 expression. C. CARM1 expression and D. PADI4 expression. 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: Protein expression of PRMT1, PRMT5 and CARM1 in GC B cells and 
three GC B cell derived LCLs.  20 ug of protein was used to detect each of the PRMTs.  The 
same blot was used to measure protein levels for each PRMT and re-probed for MCM7 to 
ensure equal loading.  The molecular weight for each protein is shown. 
 
PRMT5 
CARM1 
     GC B cells           LCL 1             LCL2               LCL 3
PRMT1 
PRMT5 
CARM1 
MCM7 
PRMT1 
  GC B cells          LCL 1              LCL2                LCL 3 
           GC B cells            LCL 1               LCL2               LCL 3 
          GC B cells           LCL 1              LCL2                LCL 3 
63 kDa 
80 kDa 
70 kDa 
45 kDa 
       
4.9 Enzymes regulating arginine methylation are differentially expressed 
in HL cell lines 
 
I next explored the expression of the enzymes regulating arginine methylation in a panel of 
five HL cell lines.  Compared with GC B cells, Q RT-PCR revealed the up-regulation of 
PRMT1 and PRMT5 in all HL cell lines (Figure 4.13 A and B). CARM1 was up-regulated in 
all cell lines with the exception of L450 in which it was down-regulated (Figure 4.13 C). 
PADI4 was down-regulated in all cell lines (Figure 4.13 D).  Western blotting confirmed up-
regulation of PRMT1, PRMT5 and CARM1 in all HL cell lines (Figure 4.14A-C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
       
   
 
      
 
 
 
Figure 4.13 A-D:  Q RT-PCR analysis of PRMT and PADI4 transcripts expressed in a 
panel of HL cell lines.  The blue bar represents GC B cells and each of the red bars 
represents a different cell line.  The expression of each cell line was compared to GC B cells.  
Each assay was carried out in triplicate and the results shown are presented as 2−∆∆CT values. 
Standard error bars show the variation of PRMT expression across the three assays. 
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Figure 4.14:  Protein expression of PRMTs in a panel of HL cell lines. 20ug of protein 
was used to detect protein expression of PRMT1, PRMT5 and CARM1. The same blot was 
used to measure protein levels for each PRMT and re-probed for MCM7 to ensure equal 
loading.  The molecular weight of each protein is shown. 
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4.10 PRMT1 and PRMT5 are up-regulated by LMP1 in GC B cells 
 
Having shown that EBV can up-regulate PRMT1, PRMT5 and CARM1 and down-regulate 
PADI4, I next explored whether the expression of these enzymes was regulated by LMP1 in B 
cells.  For these experiments, I used RNA from GC B cells obtained from different patients 
transfected with either a pSG5-LMP1expression vector or with a pSG5 vector control 
(Vockerodt et al., 2008).  I was able to show using Q-RT PCR  and RNA isolated 24 hours 
post transfection  that LMP1 up-regulated PRMT1 in both GC B cell samples (Figure 4.15 A). 
PRMT5 was up-regulated in only one of the samples (Figure 4.15 B) and neither CARM1 nor 
PADI4 were significantly changed (Figure 4.15 C and D). 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
Figure 4.15: Q RT-PCR of the relative quantity of PRMTs and PADI4 in LMP1-expressing and 
non-expressing GC B cells.  All samples were analysed in triplicate and are presented as 2−∆∆CT 
values compared with vector control (pSG5).  Standard error bars show the variation of expression 
across the three assays. 
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4.11 PRMT1 and PRMT5 are up-regulated in an LMP1-inducible 
system         
Using the tetracycline-inducible expression system described earlier (section 4.6) I was able 
to show using Q RT-PCR that LMP1 up-regulated both PRMT1 and PRMT5 in the DG75 cell 
line (Figure 4.16).   
 
 
 
 
 
 
 
Figure 4.16:  Q RT-PCR analysis of PRMT1 and PRMT5 transcripts in cell lines with 
tetracycline-inducible expression of LMP1.  Blue bars represent clones containing no LMP1 
construct and red bars represent LMP1 containing clones. Tet + indicates cells grown in the presence 
of tetracycline and Tet- indicates cells that have had tetracycline removed.   Assays were carried out in 
triplicate and results are presented as 2−∆∆CT values compared with vector controls.  A. PRMT1 
expression. B. PRMT5 expression. 
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Summary  
In this section, I have shown that the expression of the arginine methyltransferases, 
CARM1, PRMT1 and PRMT5, is up-regulated, and that of the peptidylarginine 
deiminase, PADI4, down-regulated following EBV infection of GC B cells. 
Whereas the expression of CARM1, PRMT1 and PRMT5 is increased, that of 
PADI4 is decreased in HL cell lines when compared with GC B cells. Finally, I 
have shown that PRMT1 and PRMT5 are up-regulated in B cells by the EBV 
oncogene LMP1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
Chapter 5 
 
 
The impact of EBV induced changes in the 
expression of DNA methyltransferases on 
the methylation and expression of viral 
genes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
Aims of Chapter 5 
1. To determine the DNA methylation status of the Wp and Cp promoter in GC B 
derived LCLs 
2. To measure the binding of the DNA methyltransferases to the Wp promoter in 
a) GC B derived LCLs 
b) a latency I Burkitt’s lymphoma cell line 
c) a “Wp only” LCL 
d) an LCL containing 11 BamHI W copies 
e) an LCL containing 2 BamHI W copies 
3. To determine the impact on viral gene expression, of DNMT1 and DNMT3B over-
expression in GC B cell derived LCLs. 
 
 
In the first section of this chapter, I investigate the impact of EBV-induced changes 
in the expression of the DNMT on the viral life cycle.  I first show that the Wp 
promoter is methylated in GC B cell derived LCLs before investigating how DNMT 
binding to this promoter varies in EBV positive cell lines with different latency 
patterns and with different numbers of Wp repeats. 
 
 
 
 
 
 
       
5.1    The Wp promoter is methylated in GC B cell derived LCL 
 
The EBV promoter, Wp is known to become methylated soon after primary B cell infection 
(Tierney et al., 2000).  To determine whether Wp was methylated in GC B cell derived LCLs, 
I designed using the methods described in section 2.10.2 ,two sets of pyrosequencing primers 
which encompass the promoter regions around the YY1 binding sites (region 2) and BSAP 
binding site (region 1,  Figure 5.1).  Pyrosequencing was carried out twice on each of the LCL 
samples ( primer sequences are listed in page 78).  In LCL 1, the average methylation across 5 
CpGs was 29% in region 1 of Wp, and 60% in region 2 (Figure 5.2).  Methylation levels were 
consistent across these three LCLs (Table 5.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
                                        
 
ggtgaggcccagccccctcccgcccctgtccactgccccggtccccccagaagcccccaaaagtagaggctcaggccatgcgcgccctgtcaccaggcctgccaaagagccagatctaaggc
cgggagaggcagccccaaagcgggtgcagtaacaggtaatctctggtagtgatttggacccgaaatctgacactttagagctctggaggactttaaaactctaaaaatcaaaactttagaggcgaat
gggcgccattttgtccccacgcgcgcataatggcggacctaggcctaaaacccccaggaagcgggtctatggttggctgcgctgctgctatctttagaggggaaaagaggaataagcccccaga
caggggagtgggcttgtttgtgacttcaccaaaggtcagggcccaagggggttcgcgttgctaggccaccttctcagtccagcgcgtttacgtaagccagacagcagccaattgtcagttctaggg
agggggaccactgcccctggtataaagtggtcctgcagctatttctggtcgcatcagagcgccaggagtccacacaaatgtaagagggggtcttctacctctccctagccctccgccccctccaag 
Wp +1 
CREBRFX 
 
Figure 5.1.  DNA sequence of the EBV BamHI Wp promoter regulatory region.  Coloured boxes indicate the binding sites for the transcription factors 
YY1, BSAP, RFX and CREB.  The black circles labelled 1 to 15 denote the CpG dinucleotides within the Wp promoter.  The arrows indicate the two regions 
analysed by pyrosequencing. Within the sequence the CpGs are highlighted in yellow and numbered corresponding to their position on the diagram above.  
The transcription start site is highlighted in green. 
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Figure 5.2:  Pyrogram results showing the percentage methylation at each of the CpG 
dinucleotides for two regions analysed within the Wp promoter.  The binding sites for 
transcription factors known to bind within that region are labelled above the pyrogram in 
bold. The average methylation across each region is reported in the box on the right.  
 
 
 CpG 1 
CpG 
2 
CpG 
3 
CpG 
4 
CpG 
5 
CpG 
6 
CpG 
7 
CpG 
8 
CpG 
9 
CpG 
10 
CpG 
11 
Average 
methylation 
LCL1 27 22 25 20 51 26 59 54 67 70 84 50.5% 
LCL 2 32 23 29 19 47 25 63 54 69 77 80 51.8% 
LCL 3 35 21 32 25 53 27 70 55 72 75 93 55.8% 
 
Table 5.1:  Summary of methylation results at each CpG in LCL1, LCL 2 and LCL 3.  
The average methylation over the regions is reported in the box on the far right hand side.    
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5.2  Optimization of X-ChIP antibodies  
 
To test the specificity and sensitivity of each of the DNMT antibodies to be used in the cross-
linked chromatin immunoprecipitation (X-ChIP), a series of preliminary experiments were 
performed using a protocol optimized by Dr. Laura O’Neill (Division of Immunity and 
Infection, University of Birmingham).  Two different antibodies against DNMT1, a 
polyclonal antibody (Abcam) and a monoclonal antibody (Imgenex), were compared by 
assessing their ability to bind to the HoxA7 promoter in HeLa cells.  DNMT1 has already 
been shown to bind to “region E” but not to “region F” of this promoter in these cells (Wu et 
al., 2008).   A polyclonal antibody to DNMT3A (Imgenex) previously shown to be successful 
in X-ChIP experiments, and a ChIP-grade monoclonal antibody to DNMT3B (Abcam) were 
tested for binding to the GAPDH and Sat 2 promoters in an LCL (Leu et al., 2004).  Both 
DNMT3A and DNMT3B have previously been shown to bind to Sat 2 but not to GAPDH in 
an LCL (Geiman et al., 2004). Details of the antibodies and primers used in these experiments 
are provided in section 2.13.3 Page 84)  IPs were performed as described in section 2.13 and 
the DNA purified from IP and input samples analysed using SYBR green Q-PCR.  The 
percent input method was used to calculate the enrichment in the target sequences as 
described in section 2.13.6.   
Q-PCR showed that region E  but not region F of the HoxA7 promoter was significantly 
enriched in both DNMT1 IPs compared to the control IgG and no antibody IP, and these 
findings are consistent with the X-ChIP results obtained by Wu et al., 2008 (Figure 5.3 A and 
B). To assist with the interpretation of these figures I should point out that whereas a 
substantial increase in the PCR product in the DNMT IP compared to IgG and no antibody 
controls indicates evidence of specific binding of that DNMT to that region, no enrichment in 
the DNMT IP suggests that there has been no binding.  As a greater enrichment was detected 
       
using the Abcam antibody this was used in subsequent X-ChIP experiments.  I next assessed 
the DNMT3A and DNMT3B antibodies in a LCL. When compared to controls a significant 
enrichment of DNMT3A and DNMT3B was detectable at the Sat 2 promoter (Figure 5.3 C).  
As expected the GAPDH promoter was found to be negative for DNMT binding (Figure 5.3 
D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
Figure 5.3:   Q-PCR analysis testing the efficiency of DNMT antibodies used in IP.  HeLa 
cells were used to test the efficiency of two DNMT1 antibodies.  LCLs were used to test 
DNMT3A and DNTM3B antibodies.  All results are reported as a % of input and compared to 
IgG and no antibody controls. A and B.  DNTM1 binding to the HoxA7 promoter.  Region E 
served as a positive control and region F as a negative.  C and D.  DNMT3A and DNMT3B 
binding to the highly methylated Sat 2 region and unmethylated GAPDH promoter. 
A 
B 
C 
D 
       
5.3 DNMT3A binds to the methylated Wp promoter in GC B cell derived 
LCLs 
Having successfully established the X-ChIP technique with each of the DNMT antibodies, I 
next studied the binding of DNMT1, DNTM3A and DNMT3B to Wp in the GC B cell 
derived LCLs. Figure 5.4 shows where the overlapping PCR primers were designed for 9 
regions of the Wp promoter, and one for the Cp promoter, which is known to be unmethylated 
in LCLs and therefore provides a negative control (Tierney et al., 2000).  The full list of 
primer sequences is shown in section 2.13.6, page 85. X-ChIP experiments were performed as 
before.  
 
 
 
 
 
Figure 5.4 Regions of Wp covered by X-ChIP. The nine sets of primers covering Wp and 
one at Cp are shown.  Each primer was between 300-400 bp in length.  The region covered by 
pyrosequencing is also shown. 
 
 
 
       
 
5.3.1 DNMT1 does not bind to the Wp promoter 
In each of the three LCLs studied, DNMT1 binding to regions within the Wp or Cp promoter 
did not exceed that observed in the IgG and in the no antibody controls (Figure 5.5).  
 
5.3.2  DNMT3B does not bind to the Wp promoter 
In each of the three LCLs studied, DNMT3B binding to regions within the Wp or Cp 
promoter did not exceed that observed in the IgG and in the no antibody controls (Figure 5.6). 
Sat 2 (positive control) but not GAPDH (negative control) was found to bind DNMT3B.  
 
5.3.3 DNMT3A binds to the Wp promoter 
In each of the three LCLs studied, the binding of DNMT3A to regions within Wp was 
significantly greater than that observed in the IgG and in the no antibody controls (Figure 
5.7). Enrichment was greatest in region 6 but was also detected in region 7.  Sat 2 (positive 
control) but not GAPDH (negative control) was found to bind DNMT3A.  
 
 
 
 
 
 
 
 
 
  
Figure 5.5:  SYBR green Q-PCR results of DNMT1 binding to the Wp promoter using X-ChIP.  DNMT1 binding to nine regions of the 
Wp and Cp promoter was assessed using X-ChIP.   Binding was reported as a % of input.  IgG and no antibody IPs were used as controls to 
which the antibody of interest was compared to.  Each assay was carried out in duplicate and standard error bars show the variation across the 
assays.   
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Figure 5.6:  SYBR green Q-PCR results of DNMT3B binding to the Wp promoter using X-ChIP.  DNMT3B binding to nine regions of the 
Wp and Cp promoter was assessed using X-ChIP.  Methylated Sat 2 was used as a control for binding.  Binding was reported as a % of input.  
IgG and no antibody IPs were used as controls to which the antibody of interest was compared to.  Each assay was carried out in duplicate and 
standard error bars show the variation across the assays. 
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Figure 5.7:  SYBR green Q-PCR results of DNMT3A binding to the Wp promoter using X-ChIP.  DNMT3A binding to nine regions of the 
Wp and Cp promoter was assessed using X-ChIP.  Methylated Sat 2 was used as a control for binding.  Binding was reported as a % of input.  
IgG and no antibody IPs were set up as controls to which the antibody of interest was compared to.  Each assay was carried out in duplicate and 
standard error bars show the variation across the assays. 
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So far I have studied only GC B cell derived LCLs infected with EBV carrying 11 copies of 
Wp.  In the next section I explore DNMT binding to Wp in other EBV positive cell lines with 
different latency patterns and also different numbers of Wp repeats.  All nine regions of Wp 
were analysed, however only regions 5, 6 and 7 are shown as these were the only regions that 
DNMT binding was detected. 
 
5.4 Minimal binding of DNMT to the unmethylated Wp promoter in a 
“Wp only” LCL 
X50-7 is a Wp using LCL, in which Wp is hypomethylated and transcriptionally active 
(Hutchings et al., 2006).  In this cell line, there was a minute excess  of DNMT3A and 
DNMT3B binding to regions 5 and 6 in the Wp promoter as compared to that observed in the 
IgG and in the no antibody controls (Figure 5.8).  Although initially thought to be background 
noise this minimal binding was a consistent finding across five different experiments.  
 
5.5 DNMT3A and DNMT3B binds the methylated Wp promoter in a 
latency I Burkitt’s Lymphoma cell line 
Rael-BL, is a standard latency I Burkitt’s lymphoma cell line in which Wp is reported to be 
silenced and methylated (Hutchings et al., 2006).  In this cell line, the binding of DNMT3A 
and DNMT3B to regions 5 and 6, and to a lesser extent, region 7 within the Wp promoter was 
significantly greater than that observed in the IgG and in the no antibody controls (Figure 
5.9).  The binding of DNMT1 to regions 5 and 7 within the Wp promoter was also 
significantly greater than that observed in the IgG and in the no antibody controls.  There was 
no evidence of DNMT binding to the Cp promoter. 
       
 
5.6 DNMT3A and DNMT3B bind the methylated Wp promoter in the 
11W EBV LCL 
The 11W LCL was constructed by Dr. Rose Tierney (School of Cancer Sciences, University 
of Birmingham) using a recombinant virus containing eleven BamHI W repeats. Wp is 
reported to be methylated and silenced in this LCL (Hutchings et al., 2006).  In this cell line, 
the binding of DNMT3A in regions 5, 6 and 7 within the Wp promoter was significantly 
greater than that observed in the IgG and in the no antibody controls (Figure 5.10). Binding of 
DNMT3B and DNMT1 was occasionally detected but was not a consistent finding. No 
enrichment was detected in the Cp promoter. 
 
5.7 DNMT3A and DNMT3B bind the “unmethylated” Wp promoter in 
the 2W EBV LCL 
The 2W LCL was constructed by Dr. Rose Tierney (School of Cancer Sciences, University of 
Birmingham) using a recombinant virus containing two BamHI W repeats.   Wp is reported to 
be unmethylated and transcriptionally active in this LCL (Hutchings et al., 2006).  In this cell 
line, the binding of DNMT3A in region 6 within the Wp promoter was significantly greater 
than that observed in the IgG and in the no antibody controls (Figure 5.11). No consistent 
binding of DNMT3B and DNMT1 could be detected. No enrichment was detected in the Cp 
promoter. 
 
 
  
 
       
 
     
 
 
Figure 5.8:  X-ChIP results showing DNMT3A, DNMT3B and DNMT1 binding to Wp in the 
X50-7 LCL. IPs were set up using a DNMT antibody or using IgG or no antibody as controls.  DNA 
was purified from IPs and the input sample and assayed in triplicate using SYBR green Q-PCR for 
regions in the Wp promoter; 5, 6 and 7 .  Results are expressed as a percentage of input. Results are 
representative of experiments performed five times.  
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Figure 5.9:  X-ChIP results showing DNMT3A, DNMT3B and DNMT1 binding to Wp in Rael -
BL. IPs were set up using a DNMT antibody or using IgG or no antibody as controls.  DNA was 
purified from IPs and the input sample and assayed in triplicate using SYBR green Q-PCR for regions 
in the Wp promoter; 5, 6, 7 and also for the Cp promoter (negative control).  Results are expressed as a 
percentage of input. Results are representative of an experiment performed three times.  
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Figure 5.10:  X-ChIP results showing DNMT3A, DNMT3B and DNMT1 binding to Wp in the 
11W EBV LCL.  IPs were set up using a DNMT antibody or using IgG or no antibody as controls.  
DNA was purified from IPs and the input sample and assayed in triplicate using SYBR green Q-PCR 
for regions in the Wp promoter; 5, 6, 7 and also for the Cp promoter (negative control).   Results are 
expressed as a percentage of input. Results are representative of an experiment performed three times.  
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Figure 5.11:  X-ChIP results showing DNMT3A, DNMT3B and DNMT1 binding to Wp in the 
2W EBV LCL. IPs were set up using a DNMT antibody or using IgG or no antibody as controls.  
DNA was purified from IPs and the input sample and assayed in triplicate using SYBR green Q-PCR 
for regions in the Wp promoter; 5, 6, 7 and also for the Cp promoter (negative control).  Results are 
expressed as a percentage of input. Results are representative of an experiment performed three times.  
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5.8 Methylation status of the Wp promoter in the 2W EBV LCL-revisited 
 
In the preceding section I have shown that DNMT3A binds to the Wp promoter in the 2W 
EBV LCL. This was a surprising finding because the Wp promoter in this cell line is reported 
to be unmethylated (Hutchings et al., 2006).  Therefore, using pyrosequencing, I examined 
the methylation status of this promoter and found that methylated CpGs could be detected in 
Wp (Figure 5.12).  On revisiting the data presented in the manuscript, I found that some 
clones were methylated at certain CpGs when examined using bisulphite genomic sequencing 
Therefore the results of my X-ChIP experiment demonstrating DNMT3A binding to the Wp 
promoter are consistent with the results of my pyrosequencing and with the data originally 
presented.   
     Region 1 
 
      Region 2                                
 
Figure 5.12:  Pyrosequencing results for the Wp promoter in the 2W EBV LCL.  The 
percentage methylation at each CpG is reported in the blue boxes above the program. The 
average methylation for the region is also reported. 
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In this section, I have shown that the Wp promoter is methylated and bound by 
DNMT3A in a region approximately 350bp up-stream of its transcription start site. 
The binding of DNMT to the Wp promoter in other EBV positive cell lines was 
broadly consistent with the previously reported methylation status of this promoter 
in these lines. Contrary to the impression left by an earlier report, I found that the 
Wp promoter is both bound by DNMT and methylated in the 2W EBV LCL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
  
Having shown in the preceding chapter that DNMT1 and DNMT3B are down-
regulated in GC B cell derived LCLs.  I have attempted to examine the impact on 
viral gene expression of re-expressing DNMT1 and DNMT3B in these cell lines. 
 
 
5.9 Transient transfection of GC B derived LCLs with DNMT1 and 
DNMT3B using electroporation is followed by the up-regulation of 
these enzymes at the RNA level but not at the protein level 
In the previous chapter, I showed that DNMT1 and DNMT3B are down-regulated in GC B 
cells following infection with EBV.  Therefore, I next wanted to know what would be the 
effect on viral gene expression were I to re-express these proteins in GC B cell derived LCLs.  
Towards this end, I used pCDNA3-DNMT1 and pCDNA-DNMT3B plasmids provided by 
Dr. Keith Robertson (Department of Biochemistry and Molecular Biology, Shands Cancer 
Center, University of Florida).  GC B cell derived LCLs (1 x107 cells) were transfected using 
electroporation with  10 µg, or 20 µg of pCDNA3-DNMT1, pCDNA-DNMT3B or vector 
control plasmid according to conditions specified in section 2.12.  RNA and protein were 
extracted at 24 and 48 hours post transfection.  
 
 Q-RT PCR showed up-regulation of DNMT1 and DNMT3B 24 and 48 hours post 
transfection (Figure 5.13).  However western blotting showed no up-regulation of DNMT1 or 
DNMT3B protein (Figure 5.14).  The blots were re-probed for the plasmids HA tag but this 
too could not be detected.  When cytospins were made from transfected cells as described in 
       
section 2.14, immunohistochemistry revealed that only 1% of the cells had been successfully 
transfected compared to the vector control (Figure 5.15).  When performing these experiments 
I recorded that there was approximately 50% cell death following transfection. Therefore I 
came to the conclusion that these cells could not tolerate the over-expression of DNMT1 or 
DNMT3B.  Transfection experiments were repeated using Lipofectamine but with essentially 
identical results (data not shown). 
                      
     
 
Figure 5.13: DNMT1 and DNMT3B mRNA expression following transfection of GC B 
cell derived LCLs.  LCLs were transfected with 10µg or 20 µg of DNMT1 or DNMT3B and 
the expression was analysed 24 and 48 hours post transfection.  All Q RT-PCR samples were 
analysed in triplicate and are presented as 2−∆∆CT values compared with the vector control. 
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Figure 5.14: Western blotting of DNMT1 and DNMT3B following electroporation.  
DNMT1 and DNTM3B expression was detected using 20 µg of protein.  MCM7 was used as 
a loading control. 
 
 
        
 
                                        
 
 
 
Figure 5.15:   DNMT1 and DNMT3B expression in GC B cell derived LCL. 
Immunohistochemistry for the HA tag expressed by LCLs successfully electroporated with 
pCDNA3- DNMT1 or pCDNA3- DNMT3B.  A.  Cells transfected with the pCDNA3 vector 
control. B. Cells transfected with pCDNA3-DNMT1.  C. Cells transfected with pCDNA3-
DNMT3B. 
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5.10 Transient transfection of the marmoset cell line B95.8 with DNMT1 
and DNMT3B using electroporation is followed by the up-regulation 
of these enzymes at the RNA and protein level 
 
I next explored the possibility that the pCDNA3-DNMT1 and pCDNA3-DNMT3B plasmids 
would be less “toxic” in another LCL.  Towards this end, these plasmids were transfected 
using electroporation into the B95.8 cell line which I selected because I had previously shown 
that the pattern of DNMT expression in this cell line compared to GC B cells is similar to that 
observed in EBV infected GC B cells (Figure 5.16). 
 
 
              
 
Figure 5.16: DNMT1, DNMT3A and DNMT3B mRNA expression in B95.8 cells.    
DNMT expression in B95.8 LCL was compared to GC B cells.  Assays were carried out in 
triplicate and results are presented as 2−∆∆CT values.  Standard error bars show the variation in 
relative DNMT expression across three independent experiments. 
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Q-RT PCR showed up-regulation of DNMT1 and DNMT3B, 48 hours post transfection 
(Figure 5.17).  On this occasion, western blotting showed an up-regulation of DNMT1 and 
DNMT3B at the protein level (Figure 5.18).    When cytospins were made from transfected 
cells as described in section 2.14, immunohistochemistry confirmed the expression of HA-
tagged DNMT1 and DNTM3B and revealed that approximately 10% of cells had been 
transfected (Figure 5.19).   
 
                   
Figure 5.17: DNMT1 and DNMT3B mRNA expression following transfection of B95.8 
cells. B95.8 cells were transfected with 10µg or 20 µg of DNMT1 or DNMT3B and the 
expression was analysed 48 hours post transfection.  All Q RT-PCR samples were analysed in 
triplicate and are presented as 2−∆∆CT values compared with the vector control. 
 
                                  
                                            
 
Figure 5.18: Western blotting of DNMT1 and DNMT3B following electroporation into 
B95.8 cells.  DNMT1 and DNTM3B expression was detected using 20 µg of protein.  MCM7 
was used as a loading control. 
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Figure 5.19:  DNMT1 and DNMT3B expression in B95.8 LCL. 
Immunohistochemistry for the HA tag expressed by LCLs successfully electroporated with 
pCDNA3- DNMT1 or pCDNA3- DNMT3B.  A.  Cells transfected with the pCDNA3 vector 
control (no HA tag expression). B. Cells transfected with pCDNA3-DNMT1.  C. Cells 
transfected with pCDNA3-DNMT3B. 
 
5.11 DNMT1 increases the expression of BZLF1 in B95.8 cells 
Having successfully transfected the B95.8 cells with DNMT1 and DNMT3B, I next explored 
whether over-expression of these enzymes affected viral gene expression. Q-RT PCR 
performed on each of the samples transfected with DNMT1 revealed up-regulation of BZLF1 
compared to the vector control. There was no change in expression of BZLF1 following 
transfection with DNMT3B (Figure 5.20).  The expression of LMP1, LMP2A, EBNA1, 
EBNA2, Wp, and Cp was unchanged following transfection with either DNMT1 or 
DNMT3B. I confirmed the increased expression of BZLF1 following transfection with 
DNMT1 using immunohistochemistry (Figure 5.21). 
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Figure 5.20:  Expression of viral genes following DNMT1 and DNMT3B over-expression in 
B95.8 cells.  All Q RT-PCR samples were analysed in triplicate and are presented as 2−∆∆CT values 
compared with the vector control. 
 
 
          
 
 
     
     
             
 
Figure 5.21: BZLF1 expression in B95.8 cells transfected with DNMT1. Cells expressing 
BZLF1 are stained brown, blue counterstained cells are negative for BZLF1 expression.  A.  
Cells transfected with the pCDNA3 vector control expressing BZLF1. B. Cells transfected 
with pCDNA3-DNMT1 expressing BZLF1.   
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5.12 DNMT1 does not bind to the lytic genes, BZLF1, BRRF1 or BRLF1 
in B95.8 cells  
Having shown that BZLF1 was up-regulated following transfection of DNMT1, I next 
explored using X-ChIP whether this was associated with binding of DNMT1 to BZLF1.  The 
X-ChIP analysis was extended to include the EBV lytic genes BRRF1 and BRLF1 which 
control the expression of BZLF1 and which themselves have been shown to be regulated by 
methylation (Dickerson et al., 2009, Bhende et al., 2005).    
X-ChIP primers were designed to cover the BZLF1, BRRF1 and BRLF1 promoters and are 
shown in section 2.13.6 (page 85). Cells transfected with either DNMT1 or the vector control 
were harvested 48 hours post transfection and their chromatin prepared for X-ChIP as 
described in section 2.13. However I found no evidence of DNMT1 binding to the lytic genes 
BZLF1 (Figure 5.22), BRRF1 or BRLF1 (Figure 5.23). 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
Figure 5.22: SYBR green Q-PCR results of DNMT1 binding to BZLF1 by X-ChIP 
analysis. DNMT1 binding to four regions of BZLF1 was assessed using X-ChIP.  Transfected 
cells were compared to pCDNA3 vector control transfected cells. IgG and no antibody IPs 
were used as controls. Each assay was carried out in triplicate and standard error bars show 
the variation across the assays.     
       
 
 
 
 
 
Figure 5.23: SYBR green Q-PCR results of DNMT1 binding to BRRF1 or BRLF1 by X-
ChIP analysis. DNMT1 binding of two regions of BRRF1 and two regions of BRLF1 was 
assessed using X-ChIP.  Transfected cells were compared to pCDNA3 vector control 
transfected cells. IgG and no antibody IPs  were used as controls. Each assay was carried out 
in triplicate and standard error bars show the variation across the assays.     
       
5.13 DNMT1 transfection of B95.8 cells is not followed by a change in the 
methylation of BZLF1, BRRF1 or BRLF1 
Given that both the expression of BZLF1 and of those other lytic genes (BRRF1 and BRLF1) 
which control its expression are regulated by methylation, I next investigated whether 
DNMT1 transfection was followed by a change in methylation at the promoters of these 
genes. However, pyrosequencing revealed no change in methylation at the promoters of these 
genes following DNMT1 transfection (Figure 5.24). 
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Figure 5.24: Pyrosequencing results for a region of the BZLF1, BRRF1 and BRLF1 
promoters in B95.8 cells transfected with DNMT1.  The percentage methylation at each 
CpG is reported in the blue boxes above the program.  
 
 
I have described in this section how I over-expressed DNMT1 and DNMT3B in 
the B95.8 cell line. Although I showed an up-regulation of BZLF1 following 
transfection with DNMT. I was not able to show DNMT1 binding to the BZLF1, 
BRLF1 or BRRF1 promoters.  I was also unable to show a change in methylation 
at these promoters following DNMT1 transfection. Therefore I have no 
compelling evidence to suggest that DNMT1 directly regulates the expression of 
BZLF1. 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
Chapter 6 
 
Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
One of the difficulties faced when investigating the early events contributing to the 
pathogenesis of Hodgkin’s lymphoma is the identification of an appropriate cell line model. 
Cell lines derived from lymphomas are already fully transformed, rarely resemble their 
progenitor cell and are likely to have culture-associated genetic and epigenetic changes.  To 
investigate those early EBV-associated changes contributing to the pathogenesis of HL, I 
chose as my cell line model, an LCL derived from GC B cells, the presumed progenitor cells 
of HL. To determine the relevance of this model to the pathogenesis of HL, I compared the 
transcriptional profile of EBV-infected GC B cells with that of HL cell lines, micro-dissected 
HRS cells and GC B cells transfected with the EBV latent genes, LMP1 and LMP2A. 
Although I was obliged to compare the transcriptional profile of my GC B cell derived LCLs 
with that of GC B cells obtained from donors different from those initially infected with EBV, 
the results of this validation exercise were encouraging. Substantial and significant over-laps 
were found between the transcriptional profile of EBV infected GC B cells and those of 
micro-dissected HRS cells and of GC B cells transfected with LMP1, the major EBV 
oncogene. Perhaps the most compelling result was the finding that 80% of the genes down-
regulated in HL cell lines and 76% of those up-regulated were concordantly regulated in EBV 
infected GC B cells. The strength and consistency of these associations suggest that EBV 
infected GC B cells are a useful model for investigating early virus associated epigenetic and 
transcriptional changes contributing to the pathogenesis of HL.  As to whether I would see 
similar transcriptional changes if I compared my EBV infected GC B cell arrays to BL cell 
line arrays remains moot, as there are no BL arrays available for me to compare my arrays to.  
 
 
 
       
In common with other oncogenic viruses, EBV de-regulates the expression of the DNA 
methyltransferases (Flanagan 2007). However, their pattern of expression in EBV infected 
GC B cells, is markedly different from that associated with other oncogenic viruses. Whereas 
these oncogenic viruses consistently up-regulate DNMT1, DNMT3A and DNMT3B, I found 
that EBV down-regulates DNMT1 and DNMT3B and up-regulates DNMT3A in GC B cells.  
I have also shown that LMP1, the major EBV oncogene, is responsible for the down-
regulation of DNMT1. However, I could find no evidence to suggest that either DNMT3A or 
DNMT3B   were down-regulated in GC B cells by the EBV latent genes, LMP1, EBNA1 or 
LMP2A. It is worth pointing out that EBV-induced changes in the expression of these 
epigenetic regulators are likely to be cell type-specific.  DNMT1, DNMT3A and DNMT3B  
are up-regulated in  nasopharyngeal cancer cell lines by the major EBV oncogene, LMP1, and 
DNMT1 is reported to be up-regulated in a gastric cancer cell line by another EBV latent 
gene, LMP2A (Tsai et al., 2002, Seo et al., 2008, Hino et al., 2009).  Furthermore, although 
DNMT1, DNMT3A and DNMT3B are consistently over-expressed in cancer at a wide range 
of sites, I found that DNMT1 and DNMT3B were down-regulated, and DNMT3A up-
regulated in a panel of HL cell lines. This pattern of expression is consistent with the results 
of gene expression profiling performed on micro-dissected HRS cells (Brune et al., 2008). 
Although each of the HL cell lines showed an increase in DNMT3A and a decrease in 
DNMT3B and DNMT1 at the protein level, the transcriptional results did not always 
correlate.  For example, DNMT3A was not up-regulated in L428 at the transcriptional level, 
this could point to a possible role for post-transcriptional modifications such as miRNA 
regulation of  DNMTA in this cell line, or it could also be due to a mutation within the region 
being analysed by Q-RT-PCR, which could be checked by sequencing the region covered by 
the Q- RT PCR primers.   
       
My observations offer some clues as to how EBV-induced de-regulation of the DNA 
methyltransferases might contribute to viral persistence and to the pathogenesis of HL. For 
example, DNMT1 has been shown to have an essential role in maintaining the progenitor state 
of constantly replenishing somatic tissue (Sen et al., 2010).  Depletion of DNMT1 is followed 
by the exit of cells from the progenitor compartment and their premature differentiation. This 
transition is associated with the down-regulation of UHRF1, a component of the cell’s DNA 
methylation machinery, and with the up-regulation of GADD45, a putative DNA 
demethylase.  Similar transcriptional changes are seen during normal B cell differentiation 
when DNMT1 and UHRF1 are down-regulated and GADD45A up-regulated in both plasma 
cells and memory cells compared with centrocytes (Brune et al., 2008, supplemental 
information). I have confirmed  that DNMT1 expression falls in B cell subsets with  
increasing  stage of differentiation and  have shown using gene expression profiling  that the 
down-regulation of DNMT1 observed in EBV infected GC B cells is associated with both the 
down-regulation of UHRF1 (fold change, 2.8) and with  the up-regulation of GADD45A (fold 
change, 2.4) Therefore, LMP1-induced down-regulation of DNMT1 in GC B cells may 
explain in part how this  viral oncogene drives cells towards a post GC stage while at the 
same time  hijacking the B cell transcriptional programme and subverting normal B cell 
differentiation. These are important considerations given that DNA demethylating agents 
which deplete DNMT1 are already in Phase II trials for the treatment of HL. 
(http://forums.lymphoma.com/archive/index.php/t-24166.html).   
 
 
 
 
       
My observations also reveal how EBV-induced changes in the expression of the DNMTs 
might contribute to the establishment of persistent viral infection. Although Wp is the first 
viral promoter to be activated during the in vitro transformation of primary resting B cells, 
levels of Wp-initiated transcripts decline and Cp becomes the dominant EBNA promoter in 
most established LCL. This flexibility of latent promoter usage has been considered critical to 
the virus' strategy for persistence in vivo (Hutchings et al., 2006). While it has been known 
for some time that Wp is silenced by DNA methylation, I was able to reveal a potential role 
for EBV induced up-regulation of DNMT3A in maintaining viral persistence by 
demonstrating that this enzyme binds to and is associated with methylation of the Wp 
promoter.  However, I was less successful in showing how EBV-induced down-regulation of 
DNMT1 and DNMT3B might contribute to the viral life cycle. Although I found that over-
expression of DNMT1 in B95.8 cells was followed by the up-regulation of the early lytic gene 
BZLF1, I was unable to show DNMT1 binding to the BZLF1promoter. Nor was I was able to 
show that over-expression of DNMT1 was followed by a change in methylation status at 
either the BZLF1 promoter or those of the other lytic cycle genes, BRRF1 and BZLF1 which 
regulate its expression. Therefore, I have to conclude that the observed up-regulation of 
BZLF1 which I observed is not a direct consequence of the over-expression of DNMT1. 
Turning now to the methylation arrays which I performed on EBV infected GC B cells. As 
this was the first time methylation arrays had been performed in the School of Cancer 
Sciences, and no bespoke method was available for their analysis, I was fortunate to have the 
assistance of Dr Wenbin Wei, Head of Bioinformatics in this School. After much 
consideration and some preliminary validation studies, we decided to analyse my arrays using 
the Tilemap software programme and the moving average method. This software has since 
been used by others when analysing tiling arrays (Akkers et al., 2010, Zinzen et al., 2009, 
       
Reed et al., 2008).  Although I found that pyrosequencing confirmed almost all the changes 
predicted on my methylation array, the magnitude of these changes was often surprisingly 
small. This is perhaps inevitable given that methylation arrays are performed on methyl-
enriched samples whereas pyrosequencing is performed on un-enriched DNA. Whereas the 
former method selects only those cells which are methylated, the latter must detect 
methylation changes which are dispersed through the total cell population. An alternative way 
to confirm changes predicted on the methylation array would have been to methyl-enrich the 
sample and then to look for methylated forms using Q-PCR. 
EBV-induced changes in the expression of the DNMT in GC B cells were associated with 
methylation changes in a substantial number of cellular genes. However,   these changes were 
not randomly distributed across the genome but appeared to cluster at certain chromosomal 
locations. Concordant methylation of adjacent CpG island gene promoters has also been 
reported for a number of gene clusters in cancer, and recent genome-wide analyses have 
identified other large chromosomal regions containing several CpG islands which are often 
methylated and transcriptionally repressed in cancer (Coolen et al., 2010), Although these 
observations suggest that coordinated epigenetic control over large regions is common in 
cancer, this phenomenon has not previously been reported following the  infection of primary 
cells with an oncogenic virus (Davidsson et al., 2009, Taylor et al., 2007).    
 
 
 
 
 
       
As to why some genes become more or less methylated following EBV infection of GC B 
cells, and others not, also appear to depend on their CpG content.  Whereas promoters with a 
high CpG content were significantly more likely to become methylated following EBV 
infection, those with a low CpG content were more likely to become less methylated This 
relationship between CpG content and methylation change has been described before and 
appears to be context dependent. For example, in melanoma, prostate cancer, and in non-
Hodgkin lymphomas, the trend is the same as that observed following EBV infection: genes 
with a high CpG content are more likely to have increased methylation whereas those with a 
low CpG content are more likely to be hypomethylated (Koga et al., 2009, Martin-Subero et 
al., 2009, Gal-Yam et al., 2008). In contrast, Weber et al., 2007 found that during normal 
development, promoters with a low CpG content were more likely to be targeted by 
methylation whereas those with a high CpG content remained un-methylated.  
Subsequent to undertaking the work presented in this thesis, I have performed methylation 
arrays on foreskin keratinocytes transfected with episomal HPV16. The analysis of these 
arrays showed that the relationship between CpG content and the direction of HPV-induced 
methylation changes is almost identical to the pattern observed following EBV infection of 
GC B cells.  Thus it would appear that in cancer and in primary cells exposed to oncogenic 
viruses, de novo methylation changes are determined in part by cis-acting susceptibility 
factors such as promoter CpG content. 
 
 
 
 
 
       
One of the objectives of my thesis was to determine how often EBV-associated methylation 
events predicted virus-associated transcriptional changes. My results were perhaps surprising 
given the widely held belief that an increase in methylation is inevitably associated with 
transcriptional down-regulation, and a decrease in methylation with transcriptional up-
regulation. In fact, I found that genes with increased methylation following EBV infection of 
GC B cells were significantly more likely to be either transcriptionally increased, whereas 
those with decreased methylation were significantly less likely to be changed in either 
direction. Others who have performed integrated methylation and transcriptional profiling 
have concluded that the relationship between methylation and transcriptional change is more 
complex than was previously thought (Boellmann et al., 2010, Shann et al., 2008,).   In my 
introduction, I have provided specific examples of where methylated sequences can facilitate 
and inhibit the binding of transcription factors.   I now discuss more generally the 
interpretation of integrated epigenetic-transcriptional profiling studies.  
One of the problems when attempting to correlate methylation and transcriptional changes is 
that these changes cannot be linked at the level of the individual cell. There is no way of 
knowing which cells have been affected by methylation change and which have undergone a 
transcriptional change. Although pyrosequencing can provide an estimate of the proportion of 
cells which contain methylated forms of a gene, transcriptional read-outs can only provide a 
summary measure across all cells in the sample, one which necessarily reflects the net effect 
of competing regulatory pressures within individual cells and across different cells. The 
kinetics of methylation induced transcriptional change are likely to be complex, and to be 
both gene and context dependent. Consider for example, PRDM1, the master regulator of 
plasma cell differentiation. A fellow PhD student (Katerina Vrzalicova) is investigating how 
EBV-induced changes in the expression of this gene contributes to abnormal B cell 
       
differentiation. This gene has an alpha isoform and a beta isoform which is normally silenced 
in GC B cells. My methylation array predicted that the beta isoform became less methylated 
following EBV infection of GC B cells, a prediction I confirmed using pyrosequencing. 
Whereas this isoform  was found to be methylated in 28% of uninfected GC B cell, the 
proportion of infected cells fell to 10 % six weeks following infection with EBV, at which 
point Katerina was able to show using Q-RT-PCR that its expression had been induced. For 
this particular isoform in this cell background, an 18% reduction in the number of cells 
containing methylated forms was sufficient to induce gene expression. For another gene, the 
fall in the number of cells containing methylated form necessary to trigger transcription would 
almost certainly be different. This example illustrates another difficulty which may arise when 
attempting to correlate methylation and transcriptional changes using observations based on 
only two time-points. I have shown that EBV associated methylation changes in GC B cells 
are progressive, probably as a consequence of a monoclonal population growing out and 
becoming polyclonal. It follows from this that observations made earlier than six weeks might 
have revealed methylation changes in a particular gene but failed to reveal methylation-
associated transcriptional changes because sufficient cells had yet to acquire methylated 
forms.   
When attempting to interpret the results of integrated methylation-transcriptional profiling, 
there are also technical constraints relating to the coverage and resolution provided by the 
array platforms. These may frustrate attempts to reveal the true relationship between 
methylation and transcriptional changes. For example, when I started my thesis, the emphasis 
was on detecting methylation changes in or immediately adjacent to the gene promoter. 
Although the Affymetrix platform used in my experiments provides extensive coverage of 
gene promoters, this approximates to only 7% of the genome. This is an important 
       
consideration given that it has recently been shown that intragenic methylation may be an 
important determinant of transcriptional change (Maunakea et al., 2010). Furthermore the 
U133 Affymetrix array used in my transcriptional analysis does not have probes for all known 
isoforms of each gene. For example, whereas it was possible to distinguish methylation 
changes in the different isoforms of the PRDM1 gene on the Affymetrix promoter array, only 
probes for the alpha isoform and not the beta isoform are included on the transcriptional array. 
 Although I found that only one TSG (TP73) silenced by DNA methylation in HL was also 
methylated in GC B cells by EBV, my literature search identified only twenty-two 
epigenetically silenced TSG in HL, and no instance of a gene being hypomethylated in this 
lymphoma. In these circumstances, evidence of absence may simply reflect absence of 
evidence.   For these reasons, a final judgment on the relevance of the early methylation 
changes revealed on my GC B cell derived LCL to the pathogenesis of HL must be postponed 
until we have the results of a comparable methylation array performed on micro-dissected 
HRS cells. Performing methylation arrays on HRS cells would be technically challenging 
given the number of cells that would need to be micro-dissected in order to perform a MeDIP.  
However, technical advances now make it possible to perform these assays on much smaller 
cell numbers than before (Active Motif, MethylCollector™ Ultra). 
 
 
 
 
 
 
       
Finally, one of the unexpected findings on my transcriptional array was the up-regulation of 
genes that modulate another epigenetic mark, arginine methylation, In a series of preliminary 
experiments, I have confirmed that EBV infection of GC B cells, the presumptive progenitors 
of the HRS cells found in HL, is followed by the up-regulation of the protein arginine 
methyltransferases CARM1, PRMT1 and PRMT5, and the down-regulation of the arginine 
deiminase, PADI4.  This pattern of expression is recapitulated in HL cell lines and in primary 
HL, and is entirely consistent with the results of gene expression profiling performed on 
micro-dissected HRS cells (Brune et al., 2008, supplemental information). My finding that the 
expression of CARM1 was increased at the protein level in the HL cell line L450 but 
decreased at the RNA level points to a possible role for post-transcriptional modification in 
the regulation of the arginine methyltransferases. Increased protein expression of PRMT5 has 
also been reported in transformed lymphoid cells despite levels of mRNA substantially less 
than those observed in normal cells (Pal et al., 2007). This discrepancy has been causally 
attributed to the down-regulation of two miRNA, one of which, mir-96, has also been shown 
to be selectively down-regulated in EBV positive HL (Navarro et al., 2008). EBV-induced 
changes in the expression of the PRMTs may also contribute to the viral life cycle.  For 
example both PRMT1 and PRMT5 bind to the Epstein-Barr virus protein EBNA1 which is 
important for the replication and mitotic segregation of viral genomes, and which is re-
localised following inhibition of PRMT1 (Shire et al., 2006). Arginine dimethylation of 
another EBV oncoprotein, EBNA2, is necessary for its efficient association with DNA bound 
transcription factors and with other viral promoters (Gross et al., 2010). 
My observations offer some insights as to how EBV-induced changes in the expression of the 
PRMT might contribute to disturbances of B cell differentiation. Signals processed through 
the B cell antigen receptor control both proliferation and differentiation. PRMT,1 which I 
       
have shown to up-regulated by LMP1 in GC B cells, methylates a conserved arginine in the 
CD79A subunit of the B cell receptor (BCR). This modification negatively regulates the 
calcium and PI-3 kinase pathways in the BCR while promoting signals leading to B cell 
differentiation (Infantino et al., 2010). LMP1 has also been shown to increase the storage of 
Ca++ in the endoplasmic reticulum and to down-regulate the PI-3 kinase pathway in B cells 
(Dellis et al., 2009).  Given that our laboratory has shown that LMP1 can drive cells towards 
a post GC stage of differentiation, it will be important to investigate further the contribution 
of virus-induced de-regulation of PRMT1 to abnormal B cell differentiation (Vockerodt et al., 
2008). Additional evidence linking EBV induced de-regulation of the PRMTs to the 
pathogenesis of HL is possibly provided by the observation that knockdown of PRMT5 
reduces proliferation in transformed B cells and restores expression of RBL2.  We have found 
using gene expression profiling that LMP1 down regulates this pocket protein in GC B cells, 
and we and others have shown that it is also down-regulated in both HL cell lines and in 
micro-dissected HRS cells (Wang  et al., 2008, Vockerodt et al., 2008, supplemental 
information, Brune et al., 2008, supplemental information). 
More than thirty years ago inhibition of PRMT1 was shown to inhibit Rous sarcoma virus 
induced chick embryo fibroblast transformation (Enouf et al., 1979). More recently an 
inhibitor of arginine methyltranferases was shown to reduce Tax transactivation in HTLV-1 
transformed cells while at the same reducing NF Kappa B activity and inducing apoptosis 
(Dasgupta et al., 2008). The continuing intensive effort to identify specific arginine 
methylation provides compelling reasons for endeavouring to dissect the contribution to 
transformation of virus induced changes in those proteins which regulate arginine 
methylation. 
 
       
 
 
 
 
 
 
 
Bibliography 
 
 
 
 
 
 
 
 
 
 
 
       
Akkers RC, van Heeringen SJ, Manak JR, Green RD, Stunnenberg HG, Veenstra GJ (2010).  
ChIP-chip designs to interrogate the genome of Xenopus embryos for transcription factor 
binding and epigenetic regulation. PLoS One 5: 8820-8831.  
 
Alfieri C, Birkenbach M, Kieff E (1991). Early events in Epstein-Barr virus infection of 
human B lymphocytes. Virology 181: 595-608. 
 
Allan GJ, Inman GJ, Parker BD, Rowe DT, Farrell PJ (1992). Cell growth effects of Epstein-
Barr virus leader protein. J Gen Virol 73: 1547-1551. 
Allan GJ, Rowe DT (1989). Size and stability of the Epstein-Barr virus major internal repeat 
(IR-1) in Burkitt's lymphoma and lymphoblastoid cell lines. Virology 173: 489-98. 
Allday MJ, Kundu D, Finerty S, Griffin BE (1990).  CpG methylation of viral DNA in EBV-
associated tumours. Int J Cancer 45: 1125-1130. 
Ambinder RF, Robertson KD, Tao Q (1999). DNA methylation and the Epstein-Barr virus. 
Semin Cancer Biol 9: 369-375. 
Ancelin K, Lange UC, Hajkova P, Schneider R, Bannister AJ, Kouzarides T, Surani MA 
(2006).  Blimp1 associates with Prmt5 and directs histone arginine methylation in mouse 
germ cells. Nat Cell Biol 8: 623-630.  
Appanah R, Dickerson DR, Goyal P, Groudine M, Lorincz MC (2007). An unmethylated 3' 
promoter-proximal region is required for efficient transcription initiation. PLoS Genet 3: 27- 
34.  
       
Barreto G, Schäfer A, Marhold J, Stach D, Swaminathan SK, Handa V, Döderlein G, Maltry 
N, Wu W, Lyko F, Niehrs C (2007).  Gadd45a promotes epigenetic gene activation by repair-
mediated DNA demethylation. Nature 445:  671-675. 
 
Bechtel D, Kurth J, Unkel C, Kuppers R (2005). Transformation of BCR-deficient germinal-
center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and 
posttransplantation lymphomas. Blood 106: 4345-4350. 
 
Bedford MT, Clarke SG (2009). Protein arginine methylation in mammals: who, what, and 
why. Mol Cell 33: 1-13.  
 
Bedford MT, Richard S (2005). Arginine methylation an emerging regulator of protein 
function. Mol Cell 18: 263-272.  
 
Ben-Sasson SA, Klein G (1981). Activation of the Epstein-Barr virus genome by 5-aza-
cytidine in latently infected human lymphoid lines. Int J Cancer 28:131-5. 
 
Bestor TH (2005). Transposons reanimated in mice. Cell 122: 322-325.  
 
Bhende PM, Seaman WT, Delecluse HJ, Kenney SC (2004). The EBV lytic switch protein, Z, 
preferentially binds to and activates the methylated viral genome. Nat Genet 36: 1099-1104.  
 
Bhende PM, Seaman WT, Delecluse HJ, Kenney SC (2005). BZLF1 activation of the 
methylated form of the BRLF1 immediate-early promoter is regulated by BZLF1 residue 186. 
J Virol 79: 7338-7348. 
       
 
Biggin M, Bodescot M, Perricaudet M, Farrell P (1987). Epstein-Barr virus gene expression 
in P3HR1-superinfected Raji cells. J Virol 61: 3120-3132. 
 
Bird A (2001). Methylation talk between histones and DNA. Science 294: 2113-2115.  
 
Bird A (2002).  DNA methylation patterns and epigenetic memory. Genes Dev 16: 6-21. 
 
Boellmann F, Zhang L, Clewell HJ, Schroth GP, Kenyon EM, Andersen ME, Thomas RS 
(2010). Genome wide analysis of DNA methylation and gene expression changes in the 
mouse lung following subchronic arsenate exposure. Toxicol Sci Epub ahead of print. 
 
Bourc'his D, Xu GL, Lin CS, Bollman B, Bestor TH (2001).  Dnmt3L and the establishment 
of maternal genomic imprints. Science 294: 2536-2539.  
Brune V, Tiacci E, Pfeil I, Döring C, Eckerle S, van Noesel CJ, Klapper W, Falini B, von 
Heydebreck A, Metzler D, Bräuninger A, Hansmann ML, Küppers R (2008). Origin and 
pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global 
gene expression analysis. J Exp Med 205: 2251-2268. 
Burgers WA, Blanchon L, Pradhan S, de Launoit Y, Kouzarides T, Fuks F (2007). Viral 
oncoproteins target the DNA methyltransferases. Oncogene 26: 1650-1655.  
       
Butcher DT, Rodenhiser DI (2007). Epigenetic inactivation of BRCA1 is associated with 
aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast 
tumours. Eur J Cancer 43: 210-219. 
 
Caldwell RG, Wilson JB, Anderson SJ, Longnecker R (1998). Epstein-Barr virus LMP2A 
drives B cell development and survival in the absence of normal B cell receptor signals. 
Immunity 9: 405-411. 
Cai X, Schäfer A, Lu S, Bilello JP, Desrosiers RC, Edwards R, Raab-Traub N, Cullen BR 
(2006). Epstein-Barr virus microRNAs are evolutionarily conserved and differentially 
expressed.  PLoS Pathog 23. 
 
Chan AT, Tao Q, Robertson KD, Flinn IW, Mann RB, Klencke B, Kwan WH, Leung TW, 
Johnson PJ, Ambinder RF (2004). Azacitidine induces demethylation of the Epstein-Barr 
virus genome in tumors. J Clin Oncol 22: 1373-1381.  
 
Chen J, Ueda K, Sakakibara S, Okuno T, Parravicini C, Corbellino M, Yamanishi K (2001). 
Activation of latent Kaposi's sarcoma-associated herpesvirus by demethylation of the 
promoter of the lytic transactivator. Proc Natl Acad Sci U S A 98: 4119-4124. 
 
Chen T, Hevi S, Gay F, Tsujimoto N, He T, Zhang B, Ueda Y, Li E (2007). Complete 
inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells. Nat Genet 39: 
391-396. 
 
       
Chen T, Ueda Y, Dodge JE, Wang Z, Li E (2003).  Establishment and maintenance of 
genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Mol 
Cell Biol 23: 5594-5605. 
 
Cheng D, Côté J, Shaaban S, Bedford MT (2007). The arginine methyltransferase CARM1 
regulates the coupling of transcription and mRNA processing. Mol Cell 25: 71-83. 
Cohen JI, Lekstrom K (1999).  Epstein-Barr virus BARF1 protein is dispensable for B-cell 
transformation and inhibits alpha interferon secretion from mononuclear cells. J Virol 73: 
7627-7632. 
Coolen MW, Stirzaker C, Song JZ, Statham AL, Kassir Z, Moreno CS, Young AN, Varma V, 
Speed TP, Cowley M, Lacaze P, Kaplan W, Robinson MD, Clark SJ (2010). Consolidation of 
the cancer genome into domains of repressive chromatin by long-range epigenetic silencing 
(LRES) reduces transcriptional plasticity. Nat Cell Biol 12: 235-246. 
 
Dacwag CS, Ohkawa Y, Pal S, Sif S, Imbalzano AN (2007). The protein arginine 
methyltransferase Prmt5 is required for myogenesis because it facilitates ATP-dependent 
chromatin remodeling. Mol Cell Biol 27: 384-394.  
 
Dalla-Favera R, Lombardi L, Pelicci PG, Lanfrancone L, Cesarman E, Neri A (1987).  
Mechanism of activation and biological role of the c-myc oncogene in B-cell 
lymphomagenesis. Ann N Y Acad Sci 511: 207-218.  
 
       
Dasgupta A, Jung KJ, Jeong SJ, Brady JN (2008).  Inhibition of methyltransferases results in 
induction of g2/m checkpoint and programmed cell death in human T-lymphotropic virus type 
1-transformed cells. J Virol 82: 49-59. 
Daskalos A, Nikolaidis G, Xinarianos G, Savvari P, Cassidy A, Zakopoulou R, Kotsinas A, 
Gorgoulis V, Field JK, Liloglou T (2009).  Hypomethylation of retrotransposable elements 
correlates with genomic instability in non-small cell lung cancer. Int J Cancer 124: 81-81. 
Davidsson J, Lilljebjörn H, Andersson A, Veerla S, Heldrup J, Behrendtz M, Fioretos T, 
Johansson B (2009).  The DNA methylome of pediatric acute lymphoblastic leukemia.   Hum 
Mol Genet 18: 4054-4065. 
Dellis O, Arbabian A, Brouland JP, Kovàcs T, Rowe M, Chomienne C, Joab I, Papp B 
(2009).  Modulation of B-cell endoplasmic reticulum calcium homeostasis by Epstein-Barr 
virus latent membrane protein-1. Mol Cancer. 8: 59-68. 
 
Deng T, Kuang Y, Wang L, Li J, Wang Z, Fei J (2009).  An essential role for DNA 
methyltransferase 3a in melanoma tumorigenesis. Biochem Biophys Res Commun 387: 611-
616. 
Di Bartolo DL, Cannon M, Liu YF, Renne R, Chadburn A, Boshoff C, Cesarman E (2008).  
KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type 
II receptor. Blood 111: 4731-4740.  
Dickerson SJ, Xing Y, Robinson AR, Seaman WT, Gruffat H, Kenney SC (2009). 
Methylation-dependent binding of the epstein-barr virus BZLF1 protein to viral promoters. 
PLoS Pathog 5: 1000356-1000364. 
       
 
Diehl V, Kirchner HH, Burrichter H, Stein H, Fonatsch C, Gerdes J, Schaadt M, Heit W, 
Uchanska-Ziegler B, Ziegler A, Heintz F, Sueno K (1982). Characteristics of Hodgkin's 
disease-derived cell lines. Cancer Treatment Reports 66: 615-632. 
 
Doerr JR, Malone CS, Fike FM, Gordon MS, Soghomonian SV, Thomas RK, Tao Q, Murray 
PG, Diehl V, Teitell MA, Wall R (2005). Patterned CpG methylation of silenced B cell gene 
promoters in classical Hodgkin lymphoma-derived and primary effusion lymphoma cell lines. 
J Mol Biol 350: 631-640. 
Dong CW, Zhang YB, Lu AJ, Zhu R, Zhang FT, Zhang QY, Gui JF (2007). Molecular 
characterisation and inductive expression of a fish protein arginine methyltransferase 1 gene 
in response to virus infection. Fish Shellfish Immunol 22: 380-393. 
 
Dressler GR, Rock DL, Fraser NW (1987). Latent Herpes Simplex Virus Type 1 DNA Is Not 
Extensively Methylated in vivo. J gen Virol 68: 1761-1765. 
 
Drexler HG, Leber BF, Norton J, Yaxley J, Tatsumi E, Hoffbrand AV, Minowada J (1988). 
Genotypes and immunophenotypes of Hodgkin's disease-derived cell lines. Leukemia 2: 371-
376. 
 
Eden A, Gaudet F, Waghmare A, Jaenisch R (2003). Chromosomal instability and tumors 
promoted by DNA hypomethylation. Science 300: 455-463. 
Egger G, Jeong S, Escobar SG, Cortez CC, Li TW, Saito Y, Yoo CB, Jones PA, Liang G 
(2006). Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic 
       
knockouts suggests an essential role for DNMT1 in cell survival. Proc Natl Acad Sci U S A 
103: 14080-14085. 
Ehlers A, Oker E, Bentink S, Lenze D, Stein H, Hummel M (2008). Histone acetylation and 
DNA demethylation of B cells result in a Hodgkin-like phenotype. Leukemia 22: 835-841.  
Enouf J, Lawrence F, Tempete C, Robert-Gero M, Lederer E (1979).  Relationship between 
inhibition of protein methylase I and inhibition of Rous sarcoma virus-induced cell 
transformation. Cancer Res 39: 4497-4502. 
 
Epstein MA, Achong BG (1979). The Epstein-Barr virus. Springer-Verlag, Berlin, 
Heildelberg, New York. 
 
Ernberg I, Falk K, Minarovits J, Busson P, Tursz T, Masucci MG, Klein G (1989). The role of 
methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and 
latent membrane protein genes in cells latently infected with Epstein-Barr virus. J Gen Virol 
70: 2989-3002.  
 
Esteller M (2005). Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev 
Pharmacol Toxicol 45: 629-656.  
 
Etoh T, Kanai Y, Ushijima S, Nakagawa T, Nakanishi Y, Sasako M, Kitano S, Hirohashi S 
(2004). Increased DNA methyltransferase 1 (DNMT1) protein expression correlates 
significantly with poorer tumor differentiation and frequent DNA hypermethylation of 
multiple CpG islands in gastric cancers. Am J Pathol 164: 689-699. 
       
Fabbrizio E, El Messaoudi S, Polanowska J, Paul C, Cook JR, Lee JH, Negre V, Rousset M, 
Pestka S, Le Cam A, Sardet C (2002). Negative regulation of transcription by the type II 
arginine methyltransferase PRMT5. EMBO Rep 3: 641-645. 
Falk KI, Szekely L, Aleman A, Ernberg I (1998). Specific methylation patterns in two control 
regions of Epstein-Barr virus latency: the LMP-1-coding upstream regulatory region and an 
origin of DNA replication (oriP). J Virol 72: 2969-2974. 
Falk KI, Zou JZ, Lucht E, Linde A, Ernberg I (1997). Direct identification by PCR of EBV 
types and variants in clinical samples. J Med Virol 51: 355-363. 
 
Falk MH, Tesch H, Stein H, Diehl V, Jones DB, Fonatsch C, Bornkamm GW (1987). 
Phenotype versus immunoglobulin and T-cell receptor genotype of Hodgkin-derived cell 
lines: activation of immature lymphoid cells in Hodgkin's disease. Int J Cancer 40: 262-269. 
 
Farina A, Feederle R, Raffa S, Gonnella R, Santarelli R, Frati L, Angeloni A, Torrisi MR, 
Faggioni A, Delecluse HJ (2005). BFRF1 of Epstein-Barr virus is essential for efficient 
primary viral envelopment and egress. J Virol 79: 3703-3712. 
 
Farrell, C.J., Lee, J.M., Shin, E.C., Cebrat, M., Cole, P.A. and Hayward, S.D. (2004) 
Inhibition of Epstein–Barr virus-induced growth proliferation by a nuclear antigen EBNA2-
TAT peptide. Proc. Natl. Acad. Sci. U.S.A. 101, 4625–4630 
       
Feederle R, Shannon-Lowe C, Baldwin G, Delecluse HJ (2005).  Defective infectious 
particles and rare packaged genomes produced by cells carrying terminal-repeat-negative 
epstein-barr virus. J Virol 79: 7641-7647. 
 
Feinberg AP, Vogelstein B (1983). Hypomethylation distinguishes genes of some human 
cancers from their normal counterparts. Nature 301: 89-92. 
Fejer G, Koroknai A, Banati F, Györy I, Salamon D, Wolf H, Niller HH, Minarovits J (2008). 
Latency type-specific distribution of epigenetic marks at the alternative promoters Cp and Qp 
of Epstein-Barr virus. J Gen Virol 89: 1364-1370. 
Fernandez AF, Rosales C, Lopez-Nieva P, Graña O, Ballestar E, Ropero S, Espada J, Melo 
SA, Lujambio A, Fraga MF, Pino I, Javierre B, Carmona FJ, Acquadro F, Steenbergen RD, 
Snijders PJ, Meijer CJ, Pineau P, Dejean A, Lloveras B, Capella G, Quer J, Buti M, Esteban 
JI, Allende H, Rodriguez-Frias F, Castellsague X, Minarovits J, Ponce J, Capello D, Gaidano 
G, Cigudosa JC, Gomez-Lopez G, Pisano DG, Valencia A, Piris MA, Bosch FX, Cahir-
McFarland E, Kieff E, Esteller M (2009). The dynamic DNA methylomes of double-stranded 
DNA viruses associated with human cancer. Genome Res 19: 438-451.  
 
Filion GJ, Zhenilo S, Salozhin S, Yamada D, Prokhortchouk E, Defossez PA (2006). A family 
of human zinc finger proteins that bind methylated DNA and repress transcription. Mol Cell 
Biol 26: 169-181.  
 
Flanagan JM (2007). Host epigenetic modifications by oncogenic viruses.  Br J Cancer 96: 
183-188. 
 
       
Floettmann JE, Ward K, Rickinson AB, Rowe M (1996). Cytostatic effect of Epstein-Barr 
virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell 
lines. Virology 223: 29-40. 
 
Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, Plass C, Niemeyer CM, Lübbert 
M (2009). The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert 
differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23: 
1019-1028.  
 
Flower K, Hellen E, Newport MJ, Jones S, Sinclair AJ (2010). Evaluation of a prediction 
protocol to identify potential targets of epigenetic reprogramming by the cancer associated 
Epstein Barr virus. PLoS One 5: 9443-9449. 
 
Gal-Yam EN, Egger G, Iniguez L, Holster H, Einarsson S, Zhang X, Lin JC, Liang G, Jones 
PA, Tanay A (2008).   Frequent switching of Polycomb repressive marks and DNA 
hypermethylation in the PC3 prostate cancer cell line.  Proc Natl Acad Sci U S A 105: 12979-
12984. 
Gaudet F, Talbot D, Leonhardt H, Jaenisch R (1998). A short DNA methyltransferase isoform 
restores methylation in vivo. J Biol Chem 273: 32725-32729. 
 
Gebhard C, Benner C, Ehrich M, Schwarzfischer L, Schilling E, Klug M, Dietmaier W, 
Thiede C, Holler E, Andreesen R, Rehli M (2010). General transcription factor binding at 
CpG islands in normal cells correlates with resistance to de novo DNA methylation in cancer 
cells. Cancer Res 70: 1398-1407.  
       
 
Gires O, Kohlhuber F, Kilger E, Baumann M, Kieser A, Kaiser C, Zeidler R, Scheffer B, 
Ueffing M, Hammerschmidt W (1999). Latent membrane protein 1 of Epstein-Barr virus 
interacts with JAK3 and activates STAT proteins. EMBO J 18: 3064-3073. 
 
Given D, Kieff E. DNA of Epstein-Barr virus (1979). VI. Mapping of the internal tandem 
reiteration. J Virol 31: 315-324. 
 
Gompels UA, Nicholas J, Lawrence G, Jones M, Thomson BJ, Martin ME, Efstathiou S, 
Craxton M, Macaulay HA(1995). The DNA sequence of human herpesvirus-6: structure, 
coding content, and genome evolution. Virology 209:29-51.  
 
Gross H, Barth S, Palermo RD, Mamiani A, Hennard C, Zimber-Strobl U, West MJ, 
Kremmer E, Grässer FA (2010).  Asymmetric Arginine dimethylation of Epstein-Barr virus 
nuclear antigen 2 promotes DNA targeting. Virology 397: 299-310. 
 
Grundhoff A, Sullivan CS, Ganem D (2006). A combined computational and microarray-
based approach identifies novel microRNAs encoded by human gamma-herpesviruses. RNA 
12: 733-750. 
Gutensohn N, Cole P (1980). Epidemiology of Hodgkin's disease. Semin Oncol 7: 92-102. 
Günther T, Grundhoff A (2010). The epigenetic landscape of latent Kaposi sarcoma-
associated herpesvirus genomes. PLoS Pathog e1000935. 
 
       
Hansen RS, Wijmenga C, Luo P, Stanek AM, Canfield TK, Weemaes CM, Gartler SM 
(1999).  The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency 
syndrome. Proc Natl Acad Sci U S A 96: 14412-14417. 
 
Hata K, Okano M, Lei H, Li E (2002).  Dnmt3L cooperates with the Dnmt3 family of de novo 
DNA methyltransferases to establish maternal imprints in mice. Development 129: 1983-
1993. 
 
Hayes DP, Brink AATP, Vervoort MB, Middeldorp JM, Meijer CJ, van den Brule AJ (1999). 
Expression of Epstein-Barr virus (EBV) transcripts encoding homologues to important human 
proteins in diverse EBV associated diseases. Mol Pathol 52: 97-103. 
Heather J, Flower K, Isaac S, Sinclair AJ (2009). The Epstein-Barr virus lytic cycle activator 
Zta interacts with methylated ZRE in the promoter of host target gene egr1. J Gen Virol 90: 
1450-1454.  
Heid CA, Stevens J, Livak KJ, Williams PM (1996). Real time quantitative PCR. Genome 
Res 6: 986-994. 
 
Henderson A, Ripley S, Heller M, Kieff E (1983). Chromosome site for Epstein-Barr virus 
DNA in a Burkitt tumor cell line and in lymphocytes growth-transformed in vitro. Proc Natl 
Acad Sci U S A 80: 1987-1991. 
 
       
Hendrich B, Guy J, Ramsahoye B, Wilson VA, Bird A (2001).  Closely related proteins 
MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes Dev 
15: 710-723. 
 
Henle W, Diehl V, Kohn G, Zur Hausen H, Henle G (1967). Herpes-type virus and 
chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science 
157: 1064-1065. 
Herman JG, Baylin SB (2003). Gene silencing in cancer in association with promoter 
hypermethylation. N Engl J Med 349: 2042-2454. 
 
Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki A, Ishikawa S, Morikawa T, Nakaya T, 
Sakatani T, Takada K, Fukayama M (2009).  Activation of DNA methyltransferase 1 by EBV 
latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric 
carcinoma. Cancer Res 69: 2766-2764. 
 
Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki A, Ishikawa S, Morikawa T, Nakaya T, 
Sakatani T, Takada K, Fukayama M (2009). Activation of DNA methyltransferase 1 by EBV 
latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric 
carcinoma. Cancer Res 69: 2766-2774. 
 
Hollyoake M, Stühler A, Farrell P, Gordon J, Sinclair A (1995). The normal cell cycle 
activation program is exploited during the infection of quiescent B lymphocytes by Epstein-
Barr virus. Cancer Res 55: 4784-4787. 
 
       
Honda T, Tamura G, Waki T, Kawata S, Terashima M, Nishizuka S, Motoyama T (2004). 
Demethylation of MAGE promoters during gastric cancer progression. Br J Cancer 90: 838-
843. 
 
Hu J, Fan H, Liu D, Zhang S, Zhang F, Xu H (2010). DNMT3B promoter polymorphism and 
risk of gastric cancer. Dig Dis Sci 55: 1011-1016. 
 
Huen DS, Henderson SA, Croom-Carter D, Rowe M (1995). The Epstein-Barr virus latent 
membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype 
via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10: 549-560. 
Hutchings IA, Tierney RJ, Kelly GL, Stylianou J, Rickinson AB, Bell AI (2006).  
Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and 
promoter activity: analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines. J 
Virol 80: 10700-10711. 
 
Illingworth RS, Bird AP (2009).  CpG islands--'a rough guide'. FEBS Lett 583: 1713-1720. 
Imai S, Koizumi S, Sugiura M, Tokunaga M, Uemura Y, Yamamoto N, Tanaka S, Sato E, 
Osato T (1994). Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-
Barr virus latent infection protein. Proc Natl Acad Sci U S A 91: 9131-9135. 
Infantino S, Benz B, Waldmann T, Jung M, Schneider R, Reth M (2010).  Arginine 
methylation of the B cell antigen receptor promotes differentiation. J Exp Med 207: 711-719. 
Jair KW, Bachman KE, Suzuki H, Ting AH, Rhee I, Yen RW, Baylin SB, Schuebel KE 
(2006). De novo CpG island methylation in human cancer cells. Cancer Res 66: 682-692. 
       
 
Jansson A, Masucci M, Rymo L (1992). Methylation of discrete sites within the enhancer 
region regulates the activity of the Epstein-Barr virus BamHI W promoter in Burkitt 
lymphoma lines. J Virol 66: 62-69. 
 
Jeltsch A (2006). Molecular enzymology of mammalian DNA methyltransferases. Curr Top 
Microbiol Immunol 301: 203-225. 
 
Jin B, Tao Q, Peng J, Soo HM, Wu W, Ying J, Fields CR, Delmas AL, Liu X, Qiu J, 
Robertson KD (2008).  DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome 
lead to altered epigenetic modifications and aberrant expression of genes regulating 
development, neurogenesis and immune function. Hum Mol Genet 17: 690-709. 
Jin SG, Guo C, Pfeifer GP (2008).  GADD45A does not promote DNA demethylation. PLoS 
Genet 4: 1000013-1000022. 
Jones PA, Laird PW (1999). Cancer epigenetics comes of age. Nat Genet 21: 163-167. 
Jones PA, Liang G (2009). Rethinking how DNA methylation patterns are maintained. Nat 
Rev Genet 10: 805-811. 
 
Kalla M, Schmeinck A, Bergbauer M, Pich D, Hammerschmidt W (2010). AP-1 homolog 
BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of 
the viral genome. Proc Natl Acad Sci U S A 107: 850-855.  
 
       
Kamesaki H, Fukuhara S, Tatsumi E, Uchino H, Yamabe H, Miwa H, Shirakawa S, Hatanaka 
M, Honjo T (1986). Cytochemical, immunologic, chromosomal, and molecular genetic 
analysis of a novel cell line derived from Hodgkin's disease. Blood 68: 285-292. 
 
Kanai Y, Ushijima S, Kondo Y, Nakanishi Y, Hirohashi S (2001). DNA methyltransferase 
expression and DNA methylation of CPG islands and peri-centromeric satellite regions in 
human colorectal and stomach cancers. Int J Cancer 91: 205-512. 
 
Kangaspeska S, Stride B, Métivier R, Polycarpou-Schwarz M, Ibberson D, Carmouche RP, 
Benes V, Gannon F, Reid G (2008). Transient cyclical methylation of promoter DNA. Nature 
452: 112-115. 
 
Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, 
Shan J, Andreeff M, Keating M, Talpaz M (2003). Results of decitabine (5-aza-
2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98: 
522-528. 
 
Kanzler H, Hansmann ML, Kapp U, Wolf J, Diehl V, Rajewsky K, Kuppers R (1996b). 
Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell 
line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient. Blood 
87: 3429-3436. 
       
Kareta MS, Botello ZM, Ennis JJ, Chou C, Chédin F (2006). Reconstitution and mechanism 
of the stimulation of de novo methylation by human DNMT3L. J Biol Chem 281: 25893-
25902. 
Karlsson QH, Schelcher C, Verrall E, Petosa C, Sinclair AJ (2008). Methylated DNA 
recognition during the reversal of epigenetic silencing is regulated by cysteine and serine 
residues in the Epstein-Barr virus lytic switch protein. PLoS Pathog 4: 1000005-100011. 
Kass SU, Pruss D, Wolffe AP (1997).  How does DNA methylation repress transcription? 
Trends Genet 13: 444-449. 
 
Kaye KM, Izumi KM, Kieff E (1993). Epstein-Barr virus latent membrane protein 1 is 
essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A 90:9150-4. 
Kieff E and Rickinson AB. In: Fields Virology. Eds: Knipe DM, Howley PM, Lippincott 
Williams and Wilkins, Philadelphia, 2007 
 
Kieser A, Kilger E, Gires O, Ueffing M, Kolch W, Hammerschmidt W (1997). Epstein-Barr 
virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase 
cascade. EMBO J 16: 6478-6485. 
 
Kim KH, Choi JS, Kim IJ, Ku JL, Park JG (2006). Promoter hypomethylation and 
reactivation of MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines and cancer 
tissues. World J Gastroenterol 12: 5651-5657. 
       
Kintner CR, Sugden B (1979).  The structure of the termini of the DNA of Epstein-Barr virus. 
Cell 17: 661-671. 
Klein G (1983). Specific chromosomal translocations and the genesis of B-cell-derived 
tumors in mice and men. Cell 32: 311-315.  
Kleinschmidt MA, Streubel G, Samans B, Krause M, Bauer UM (2008). The protein arginine 
methyltransferases CARM1 and PRMT1 cooperate in gene regulation. Nucleic Acids Res 36: 
3202-3213.  
Klimasauskas S, Kumar S, Roberts RJ, Cheng X (1994). HhaI methyltransferase flips its 
target base out of the DNA helix. Cell 76: 357-369. 
 
Klose RJ, Bird AP (2006). Genomic DNA methylation: the mark and its mediators. Trends 
Biochem Sci 31: 89-97. 
 
Koga Y, Pelizzola M, Cheng E, Krauthammer M, Sznol M, Ariyan S, Narayan D, Molinaro 
AM, Halaban R, Weissman SM (2009).  Genome-wide screen of promoter methylation 
identifies novel markers in melanoma. Genome Res 19: 1462-1470. 
 
Kouzarides T (2007). Chromatin modifications and their function. Cell 128: 693-705.  
Krause CD, Yang ZH, Kim YS, Lee JH, Cook JR, Pestka S (2007). Protein arginine 
methyltransferases: evolution and assessment of their pharmacological and therapeutic 
potential. Pharmacol Ther 113: 50-87.  
       
Kudoh A, Fujita M, Kiyono T, Kuzushima K, Sugaya Y, Izuta S, Nishiyama Y, Tsurumi T 
(2003). Reactivation of lytic replication from B cells latently infected with Epstein-Barr virus 
occurs with high S-phase cyclin-dependent kinase activity while inhibiting cellular DNA 
replication. J Virol 77: 851-861. 
 
Küppers R (2009). Molecular biology of Hodgkin lymphoma. Hematology Am Soc Hematol 
Educ Program 491-496.  
Lacroix M, El Messaoudi S, Rodier G, Le Cam A, Sardet C, Fabbrizio E (2008).  The histone-
binding protein COPR5 is required for nuclear functions of the protein arginine 
methyltransferase PRMT5.  EMBO Rep 9: 452-458.  
Laird PW (2005). Cancer epigenetics. Hum Mol Genet 14: 65-76.  
Landais E, Saulquin X, Houssaint E (2005). The human T cell immune response to Epstein-
Barr virus. Int J Dev Biol 49: 285-292. 
 
Lee MA, Diamond ME, Yates JL (1999). Genetic evidence that EBNA-1 is needed for 
efficient, stable latent infection by Epstein-Barr virus. J Virol 73: 2974-2982. 
Lee J, Bedford MT (2002). PABP1 identified as an arginine methyltransferase substrate using 
high-density protein arrays. EMBO Rep 3: 268-273.  
Levine PH, Ablashi DV, Berard CW, Carbone PP, Waggoner DE, Malan L (1971). Elevated 
antibody titers to Epstein-Barr virus in Hodgkin's disease. Cancer 27: 416-421. 
Li E, Bestor TH, Jaenisch R (1992). Targeted mutation of the DNA methyltransferase gene 
results in embryonic lethality. Cell 69: 915-926. 
       
 
Liang G, Lin JC, Wei V, Yoo C, Cheng JC, Nguyen CT, Weisenberger DJ, Egger G, Takai D, 
Gonzales FA, Jones PA (2004). Distinct localization of histone H3 acetylation and H3-K4 
methylation to the transcription start sites in the human genome. Proc Natl Acad Sci U S A 
101: 7357-7362.  
 
Lin TS, Lee H, Chen RA, Ho ML, Lin CY, Chen YH, Tsai YY, Chou MC, Cheng YW 
(2005). An association of DNMT3b protein expression with P16INK4a promoter 
hypermethylation in non-smoking female lung cancer with human papillomavirus infection. 
Cancer Lett 226: 77-84. 
Livak KJ, Schmittgen TD (2001).  Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. 
 
Longnecker R (2000). Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-
Barr virus persistence? Adv Cancer Res 79: 175-200. 
 
Longnecker R, Kieff E (1990). A second Epstein-Barr virus membrane protein (LMP2) is 
expressed in latent infection and colocalizes with LMP1. J Virol 64: 2319-2326. 
 
Longnecker R, Miller CL (1996). Regulation of Epstein-Barr virus latency by latent 
membrane protein 2. Trends Microbiol 4: 38-42. 
 
Luger K, Mäder AW, Richmond RK, Sargent DF, Richmond TJ (1997). Crystal structure of 
the nucleosome core particle at 2.8 A resolution. Nature 389: 251-260. 
       
 
Magrath I (1990). The pathogenesis of Burkitt's lymphoma. Adv Cancer Res 55:133-270.  
Manolov G, Manolova Y (1972). Marker band in one chromosome 14 from Burkitt 
lymphomas. Nature 237: 33-34. 
Martin-Subero JI, Ammerpohl O, Bibikova M, Wickham-Garcia E, Agirre X, Alvarez S, 
Brüggemann M, Bug S, Calasanz MJ, Deckert M, Dreyling M, Du MQ, Dürig J, Dyer MJ, 
Fan JB, Gesk S, Hansmann ML, Harder L, Hartmann S, Klapper W, Küppers R, Montesinos-
Rongen M, Nagel I, Pott C, Richter J, Román-Gómez J, Seifert M, Stein H, Suela J, Trümper 
L, Vater I, Prosper F, Haferlach C, Cruz Cigudosa J, Siebert R (2009). A comprehensive 
microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One 4: 
6986-6995. 
 
Masucci MG, Contreras-Salazar B, Ragnar E, Falk K, Minarovits J, Ernberg I, Klein G 
(1989). 5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 
(EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line rael.  
J Virol 63: 3135-3141. 
 
Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D'Souza C, Fouse SD, Johnson BE, 
Hong C, Nielsen C, Zhao Y, Turecki G, Delaney A, Varhol R, Thiessen N, Shchors K, Heine 
VM, Rowitch DH, Xing X, Fiore C, Schillebeeckx M, Jones SJ, Haussler D, Marra MA, Hirst 
M, Wang T, Costello JF (2010).  Conserved role of intragenic DNA methylation in regulating 
alternative promoters. Nature 466:  253-257. 
 
       
Métivier R, Gallais R, Tiffoche C, Le Péron C, Jurkowska RZ, Carmouche RP, Ibberson D, 
Barath P, Demay F, Reid G, Benes V, Jeltsch A, Gannon F, Salbert G (2010).  Cyclical DNA 
methylation of a transcriptionally active promoter. Nature 452: 45-50. 
 
Miller G, Lipman M (1973).  Release of infectious Epstein-Barr virus by transformed 
marmoset leukocytes. Proc Natl Acad Sci U S A 70: 190-194. 
 
Miller G, Rabson M, Heston L (1984). Epstein-Barr virus with heterogeneous DNA disrupts 
latency. J Virol 50: 174-182. 
 
Minarovits J, Hu LF, Minarovits-Kormuta S, Klein G, Ernberg I (1994). Sequence-specific 
methylation inhibits the activity of the Epstein-Barr virus LMP 1 and BCR2 enhancer-
promoter regions. Virology 200: 661-667. 
 
Minarovits J, Hu LF, Minarovits-Kormuta S, Klein G, Ernberg I (1994). Sequence-specific 
methylation inhibits the activity of the Epstein-Barr virus LMP 1 and BCR2 enhancer-
promoter regions. Virology 200: 661-667. 
Moghaddam A, Rosenzweig M, Lee-Parritz D, Annis B, Johnson RP, Wang F (1997). An 
animal model for acute and persistent Epstein-Barr virus infection. Science 276: 2030-2033. 
Molesworth SJ, Lake CM, Borza CM, Turk SM, Hutt-Fletcher LM (2000).  Epstein-Barr 
virus gH is essential for penetration of B cells but also plays a role in attachment of virus to 
epithelial cells. J Virol 74: 6324-6332. 
 
       
Morrow RH (1985). Epidemiological evidence for the role of falciparum malaria in the 
pathogenesis of Burkitt's lymphoma. IARC Sci Publ. 60: 177-186. 
 
Murphy G, Pfeiffer R, Camargo MC, Rabkin CS (2009). Meta-analysis shows that prevalence 
of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. 
Gastroenterology 137: 824-833.  
 
Nan X, Meehan RR, Bird A (1993).  Dissection of the methyl-CpG binding domain from the 
chromosomal protein MeCP2. Nucleic Acids Res 21: 4886-4892. 
 
Navarro A, Gaya A, Martinez A, Urbano-Ispizua A, Pons A, Balagué O, Gel B, Abrisqueta P, 
Lopez-Guillermo A, Artells R, Montserrat E, Monzo M (2008).   MicroRNA expression 
profiling in classic Hodgkin lymphoma. Blood 111: 2825-2832. 
 
Niller HH, Wolf H, Minarovits J (2008). Regulation and dysregulation of Epstein-Barr virus 
latency: implications for the development of autoimmune diseases. Autoimmunity 41: 298-
328.  
Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, Mohammad HP, Chen W, 
Daniel VC, Yu W, Berman DM, Jenuwein T, Pruitt K, Sharkis SJ, Watkins DN, Herman JG, 
Baylin SB (2007). A stem cell-like chromatin pattern may predispose tumor suppressor genes 
to DNA hypermethylation and heritable silencing. Nat Genet 39: 237-242.  
 
Okano M, Li E (2002). Genetic analyses of DNA methyltransferase genes in mouse model 
system. J Nutr 132: 2462-2465. 
       
 
Pal S, Baiocchi RA, Byrd JC, Grever MR, Jacob ST, Sif S (2007). Low levels of miR-92b/96 
induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma.  EMBO J 
26: 3558-3569. 
Pal S, Yun R, Datta A, Lacomis L, Erdjument-Bromage H, Kumar J, Tempst P, Sif S (2003). 
mSin3A/histone deacetylase 2- and PRMT5-containing Brg1 complex is involved in 
transcriptional repression of the Myc target gene cad. Mol Cell Biol 23: 7475-7487. 
Park IY, Sohn BH, Yu E, Suh DJ, Chung YH, Lee JH, Surzycki SJ, Lee YI (2007). Aberrant 
epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. 
Gastroenterology 132: 1476-1494.  
Park JH, Jeon JP, Shim SM, Nam HY, Kim JW, Han BG, Lee S (2007). Wp specific 
methylation of highly proliferated LCLs.  Biochem Biophys Res Commun 358: 513-520.  
 
Paulson EJ, Speck SH (1999). Differential methylation of Epstein-Barr virus latency 
promoters facilitates viral persistence in healthy seropositive individuals. J Virol 73: 9959-
9968. 
 
Pearson GR, Luka J, Petti L, Sample J, Birkenbach M, Braun D, Kieff E (1987). Identification 
of an Epstein-Barr virus early gene encoding a second component of the restricted early 
antigen complex. Virology 160: 151-161. 
Pisani P, Parkin DM, Muñoz N, Ferlay J (1997). Cancer and infection: estimates of the 
attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 6: 387-400. 
       
Pfeffer S, Zavolan M, Grässer FA, Chien M, Russo JJ, Ju J, John B, Enright AJ, Marks D, 
Sander C, Tuschl T (2004). Identification of virus-encoded microRNAs. Science 304:734-
736. 
 
Raab-Traub N, Flynn K (1986). The structure of the termini of the Epstein-Barr virus as a 
marker of clonal cellular proliferation. Cell 47: 883-889. 
 
Rauch TA, Wu X, Zhong X, Riggs AD, Pfeifer GP (2009). A human B cell methylome at 
100-base pair resolution. Proc Natl Acad Sci U S A 106: 671-678. 
Reed BD, Charos AE, Szekely AM, Weissman SM, Snyder M (2008).  Genome-wide 
occupancy of SREBP1 and its partners NFY and SP1 reveals novel functional roles and 
combinatorial regulation of distinct classes of genes.  PLoS Genet 4: 1000133-1000140. 
 
Reik W (2007). Stability and flexibility of epigenetic gene regulation in mammalian 
development. Nature 447: 425-432. 
 
Richard S, Morel M, Cléroux P (2005). Arginine methylation regulates IL-2 gene expression: 
a role for protein arginine methyltransferase 5 (PRMT5).  Biochem J 388: 379-386. 
 
Rivailler P, Cho YG, Wang F (2002). Complete genomic sequence of an Epstein-Barr virus-
related herpesvirus naturally infecting a new world primate: a defining point in the evolution 
of oncogenic lymphocryptoviruses. J Virol 76: 12055-12068. 
 
       
Roberts ML, Cooper NR (1998). Activation of a ras-MAPK-dependent pathway by Epstein-
Barr virus latent membrane protein 1 is essential for cellular transformation. Virology 240: 
93-99. 
 
Robertson ES, Lin J, Kieff E (1996). The amino-terminal domains of Epstein-Barr virus 
nuclear proteins 3A, 3B, and 3C interact with RBPJ (kappa). J Virol 70: 3068-3074. 
 
Robertson KD (2001). DNA methylation, methyltransferases, and cancer. Oncogene 20: 139-
155. 
Robertson KD (2005). DNA methylation and human disease. Nat Rev Genet 6: 597-610. 
Robertson KD, Manns A, Swinnen LJ, Zong JC, Gulley ML, Ambinder RF (1996). CpG 
methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and 
Hodgkin's disease. Blood 88: 3129-3136. 
Rooney CM, Rowe DT, Ragot T, Farrell PJ (1989). The spliced BZLF1 gene of Epstein-Barr 
virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J 
Virol 63: 3109-3116. 
 
Roughan JE, Torgbor C, Thorley-Lawson DA (2010). Germinal center B cells latently 
infected with Epstein-Barr virus proliferate extensively but do not increase in number. J Virol 
84: 1158-1168. 
 
       
Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H, Rickinson AB (1987a). 
Differences in B cell growth phenotype reflect novel patterns of Epstein–Barr virus latent 
gene expression in Burkitt’s lymphoma cells. EMBO J 6: 2743–2751. 
 
Ruike Y, Imanaka Y, Sato F, Shimizu K, Tsujimoto G (2010).  Genome-wide analysis of 
aberrant methylation in human breast cancer cells using methyl-DNA immunoprecipitation 
combined with high-throughput sequencing. BMC Genomics 11: 137-145. 
 
Saito Y, Kanai Y, Nakagawa T, Sakamoto M, Saito H, Ishii H, Hirohashi S (2003). Increased 
protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the 
malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer 
105: 527-532. 
 
Sakatani T, Kaneda A, Iacobuzio-Donahue CA, Carter MG, de Boom Witzel S, Okano H, Ko 
MS, Ohlsson R, Longo DL, Feinberg AP (2005).  Loss of imprinting of Igf2 alters intestinal 
maturation and tumorigenesis in mice. Science 307: 1976-1978.  
 
Salamon D, Takacs M, Ujvari D, Uhlig J, Wolf H, Minarovits J, Niller HH (2001). Protein-
DNA binding and CpG methylation at nucleotide resolution of latency-associated promoters 
Qp, Cp, and LMP1p of Epstein-Barr virus. J Virol 75: 2584-2596. 
 
Sample J, Young L, Martin B, Chatman T, Kieff E, Rickinson A, Kieff E (1990). Epstein-
Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol 
64: 4084-4092. 
       
 
Santos F, Hendrich B, Reik W, Dean W (2002).  Dynamic reprogramming of DNA 
methylation in the early mouse embryo. Dev Biol 241: 172-182. 
Sasai N, Defossez PA (2009). Many paths to one goal? The proteins that recognize 
methylated DNA in eukaryotes. Int J Dev Biol 53: 323-334. 
 
Sawada M, Kanai Y, Arai E, Ushijima S, Ojima H, Hirohashi S (2007). Increased expression 
of DNA methyltransferase 1 (DNMT1) protein in uterine cervix squamous cell carcinoma and 
its precursor lesion. Cancer Lett 251: 211-219. 
 
Schaadt M, Diehl V, Stein H, Fonatsch C, Kirchner HH (1980). Two neoplastic cell lines with 
unique features derived from Hodgkin's disease. Int J Cancer 26: 723-731. 
 
Schaefer M, Pollex T, Hanna K, Tuorto F, Meusburger M, Helm M, Lyko F (2010). RNA 
methylation by Dnmt2 protects transfer RNAs against stress-induced cleavage. Genes Dev 24: 
1590-1595. 
Schlager S, Speck SH, Woisetschläger M (1996). Transcription of the Epstein-Barr virus 
nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene 
promoter during the initial stages of infection in B cells. J Virol 70: 3561-3570. 
Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, Eden E, Yakhini 
Z, Ben-Shushan E, Reubinoff BE, Bergman Y, Simon I, Cedar H (2007).  Polycomb-mediated 
methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat 
Genet 39: 232-236.  
       
 
Schmitz R, Stanelle J, Hansmann ML, Küppers R (2009). Pathogenesis of classical and 
lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol 4:151-174.  
 
Sen GL, Reuter JA, Webster DE, Zhu L, Khavari PA (2010). DNMT1 maintains progenitor 
function in self-renewing somatic tissue. Nature 463: 563-567. 
 
Seo SY, Kim EO, Jang KL (2008).  Epstein-Barr virus latent membrane protein 1 suppresses 
the growth-inhibitory effect of retinoic acid by inhibiting retinoic acid receptor-beta2 
expression via DNA methylation. Cancer Lett 270: 66-76. 
 
Shah KM, Young LS (2009). Epstein-Barr virus and carcinogenesis: beyond Burkitt's 
lymphoma. Clin Microbiol Infect 15: 982-988.  
Shamay M, Krithivas A, Zhang J, Hayward SD (2006). Recruitment of the de novo DNA 
methyltransferase Dnmt3a by Kaposi's sarcoma-associated herpesvirus LANA. Proc Natl 
Acad Sci U S A 103: 14554-14559.  
Shann YJ, Cheng C, Chiao CH, Chen DT, Li PH, Hsu MT (2008). Genome-wide mapping 
and characterization of hypomethylated sites in human tissues and breast cancer cell lines. 
Genome Res 18: 791-801. 
Shannon-Lowe C, Baldwin G, Feederle R, Bell A, Rickinson A, Delecluse HJ (2005). 
Epstein-Barr virus-induced B-cell transformation: quantitating events from virus binding to 
cell outgrowth. J Gen Virol 86: 3009-3019. 
       
Sharma S, Kelly TK, Jones PA (2010). Epigenetics in cancer. Carcinogenesis 31: 27-36. 
Shire K, Kapoor P, Jiang K, Hing MN, Sivachandran N, Nguyen T, Frappier L (2006).  
Regulation of the EBNA1 Epstein-Barr virus protein by serine phosphorylation and arginine 
methylation. J Virol 80: 5261-5272. 
Siemer D, Kurth J, Lang S, Lehnerdt G, Stanelle J, Küppers R (2008). EBV transformation 
overrides gene expression patterns of B cell differentiation stages. Mol Immunol 45: 3133-
3141.  
Singh KP, Kumari R, Pevey C, Jackson D, DuMond JW (2009). Long duration exposure to 
cadmium leads to increased cell survival, decreased DNA repair capacity, and genomic 
instability in mouse testicular Leydig cells. Cancer Lett 279: 84-92. 
 
Skare J, Farley J, Strominger JL, Fresen KO, Cho MS, zur Hausen H (1985). Transformation 
by Epstein-Barr virus requires DNA sequences in the region of BamHI fragments Y and H. J 
Virol 55: 286-297. 
 
Suetake I, Shinozaki F, Miyagawa J, Takeshima H, Tajima S (2004).  DNMT3L stimulates 
the DNA methylation activity of Dnmt3a and Dnmt3b through a direct interaction. J Biol 
Chem 279: 27816-27823.  
 
Szyf M, Eliasson L, Mann V, Klein G, Razin A (1985). Cellular and viral DNA 
hypomethylation associated with induction of Epstein-Barr virus lytic cycle. Proc Natl Acad 
Sci U S A 82:8090-80944. 
       
 
Takacs M, Banati F, Koroknai A, Segesdi J, Salamon D, Wolf H, Niller HH, Minarovits J 
(2010). Epigenetic regulation of latent Epstein-Barr virus promoters. Biochim Biophys Acta 
1799: 228-235. 
Takai D, Jones PA (2002).  Comprehensive analysis of CpG islands in human chromosomes 
21 and 22. Proc Natl Acad Sci U S A 99: 3740-3745. 
 
Tang J, Frankel A, Cook RJ, Kim S, Paik WK, Williams KR, Clarke S, Herschman HR 
(2000). PRMT1 is the predominant type I protein arginine methyltransferase in mammalian 
cells. J Biol Chem 275: 7723-7730. 
 
Taniguchi Y, Nosaka K, Yasunaga J, Maeda M, Mueller N, Okayama A, Matsuoka M (2005). 
Silencing of human T-cell leukemia virus type I gene transcription by epigenetic mechanisms. 
Retrovirology 2: 64-72. 
Tao Q, Robertson KD (2003). Stealth technology: how Epstein-Barr virus utilizes DNA 
methylation to cloak itself from immune detection. Clin Immunol 109: 53-63. 
 
Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF (1998). The Epstein-Barr virus 
major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive. 
J Virol 72: 7075-7083. 
 
Taylor KH, Rahmatpanah F, Davis JW, Caldwell CW (2008). Chromosomal localization of 
DNA methylation in small B-cell lymphoma. Leukemia 22: 638-641. 
 
       
Thorley-Lawson DA (2001). Epstein-Barr virus: exploiting the immune system. Nat Rev 
Immunol 1: 75-82. 
Thorley-Lawson DA, Allday MJ (2008). The curious case of the tumour virus: 50 years of 
Burkitt's lymphoma. Nat Rev Microbiol 6: 913-924. 
Tierney RJ, Kirby HE, Nagra JK, Desmond J, Bell AI, Rickinson AB (2000). Methylation of 
transcription factor binding sites in the Epstein-Barr virus latent cycle promoter Wp coincides 
with promoter down-regulation during virus-induced B-cell transformation. J Virol 74: 
10468-10479. 
 
Tomkinson B, Kieff E (1992). Use of second-site homologous recombination to demonstrate 
that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth 
transformation in vitro. J Virol 66: 2893-2903. 
 
Tomkinson B, Robertson E, Kieff E (1993). Epstein-Barr virus nuclear proteins EBNA-3A 
and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol 67: 2014-2025. 
 
Tsai CL, Li HP, Lu YJ, Hsueh C, Liang Y, Chen CL, Tsao SW, Tse KP, Yu JS, Chang YS 
(2006). Activation of DNA methyltransferase 1 by EBV LMP1 Involves c-Jun NH(2)-
terminal kinase signaling. Cancer Res 66: 11668-11676. 
 
Tsai CN, Tsai CL, Tse KP, Chang HY, Chang YS (2002). The Epstein-Barr virus oncogene 
product, latent membrane protein 1, induces the downregulation of E-cadherin gene 
       
expression via activation of DNA methyltransferases. Proc Natl Acad Sci U S A 99: 10084-
10089. 
Turek-Plewa J, Jagodziński PP (2005).  The role of mammalian DNA methyltransferases in 
the regulation of gene expression. Cell Mol Biol Lett 10: 631-647. 
 
Ushmorov A, Leithäuser F, Sakk O, Weinhaüsel A, Popov SW, Möller P, Wirth T (2006). 
Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin 
lymphoma. Blood 107: 2493-2500.  
Ushmorov A, Ritz O, Hummel M, Leithäuser F, Möller P, Stein H, Wirth T (2004). 
Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin 
lymphoma-derived cell lines contributes to the loss of immunoglobulin expression. Blood 
104: 3326-3334.  
van Beek J, Brink AA, Vervoort MB, van Zijp MJ, Meijer CJ, van den Brule AJ, Middeldorp 
JM (2003). In vivo transcription of the Epstein-Barr virus (EBV) BamHI-A region without 
associated in vivo BARF0 protein expression in multiple EBV-associated disorders. J Gen 
Virol 84: 2647-2659. 
 
Vockerodt M, Morgan SL, Kuo M, Wei W, Chukwuma MB, Arrand JR, Kube D, Gordon J, 
Young LS, Woodman CB, Murray PG (2008). The Epstein-Barr virus oncoprotein, latent 
membrane protein-1, reprograms germinal centre B cells towards a Hodgkin's Reed-
Sternberg-like phenotype. J Pathol 216: 83-92. 
 
       
Wade PA (2001). Methyl CpG-binding proteins and transcriptional repression. Bioessays 
23:1131-1137.  
 
Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson A, Kieff E 
(1990). Epstein–Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C 
are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively 
induce CD23. J Virol 64: 2309–2318. 
Wang J, Sugden B (2005). Origins of bidirectional replication of Epstein-Barr virus: models 
for understanding mammalian origins of DNA synthesis. J Cell Biochem 94: 247-256. 
Wang L, Pal S, Sif S (2008). Protein arginine methyltransferase 5 suppresses the transcription 
of the RB family of tumor suppressors in leukemia and lymphoma cells. Mol Cell Biol 28: 
6262-6277. 
 
Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL, Schübeler D (2005). 
Chromosome-wide and promoter-specific analyses identify sites of differential DNA 
methylation in normal and transformed human cells. Nat Genet 37: 853-862.   
Weber M, Hellmann I, Stadler MB, Ramos L, Pääbo S, Rebhan M, Schübeler D (2007). 
Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the 
human genome. Nat Genet 39: 457-66. 
Weir JP (1998). Genomic organization and evolution of the human herpesviruses. Virus 
Genes 16:85-93. 
       
Weiss LM, Movahed LA (1989). In situ demonstration of Epstein-Barr viral genomes in viral-
associated B cell lymphoproliferations. Am J Pathol 134: 651-659. 
 
Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger 
DJ, Campan M, Young J, Jacobs I, Laird PW (2007). Epigenetic stem cell signature in cancer. 
Nat Genet 39:157-158.  
 
Wolf J, Kapp U, Bohlen H, Kornacker M, Schoch C, Stahl B, Mucke S, von Kalle C, 
Fonatsch C, Schaefer HE, Hansmann ML, Diehl V (1996). Peripheral blood mononuclear 
cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing 
Hodgkin-Reed Sternberg cells. Blood 87: 3418-3428. 
 
Wong KM, Levine AJ (1986). Identification and mapping of Epstein-Barr virus early antigens 
and demonstration of a viral gene activator that functions in trans. J Virol 60: 149-156. 
Wu X, Gong Y, Yue J, Qiang B, Yuan J, Peng X (2008).   Cooperation between EZH2, 
NSPc1-mediated histone H2A ubiquitination and Dnmt1 in HOX gene silencing.  Nucleic 
Acids Res 36: 3590-3599. 
Yajima M, Kanda T, Takada K (2005). Critical role of Epstein-Barr Virus (EBV)-encoded 
RNA in efficient EBV-induced B-lymphocyte growth transformation. J Virol 79: 4298-4307. 
Yang HH, Hu N, Wang C, Ding T, Dunn BK, Goldstein AM, Taylor PR, Lee MP (2010). 
Influence of genetic background and tissue types on global DNA methylation patterns. PLoS 
One 5: 9355-9363. 
       
 
Young LS, Dawson CW, Clark D, Rupani H, Busson P, Tursz T, Johnson A, Rickinson AB 
(1988). Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 
69:1051-1065. 
 
Young LS, Murray PG (2003). Epstein-Barr virus and oncogenesis: from latent genes to 
tumours. Oncogene 22: 5108-5121.  
 
Young LS, Rickinson AB (2004). Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757-
768.  
Yun Zhu J, Pfuhl T, Motsch N, Barth S, Nicholls J, Grässer F, Meister G (2009).  
Identification of Novel Epstein-Barr Virus MicroRNA Genes from Nasopharyngeal 
Carcinomas. J Virol 83: 3333-3341. 
 
Zhang X, Cheng X (2003). Structure of the predominant protein arginine methyltransferase 
PRMT1 and analysis of its binding to substrate peptides. Structure 11: 509-520. 
Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A, Reinberg D (1999).  Analysis of 
the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA 
methylation. Genes Dev 13: 1924-1935. 
 
Zhao Q, Rank G, Tan YT, Li H, Moritz RL, Simpson RJ, Cerruti L, Curtis DJ, Patel DJ, Allis 
CD, Cunningham JM, Jane SM (2009). PRMT5-mediated methylation of histone H4R3 
recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat Struct Mol 
Biol 16: 304-11.  
       
 
Zhao X, Jankovic V, Gural A, Huang G, Pardanani A, Menendez S, Zhang J, Dunne R, Xiao 
A, Erdjument-Bromage H, Allis CD, Tempst P, Nimer SD (2008). Methylation of RUNX1 by 
PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity. Genes Dev 22: 
640-653. 
 
Zheng X, Pontes O, Zhu J, Miki D, Zhang F, Li WX, Iida K, Kapoor A, Pikaard CS, Zhu JK 
(2008). ROS3 is an RNA-binding protein required for DNA demethylation in Arabidopsis. 
Nature 455: 1259-1262. 
 
Zilberman D, Coleman-Derr D, Ballinger T, Henikoff S (2008).  Histone H2A.Z and DNA 
methylation are mutually antagonistic chromatin marks. Nature 456: 125-129.  
 
Zinzen RP, Girardot C, Gagneur J, Braun M, Furlong EE (2009). Combinatorial binding 
predicts spatio-temporal cis-regulatory activity. Nature 462: 65-70. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
Annex 
 
 
 
 
 
 
 
 
 
 
 
 
       
Annex 1:  Predicted methylation changes confirmed using pyrosequencing.  For each of the 
ten genes shown below, the integrated genome browser was used to visualise the methylation 
array results (top panel) and pyrosequencing (bottom panel) used to confirm these changes.  
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Annex 2:  FGFR2 and ICMT methylation decreases over time.  Pyrosequencing results of 
FGFR2 and ICMT confirmed the decrease in methylation predicted by the promoter 
methylation  array (6 weeks post infection).   Pyrosequencing of these same genes in a 3 
month LCL revealed a further derease in methylation. 
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